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Therapeutic antibodies have revolutionized the treatment landscape of many diseases, such as 
cancers and autoimmune diseases. The high specificity and affinity of a therapeutic antibody to 
its targeted antigen enable the antibody to possess several desirable pharmacological 
characteristics, such as high potency and low off-target toxicity. Antibodies can also engage host 
immune systems to elicit treatment effects via inducing immune-target cell interactions. 
Antibody-antigen engagement and antibody-dependent cell interactions are critical components 
in antibody pharmacokinetics (PK), pharmacodynamics (PD), and dose selection. Understanding 
of target engagement of antibodies at both molecular and cellular levels is important in antibody 
development and optimizing clinical applications.   
Molecular imaging approaches have been valuable tools to evaluate PK/PD profiles of 
therapeutic antibodies in biological systems due to their high sensitivity, spatial resolutions, and 
noninvasiveness. Mechanistic PK/PD models are advantageous to elucidate complex PK/PD 
relationships and shed light on factors determining intricate dose-response relationships. In this 
dissertation research, the power of molecular imaging and mechanistic modeling methods was 
combined to investigate antibody PK/PD profiles in physiological contexts. We elucidated 
antibody-target binding dynamics in living tumors using bioluminescent resonance energy 
transfer (BRET) imaging technology and modeling methods. We investigated antibody 
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distribution kinetics and target suppression in the brain using mechanism-based PK/PD models. 
We developed a proximity-based luminescent biosensor system to detect antibody-induced 
effector-target cell clustering dynamics. Finally, we revisited and analyzed therapeutic doses of 
FDA-approved therapeutic antibodies to investigate influencing factors on dose selection using a 
model-based metric.  
This dissertation research provides valuable insights into the influence of mechanistic factors 
on antibody PK/PD and therapeutic dose selections. The molecular imaging platforms developed 
in this research are valuable for further studies on the kinetics of antibody-target engagement and 
cell-cell interaction. The findings of this research will facilitate the development of therapeutic 
agents and potentially optimize their clinical applications. 
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CHAPTER 1 
MODELING PHARMACOKINETICS AND PHARMACODYNAMICS OF 




About a century ago, Paul Ehrlich proposed the ‘magic bullet’ concept, a drug selectively 
targeting a particular pathogen without affecting normal host cells [1]. This scientific concept 
became practical with the development of advanced engineering technologies to equip antibodies 
with high specificity for their cognate targets [2,3]. By 2020, more than 90 antibody drugs had 
been approved by the U.S. Food and Drug Administration (FDA) to treat a variety of major 
diseases, such as autoimmune diseases and cancers (Figure 1A) [4]. There is no doubt that 
therapeutic antibodies have achieved significant clinical success and play central roles in 
revolutionizing the treatment landscape for many diseases (Figure 1B). 
Immunoglobulin G (IgG) is the primary molecular format for the currently marketed 
therapeutic antibodies (Figure 1C). IgG has high polarity and large molecular sizes(~150 kDa, 
approximately 14 nm) [5]. These values are remarkably greater than small-molecule drugs which 
are generally less than 0.9 kDa with sizes below 1 nm [6]. A full IgG consists of two antigen 
                                               
1 This chapter has been adapted from the paper published in the Pharmaceutics. The original citation is: Tang, Y.; 
Cao, Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and 
Future Directions. Pharmaceutics 2021, 13, doi:10.3390/pharmaceutics13030422. 
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binding fragments (Fabs), which recognize the cognate targets with high specificity, and one 
fragment crystallizable region (Fc), which binds to a range of cell-associated receptors such as 
neonatal Fc receptor (FcRn) and Fc gamma receptors (FcγR). The Fc-FcRn interaction plays a 
critical role in circumventing antibody catabolism and increasing antibody retention in the 
system, accounting for the antibody’s long half-life. IgG antibodies can engage the host immune 
system via interaction with FcγRs expressed in various effector cells. These molecular properties 
greatly influence the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic 
antibodies, providing antibodies with many therapeutic advantages such as long half-life, high 
potency, and limited off-target toxicity. 
PK/PD analyses are integral to antibody development [7,8]. Antibody PK studies are 
primarily focused on systemic persistence and antibody distribution in target tissues. Antibody 
PK influences the magnitude and duration of antibody PD (Figure 2). Antibodies elicit 
pharmacological actions through different modes of action (MoAs), including neutralizing 
pathogenic antigens, suppressing signaling pathways, or triggering effector functions [9]. 
Mechanism-based PK/PD modeling is a powerful tool used to characterize the onset, magnitude, 
and duration of antibody treatment effects. Mechanistic PK/PD models are often valuable in 
elucidating the complex PK/PD relationships and shed light on factors determining intricate 
dose-response relationships. Numerous cases have demonstrated the successful application of 
PK/PD modeling to improve the efficiency and quality of antibody discovery, preclinical 
development, translational research, and decision-making in clinical development [10]. However, 
outstanding challenges remain in antibody PK/PD characterizations, such as the limited 
distribution into target tissues, including low tissue distributions, poorly-defined binding profiles 
in living systems, and complex immunomodulatory functions (Figure 3). This chapter provides 
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an overview of the progress, challenges, and future directions in characterizing antibody PK/PD 
properties and highlights the importance of applying mechanism-based PK/PD models in 
antibody discovery and development. 
1.2 Modeling Pharmacokinetics of Therapeutic Antibodies 
IgG antibody’s systemic disposition is tightly associated with FcRn. FcRn is expressed in 
various cell types, such as vascular endothelium and hematopoietic cells [11-13]. Like 
endogenous proteins in the circulation, antibodies enter cells primarily via non-specific 
pinocytosis (e.g., fluid-phase endocytosis). Intracellular catabolism is the major elimination route 
for therapeutic antibodies [14]. While the lysosomal pathway catabolizes most proteins, a large 
proportion of IgG antibodies can be salvaged by FcRn. In early endocytic vesicles (pH 6 – 6.5), 
FcRn tightly binds to the antibody’ Fc region, protecting antibody from entering lysosomes. 
Bound antibodies are recycled back to the plasma membranes, where Fc-FcRn binding affinity 
decreases at a neutral pH (7.0 – 7.5). Antibodies are then disassociated from FcRn and released 
into the circulation. The FcRn-mediated antibody recycling protects approximately 90% of 
antibodies from catabolism and extends antibodies’ half-lives up to 20 days in humans [15]. 
Moreover, FcRn can carry the internalized antibodies across cells and release them into the 
basolateral side (e.g., tissue interstitium) [16]. Local variation in endothelial FcRn trafficking may 
significantly affect IgG tissue distribution, considering that a substantial fraction of total IgG 
resides in the extravascular space (~50%). However, the significance of FcRn-mediated 
transcytosis for antibody tissue distribution on the system level has not been convincingly 
demonstrated yet [15,17]. The majority of antibody enters tissue interstitium via convection, 
which is determined by the fluid flux from vascular space to the tissue interstitium and driven by 
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hydrostatic gradient and sieving effects [16,18]. In tissues with relatively large intercellular clefts 
on capillaries, antibodies can rapidly distribute to the interstitial space [19].  
Many antibodies show rapid systemic clearance owing to target-mediated endocytosis, a 
phenomenon called target-mediated drug disposition (TMDD). Antibodies can extensively bind 
to their targets, forming antibody-target complexes, which are subsequently internalized and 
catabolized. Unlike the non-specific clearance via pinocytosis, target-mediated elimination is 
often capacity-limited and shaped by multiple factors, including antibody dose, target binding 
affinity, target expression, target turnover, and intracellular catabolism [16]. Many marketed 
antibodies exhibit dose-dependent elimination because of TMDD [16]. Modeling TMDD kinetics 
could yield insights into antibody PK, antibody-target binding kinetics, and antibody PD.  
Although compartmental models are commonly applied in antibody PK analysis, they cannot 
provide many mechanistic insights into antibody PK (Figure 4). In contrast, physiologically 
based pharmacokinetic (PBPK) models offer an approach to characterize antibody PK in 
physiological and anatomical contexts (Figure 4). PBPK models have been widely applied to 
describe many antibody PK behaviors, including tissue uptake and elimination [20], antibody-
target binding in tissues [18], and FcRn-mediated antibody recycling [15]. Cao and Jusko reduced 
the full PBPK models into the minimal-PBPK (mPBPK) model, in which tissue compartments 
are grouped as “leaky” or “tight” based on their vascular structure and permeability (Figure 4) 
[21-24]. The key determinants of antibody PK remained in the mPBPK models, such as 
convection as the major distribution pathway and the distribution space is limited in the 
interstitial fluid [25]. The mPBPK models have been applied to characterize antibody PK profiles 
in various disease scenarios [26-32].   
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Despite successful cases in which the antibody PK profiles were well-characterized by the 
developed PK models, many ambiguities remain in antibody PK. For example, determinants of 
low tissue distribution are still not fully known [33]. Understanding these complexities in PK is 
essential in developing and evaluating novel antibody products and improving antibody 
treatment efficacy and safety. 
1.3 Assessing Antibody Low Tissue Distribution 
Antibody concentrations in most of tissues are more than tenfold lower than in plasma [18,34]. 
A clear exposure-response relationship is often evident for the antibodies with targets primarily 
in the peripheral blood. However, for antibodies with distal targets, their exposures at the site of 
actions are usually hard to characterize, obscuring exposure-response relationships. Evaluating 
antibody exposure at target sites is thus a critical task in antibody development and evaluation 
[35,36]. This section will introduce state-of-the-art tools for assessing antibody distribution in 
tissues and modeling antibody distribution determinants.   
1.3.1 Tools for evaluating tissue distribution  
Numerous bioanalytical approaches have been applied to examine antibody distribution. 
Enzyme-linked immunosorbent assay (ELISA) [37,38], liquid chromatography-mass spectrometry 
(LC-MS) [17,39-41], and radioisotope quantification [17] are commonly applied to assess antibody 
tissue concentrations but unable to support longitudinal observations. There is a growing interest 
in using non-invasive approaches to monitor antibody tissue distribution continuously. Positron 
emission tomography (PET) has become a popular method to trace and monitor antibody tissue 
distribution in a spatiotemporal manner [42-45]. However, PET imaging is challenged by 
accumulated radiotoxicity and radionuclides’ short half-lives relative to the antibodies [46,47]. 
Other techniques such as fluorescence imaging are also frequently applied to assess antibody 
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distribution by detecting the signals emitted from the fluorophores conjugated to antibodies. 
Near-infrared (NIR) fluorescent probes such as IRDye800 have been applied widely in animal 
studies and clinical settings due to their enhanced tissue penetration and high target-to-
background contrast [48-50]. One limitation in fluorescence imaging methods is the altered 
antibody disposition by fluorophore conjugation. The conjugation type and degree need to be 
optimized in order to improve the sensitivity while not altering antibody disposition [51]. 
It is worth noting that the total antibody tissue concentration is not the concentration at the 
site of action. The total antibody tissue concentration is merely a mixture of vascular, interstitial 
fluid (ISF), and intracellular antibody concentrations, which does not reveal the specific 
concentration at the target site concerning the spatial concentration gradient [52]. Antibody 
concentrations in the tissue ISF can be measured by preparing the interstitium fluid via 
ultrafiltration [53,54] or minimally invasive microdialysis [55-57]. Intravital microscope (IVM) 
imaging provides a high spatial and temporal resolution in assessing antibody distribution [58,59], 
making it a powerful tool for monitoring the spatial interactions between the antibodies and the 
target cells, characterizing antibody MoAs, and investigating underlying mechanisms of antibody 
treatment resistance.  
1.3.2 Modeling antibody tissue distribution  
Extravasation of antibodies is primarily dominated by convective transport through 
paracellular pores and restricted by low net fluid rate and paracellular pores within the vascular 
endothelium [18,34]. A two-pore formalism theory was developed to characterize the convection 
of antibodies across the endothelium [60]. Covell et al. developed the first PBPK model for 
describing IgG antibody distribution into multiple tissues [20]. Baxter et al. included the two-pore 
formalism into the PBPK model to describe antibody convective transportation into tissues [19]. 
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Many groups have spent tremendous effort in the past decade to incorporate different 
mechanistic factors in the PBPK model to predict antibody tissue distribution in a variety of 
scenarios [15,61-64]. The antibody biodistribution coefficient has been calculated by pooling 
together multiple sources of data for a general agreement about antibody distribution extents 
across species and doses [62].  
Although full PBPK models have been successfully applied to predict antibody PK and tissue 
distribution, the drug development community's broad adoption of full PBPK models is still 
limited due to the antibody’s complex structure and parameterization. In contrast, the mPBPK 
model provides a simple alternative to model antibody PK in a physiological context [21,23,24,53]. 
PBPK models are usually applied for more mechanistic exploration and species translation, 
while the mPBPK models could provide a simpler alternative at the systemic level and potential 
elaboration of tissue-of-interest. The mPBPK model has been adopted to assess the target 
binding dynamics in the target tissues and the effect of endosome trafficking on FcRn-mediated 
antibody recycling [23,26-29,31,65]. For example, Zheng et al. investigated the distribution of an 
anti-TNF antibody candidate CNTO5048 and its TNF-suppression effect by developing an 
mPBPK model with an extended compartment representing mice colon [27]. 
1.3.3 Antibody distribution in solid tumors 
Solid tumors are abnormal and heterogeneous tissues consisting of various cell types (Figure 
5A). The constant interplay between malignant cells, immune cells, blood, and lymphatic 
vessels, and tumor-associated fibroblasts compose the highly dynamic and heterogeneous tumor 
microenvironment [66]. Larger pore sizes, varying diameters, and irregular branching patterns are 
often observed in tumor blood vessels, leading to the abnormal blood supply in solid tumors 
[67,68]. Necrotic regions develop due to the lack of functional blood vessels in solid tumors and 
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the inefficient delivery of oxygen and nutrients. The complex vascular and extracellular contents 
in solid tumors significantly influence antibody spatial distribution, resulting in limited and 
variable target accessibility and suboptimal treatment effect [69]. Furthermore, due to the lack of 
lymphatic vessels, many blood macromolecules leak out of the vessel and get stuck in the tumor, 
causing high interstitial hydrostatic pressure and further restricting antibody diffusion in the 
tumor bed. The effective diffusion coefficient of antibodies in solid tumors is as low as 1.3 x 10-8 
cm2/s [70], denoting that antibodies need more than one day to diffuse 1 cm within the tumor 
bed [71].  
Compared to the slow diffusion rate, the antibody-target association rate is relatively faster. 
Such a rapid and extended antibody-target binding process can become a barrier for antibodies 
diffusing into deeper tissues, creating a barrier known as the “binding site barrier” (Figure 5A) 
[72], which is the major reason for perivascular antibody distribution in solid tumors. Many other 
tumor microenvironment (TME) components can also influence spatial antibody distribution in 
solid tumors [73,74]. For instance, stroma cells usually grow around tumor cells, giving rise to a 
dense tumor matrix network, creating a physical barrier for antibody distribution within tumors 
[75]. The stress stroma can restrict antibody diffusion leading to the accumulation of antibodies in 
stroma-rich areas [76-79].  
Agent-based modeling methods have been applied to account for antibody spatial-temporal 
distribution in tumors. In an agent-based model, individual discrete agents can represent 
antibodies or the diverse cell populations that interact with each other under defined rules. A 
tridimensional heterogeneous TME can be constructed by moving along a 3D lattice, providing 
real-time simulations of antibody diffusion in TME and the resultant cellular responses [80-84]. 
For example, Kather et al. designed a 3D agent-based model of human colorectal cancer, which 
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includes TME components such as lymphocytes and fibrotic stroma, to evaluate treatment effects 
of immunotherapy [83]. Menezes et al. developed a hybrid agent-based model to capture antibody 
delivery in solid tumors for predicting tumor killing and growth kinetics [84].  
Models involving ordinary or partial differential equations have been developed to account 
for antibody concentration gradients within tumors [71,85-88].  A simplified spatial distribution 
model derived from the Krogh cylinder model can be broadly applied to understand the dynamic 
interplays between antibody extravasation, diffusion, target affinity, and internalization. 
Antibody perivascular distribution and the influencing factors are well explained using the 
simplified model (Figure 5B) [88]. As promising as these models are, these models could be 
challenging to gain full validation, limiting their application into making clinical predictions.  
1.3.4 Antibody distribution in the brain 
The brain is a notorious tissue for antibody targeting. The tight junctions between capillary 
endothelial cells create a physical barrier for antibodies to penetrate [89]. The brain's antibody 
concentration is only ~ 0.1% of that in the peripheral blood [16]. The limited antibody 
distribution in the brain is the primary challenge in developing antibodies for neurodegenerative 
disorders, such as Alzheimer’s disease and Parkinson’s disease. This subsection will discuss the 
factors that significantly influence antibody brain penetration and the modeling and simulation 
approach in elucidating antibody brain disposition, and the current strategies to increase antibody 
brain disposition.  
Antibodies enter the brain parenchyma primarily via blood-brain-barrier (BBB) or enter the 
cerebrospinal fluid (CSF) via blood-CSF-barrier (BCSFB). Antibodies can cross those barriers 
through receptor-mediated transcytosis (RMT) [90]. In the RMT, antibodies can bind to the 
transmembrane receptor on the apical plasma membrane and are subsequently endocytosed and 
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trafficked to the basolateral plasma membrane, where the antibodies are released into the brain. 
Various receptors can participate in RMT, including transferrin receptors (TfR), insulin receptors 
(IR), and low-density lipoprotein receptors (LDLR). The role of FcRn in the RMT is still unclear 
for antibody brain penetration [61,91-95].  
Tremendous effort has been invested in improving antibody delivery into the brain [96-99]. 
For instance, Kinoshita et al. introduced a technique to increase antibody brain delivery through 
transiently disrupting the BBB by ultrasound, opening up tight cellular junctions, and facilitating 
the antibody penetration in the brain [99]. RMT-based antibody delivery has gained momentum 
as a viable method to treat central nervous system (CNS) disorders [100-104]. Most of our RMT-
based antibody delivery experience was gained from anti-TfR antibodies, which significantly 
increased antibody brain uptake compared to the conventional antibodies [103,105]. There is a 
tradeoff between antibody affinity to TfR and RMT efficiency. High affinity to TfR could 
decrease the efficiency of TfR-mediated antibody trafficking by trapping antibodies in 
endosomes. A bell-shaped relationship between TfR affinity and antibody brain exposure has 
been well documented [103,105]. Yu et al. developed a series of bispecific antibodies (bsAbs to 
target TfR and beta-secretase 1 (BACE1) with different affinities to TfR [103]. The bsAb variant 
with a relatively lower affinity to TfR had the highest brain exposure than the other variants. 
This evidence suggest the potential of applying modeling methods in optimizing the brain-
delivery efficiency of the RMT-based antibodies. 
The complex and dynamic biofluid system can substantially influence antibody distribution 
kinetics in the brain. The fluid filtered by the cerebral blood vessels joins in the cerebral 
ventricles, beginning CSF circulation. A total of 150 mL CSF fluid are present in an adult human 
brain. CSF bulk flow is approximately 24 mL/h, continuously replacing CSF as it is absorbed 
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[106,107]. It is generally believed that CSF flow plays a major role in antibody infiltrations into 
the CSF [108]. However, many studies suggest that antibody infiltration rate in the CSF could be 
significantly lower than the CSF bulk flow [109-111]. The glymphatic system, a collection of 
perivascular spaces promoting fluid exchange between CSF and brain ISF, plays a potential role 
in the convective transportation of antibodies from the CSF to the brain parenchyma, which 
could be affected by brain diseases [111-116]. The involvement of the glymphatic system in 
antibody brain distribution warrants further exploration, and engineering antibodies to target this 
system may represent a future research direction.  
The technical and ethical challenges for directly sampling and measuring antibody brain 
concentrations make mathematical modeling a helpful tool for understanding antibody brain 
distribution [107,117,118]. Chang et al. developed a whole-body PBPK model to describe a non-
specific antibody's spatial distribution in multiple brain areas and the distribution kinetics 
associated with brain biofluid flow [111]. We have characterized the brain distribution kinetics of 
anti-α-synuclein antibody candidates using an mPBPK model with an extended CSF 
compartment (data not published). Our study further has shown that antibody penetration rate 
into the CSF is significantly lower than the CSF bulk flow.  
1.4 Elucidating Antibody-target engagement 
Antibody-target engagement is the first step needed to provoke the cascade of the 
pharmacological action. The magnitude of antibody-target engagement can serve as a critical 
biomarker for selecting therapeutic doses and predicting therapeutic effect. The tools for 
measuring antibody-target engagement, the models that describe antibody-target binding 
kinetics, and the applications of the modeling methods for antibody candidate optimization will 
be discussed in this section. 
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1.4.1 Measuring antibody-target engagement 
The measurements of antibody-target engagement can be at either microscopic or 
macroscopic levels. Flow cytometry (FCM), Immunohistochemistry (IHC), and 
immunofluorescence (IF) staining can provide a time-frozen snapshot of target engagement on 
either the circulating cells or tissue-derived cells [119,120]. At the macroscopy level, radiotracer 
replacement studies are often conducted to measure target engagement based on the competitive 
binding between small doses of radiolabeled antibodies and increasing amounts of cold 
antibodies. However, rapid endocytosis of radiotracers and the residualized isotopes can 
introduce bias to such measurements. Although PET/single-photon emission computed 
tomography (PET/SPECT) and fluorescence imaging methods monitor antibody distribution and 
tissue-specific target engagement in a continuous manner [121,122], they cannot differentiate the 
signal of free antibodies from the bound antibodies, precluding the accurate estimation of target 
engagement. A non-invasive imaging method to directly monitor target engagement with 
temporal and spatial resolutions is desirable. 
Proximity-based imaging technologies, including the Förster resonance energy transfer 
(FRET) and bioluminescence resonance energy transfer (BRET), recently showed promise to 
provide a direct assessment of antibody-target engagement. These technologies detect antibody-
target interactions based upon the energy transfer between the antibody and the receptor once 
both are in proximity. In a FRET pair, the energy donor is usually a fluorophore that can be 
excited by monochromatic light [123,124], while the donor is often a luciferase in a BRET pair 
[125]. The energy acceptor in either FRET or BRET pairs are fluorophores, which usually emit 
light at a different wavelength to avoid signal interference. When the donor-to-acceptor distance 
allows the resonance energy transfer, the acceptor will re-emit the light, directly indicating the 
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interactions between the donor and the acceptor [126,127]. BRET has several advantages over 
FRET (e.g., the lack of photobleaching, making it applicable for long-term monitoring). We 
recently developed a BRET antibody-target pair to investigate antibody-target binding dynamics 
in living tumors. In this study, a bright luciferase, NanoLuc [128], was fused to EGFR as the 
BRET energy donor. A fluorophore, DY605, was covalently conjugated to anti-EGFR antibody 
cetuximab. When cetuximab binds to EGFR in solid tumors, the distance between stimulated 
NanoLuc and DY605 enables the resonance energy transfer from stimulated NanoLuc to DY605-
cetuximab. DY605 emissions from living tumors directly visualized the interactions between 
cetuximab and EGFR [129]. These proximity-dependent sensing approaches have become 
extremely attractive for quantifying antibody-target engagement, supporting continuous 
monitoring of antibody-target interactions. 
1.4.2 Modeling antibody-target binding dynamics 
Antibody-target engagement is not only a critical step in antibody dispositions but also 
influences pharmacological actions [130]. For antibodies with a high target abundance, the 
extensive target binding and the rapid internalization could confer nonlinear PK behaviors to 
antibodies, known as TMDD [130]. Many antibodies targeting transmembrane antigens 
frequently exhibit TMDD behaviors [131]. TMDD models can provide a mechanistic bridge 
between antibody PK and the pharmacological responses, depicting the intricate interactions 
among antibodies, targets, and anti-target complexes. Since Mager and Jusko proposed the first 
TMDD model  [132], many TMDD models have been developed [131]. 
Incorporating the TMDD models into the mPBPK model provides a unique aspect for 
characterizing antibody-target interaction at the site of actions and investigating the local 
environment-specific binding properties [23]. Cao and Jusko developed the first mPBPK model 
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extended with TMDD to assess target bindings properties in either the plasma or tissue ISF 
compartment [23]. This model offers the chance to elucidate antibody-target binding properties at 
different tissues. For instance, we described the PK and target suppression profiles of two anti-α-
synuclein antibody candidates in the peripheral blood and the CSF using an mPBPK model with 
an extended CSF compartment. We found that an antibody could have distinct binding dynamics 
at different anatomical sites due to local physiologic environmental influences.  
Antibody-target binding parameters including kon, koff, and KD are usually measured using in 
vitro binding assays such as surface plasmon resonance in static environments [133,134]. 
Mounting evidence has indicated that these in vitro methods lack in vivo correlation due to the 
static non-native in vitro binding conditions not revealing the physiological factors [135-139], 
such as pressure and shear force in the living tissues [140]. Modeling approaches can be a 
complementary and powerful tool for identifying the in vivo binding parameters and exploring 
the underlying mechanisms that affect antibody-receptor binding in the living system [141]. For 
instance, Li et al. investigated the impact of tissue-specific ISF turnover rates on the binding 
kinetics between antibodies and soluble targets [65]. In the tissues with low ISF turnover, 
antibodies with a relatively lower koff can achieve a greater target suppression. Antibodies with a 
high kon are favored in the tissues with high ISF turnover. These findings explain why etanercept 
showed relatively higher treatment efficacy in rheumatoid arthritis than in Crohn’s disease, as the 
relatively high kon allows etanercept to have higher efficacy in suppressing the TNF in joint 
synovium than in the colon. 
Physical structures and restrictions in the target tissues can also alter the target binding 
dynamics, especially in solid tumors. Tumor stromal cells can cause spatial hindrance and 
mechanical stress in solid tumors, influencing the dynamics of antibody-antigen interactions. We 
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developed a spatially-resolved computational model to characterize cetuximab-EGFR binding 
kinetics and compare it between the stroma-rich area and the stroma-poor area within solid 
tumors [142]. Restricted diffusion of cetuximab in solid tumors makes cetuximab-EGFR binding 
to a slower-but-tighter degree in the living tumor compared to the in vitro systems. Compared to 
the tumor regions that lack stroma cells, cetuximab had a slower disassociation rate constant in 
the stroma-rich areas, which was further confirmed in the immunofluorescent staining showing 
that a high fraction of cetuximab stayed bound in the stroma-rich tumor regions. These studies 
demonstrate the essential role of modeling in elucidating antibody-target binding dynamics in 
physiological contexts. 
1.4.3 Optimizing target binding affinity 
TMDD models have been widely applied in model-informed drug development of 
therapeutic antibodies. Antibody-target binding kinetics can be considered in the PK/PD models 
to predict the desirable antibody properties [143]. Antibodies with a high target affinity are 
desirable in the early stage of development for achieving a high and durable target coverage 
[144]. However, higher antibody affinity is not always associated with better treatment efficacy 
[145]. The optimal antibody affinity should be made by considering multiple factors, including 
the target properties, antibody disposition at the site of action, and MoA [146].  
For antibodies acting through neutralizing soluble ligands or suppressing membranous 
signaling, increasing affinity may not always enhance treatment effects. Tiwari et al. 
demonstrated that the target baseline concentrations significantly affect the optimal KD for 
antibodies neutralizing soluble targets [145]. In contrast, the optimal KD for antibodies 
suppressing membranous signaling is contingent on antibody-target complex internalization rate. 
Concerning almost all of the current antibody products having their reported KD values falling 
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within the optimal range, this study suggests that when developing an antibody candidate with 
the same target and MoA as a marketed antibody, optimizing KD is less necessary to improve its 
treatment outcomes [145]. Many other studies achieved similar conclusions [10,147-149]. Agoram 
et al. demonstrated that a decrease in the KD of omalizumab, an anti-IgE antibody, did not 
increase treatment efficacy [10]. Penney and Agoram later observed that KD values of current 
antibody products only affect treatment effect to a limited extent due to the influences of many 
other PK and target-associated parameters [147]. Overall, these findings suggest that the target 
affinity should be assessed along with many other PK/PD parameters. Using PK/PD modeling to 
identify optimal KD values can avoid the wasteful investments in multiple cycles of affinity 
maturation to generate high-affinity antibodies.  
Antibody binding properties are also associated with antibody tissue penetration and 
retention [146]. An inverse relationship between antibody-target binding affinity and antibody 
spatial dispersal has been widely observed. For instance, single-chain Fv antibody molecules 
with high affinity may confer high endocytosis and shorter durations of antibody-target complex 
on the cell membrane, leading to greater degradation and limited tumor penetration [150]. 
Antibodies with moderate affinities could diffuse more widely than those with high affinities 
[150]. Similar findings were reported by Adams et al. [149]. PK/PD modeling can help investigate 
the desired binding properties to achieve optimal PK profiles. Gadkar et al. tested different 
variants of anti-TfR/BACE1 antibodies and found the variant with a higher affinity to TfR 
showed a higher systemic clearance and a lower brain uptake. The PK/PD profiles of the bsAb 
candidates with a range of affinities to TfR were further simulated to determine the optimal 
affinity and guide candidate selection [151]. In summary, these examples emphasized that PK/PD 
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modeling the antibody-target binding can be invaluable in the design and development of 
therapeutic antibodies. 
1.5 Modeling Pharmacodynamics of Therapeutic Antibodies 
Antibodies can activate and engage innate immune cells through the Fc-FcγR interactions. 
The activated effector cells, mainly natural killer (NK) cells, can release perforin or granzyme B 
to lyse the target cell. This effect is also known as antibody-dependent cellular cytotoxicity 
(ADCC) [152,153]. Another Fc-mediated effector function is antibody-dependent cellular 
phagocytosis (ADCP), by which antibody-opsonized target cells can activate macrophages and 
induce phagocytosis, leading to target cell degradation through phagosome acidification. 
Antibodies can also engage the complement system to trigger complement-dependent 
cytotoxicity (CDC). The Fc region recruits the complement cascade via interacting with C1q, 
ultimately leading to the targeted cells' apoptosis. These Fc-dependent effector mechanisms are 
crucial for many marketed antibodies, especially for anti-tumor antibodies [154]. Although 
broadly evidenced in vitro, these mechanisms have incompletely-understood participations in in 
vivo efficacy, which vary across antibodies, target antigens, tumor types, and patient populations 
[152,155-158]. For example, Cartron et al. demonstrated that the increased FcγR affinity to human 
IgG1 was associated with enhanced responses to rituximab in follicular lymphoma patients [157]. 
Trivedi et al. showed that anti-EGFR antibodies could activate multiple cellular immune 
responses, involving NK cells, neutrophils, and dendritic cells. These multicellular immune 
responses are critical for anti-EGFR antibodies in head and neck cancer patients [158]. Although 
having similar EGFR signaling suppression functions, panitumumab is less effective in 
activating cellular immune responses than cetuximab. However, the relative participation of Fc-
mediated effector functions in the treatment effects is not clear.  
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Antibodies such as immune checkpoint blockades (ICBs) can deploy the host adaptive 
immune system via blocking the immune checkpoint inhibitors, such as CTLA-4 and PD-1/PD-
L1, enabling T-cell activation and proliferation [159,160]. The treatment efficacy of ICBs is 
highly dependent on the tumor immune environments. The tumors with high T cell infiltrations 
and high expressions of these checkpoint inhibitors tend to respond better to ICBs [161]. Locally 
rejuvenated or peripherally active T cells can both greatly contribute to the effect of ICBs. 
Recent studies have suggested that newly-recruited anti-tumor immunity from the periphery may 
have greater contributions to the response than locally reinvigorated immunity [162-164]. For 
antibodies with systemic effects, namely the ability to recruit immune cells from the peripheral 
lymphatic systems, antibody distribution at the primary target locations may not significantly 
influence the treatment effects. One recent study showed that metastases at multiple anatomical 
sites responded to a similar degree to pembrolizumab, even though these anatomical sites could 
have different antibody distribution degrees [45,165,166]. There is an increasing need to use the 
modeling approach to elucidate the roles of tissue disposition and immune functions in ICB 
treatment effects. 
One major challenge to develop mechanism-based PD models for antibodies is the lack of 
techniques to longitudinally assess the immunomodulatory functions in the living system, 
particularly in the evolving TME [167,168]. In vitro measurements of immunomodulatory 
functions are used mainly for mechanistic exploration and are limited in predicting the in vivo 
immune dynamics due to the lack of physiological context [169,170]. Many biomarkers only 
provide a time-frozen snapshot of the immune status but fail to reveal dynamically immune 
functions [171]. Longitudinally monitoring the immune signatures in tumor samples could yield 
insights into the response and resistance mechanisms to ICBs [172]. Liu et al. developed a 
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dynamic matrix-based biomarker that integrates the interferon γ cytokine secretion as a 
biomarker to predict the immunomodulatory effects of anti-PD-1 antibodies [173]. Litchfield et 
al. performed a pan-tumor analysis to reveal the relative importance of tumor-cell-intrinsic and 
TME features underpinning ICB responses and resistance [174]. Despite these efforts, it is still 
challenging to accurately project the effector functions in vivo and the pharmacodynamic 
responses of immunotherapies.   
1.6 Significance and Specific Aims 
Therapeutic antibodies have achieved remarkable success in treating many diseases. 
However, therapeutic antibodies still face many outstanding issues associated with their PK, PD, 
and dose selection, including low tissue distributions, poorly-defined binding profiles in living 
systems, and complex immunomodulatory functions. We hypothesize that the influences of 
mechanistic factors on antibody PK/PD and dose selection can be further understood by 
leveraging the power of molecular imaging and modeling methods. This thesis is split into six 
specific chapters, which include: Determining antibody-receptor occupancy in vivo by using a 
bioluminescence resonance energy transfer (BRET) based approach (Chapter 2), Modeling the 
dynamics of antibody-target binding living tumors (Chapter 3), Characterizing the distribution 
and target suppression of anti-α-synuclein antibodies in cerebrospinal fluid (Chapter 4), 
Visualizing antibody-induced immune-tumor cell clustering dynamics using a proximity-
dependent biosensor system (Chapter 5), and Investigating the influencing factors in antibody 
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Figure 1: Therapeutic indications, approvals per year, and formats of the FDA-approved therapeutic 














Figure 2: Antibody pharmacokinetics-pharmacodynamics relationships.  
  
 




Figure 3: The fruit tree model presents the current progress and challenges for modeling the  
pharmacokinetics/pharmacodynamics (PK/PD) of therapeutic antibodies.  
PK/PD modeling has been widely used in antibody development to characterize antibody PK, assess tissue 
distribution, elucidate antibody-target engagement, and describe the pharmacodynamics (enclosed in solid lines). 
This thesis focuses on the challenges associated with antibody PK/PD properties, namely the “high-hanging fruits” 
for PK/PD modeling (enclosed in dash-lines).  
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Figure 4: Complexity and Physiological relevance of compartmental models, mPBPK models, and full  
PBPK models. 
Compartmental models are feasible for antibody PK analysis but unable to provide many mechanistic insights into 
antibody PK. PBPK models offer an approach to characterize antibody PK in physiological and anatomical contexts 
with high complexity levels. The mPBPK model provides a simple alternative to model antibody PK in a 
physiological context. Courtesy of Dr. Yanguang Cao.  
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Figure 5: Antibody spatial distribution in tumors.  
(A) Target interaction and tumor microenvironment influence antibody spatial distribution. After extravasation into 
the tumor interstitium, antibodies rapidly associate with its targets in perivascular tumor cells, forming a binding site 
barrier and limiting its diffusion to the deeper tumor. Antibodies bound to the targets can be endocytosed and 
degraded. Other components, such as tumor-associated stromal cells, also hinder antibody interaction with its targets 
and antibody diffusion. (B) A simplified antibody spatial distribution model in tumors. The plasma, normal tissues, 
and the tumor were included in a simplified Krogh Cylinder model. The arrows indicated antibody movements 
between compartments.  The arrows indicated antibody movements between compartments. The antibody 
extravasation was a function of P (the permeability coefficient for antibody across the tumor capillary wall), Rcap 
(the capillary radius in the tumor), RKrogh (the average radius of tissue surrounding each blood vessel), [Ab]p 
(antibody concentration in the plasma), [Ab]free (free antibody concentration in the tumor), and ε (void fraction). In 
the equation describing antibody binding, kon is association rate constant, koff is disassociation rate constant, [Ag] is 
the target concentration in the tumor, and [Ab]bound is the concentration of bound antibodies. Bound antibody 
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CHAPTER 2 
A BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) BASED 
APPROACH FOR DETERMINING ANTIBODY-RECEPTOR OCCUPANCY IN VIVO2 
 
2.1 Overview 
Elucidating receptor occupancy (RO) of monoclonal antibodies (mAbs) is a crucial step in 
characterizing the therapeutic efficacy of mAbs. However, the in vivo assessment of RO, 
particularly within peripheral tissues, is greatly limited by current technologies. In the present 
study, we developed a bioluminescence resonance energy transfer (BRET) based system that 
leverages the large signal:noise ratio and stringent energy donor-acceptor distance dependency to 
measure antibody RO in a highly selective and temporal fashion. This versatile and minimally 
invasive system enables longitudinal monitoring of the in vivo antibody-receptor engagement over 
several days. As a proof-of-principle, we quantified cetuximab-EGFR binding kinetics using this 
system and assessed cetuximab RO in a tumor xenograft model. Incomplete ROs were observed, 
even at a supratherapeutic dose of 50 mg/kg, indicating fractional target accessibility is achieved. 
The BRET-based imaging approach enables quantification of antibody in vivo RO and provides 
critical information required to optimize therapeutic mAb efficacy. 
                                               
2 This chapter has been adapted from the paper published in the iScience. The original citation is Tang, Y.; 
Parag-Sharma, K.; Amelio, A.L.; Cao, Y. A Bioluminescence Resonance Energy Transfer-Based 
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2.2 Introduction 
Monoclonal antibodies (mAbs) are often regarded as “magic bullets” [175], which have been 
applied towards the treatment of an array of human diseases [176]. These therapeutic mAbs are 
engineered to specifically bind their cognate antigens with high affinities and have been 
deployed for neutralizing pathologic factors, blocking cellular signaling, and/or stimulating 
immune functions [177]. Therapeutic mAbs have shown great promise in cancer treatments given 
their therapeutically desirable characteristics of long plasma half-lives, high selectivity, and 
limited off-target toxicity [16]. To date, over 30 mAbs (and rising) have been approved for 
treatment of various types of cancers, including hematologic malignancies and solid tumors [178-
182]. 
Like other targeted therapies, mAbs can only elicit their desired pharmacologic effects when 
directly bound to their cognate targets. Therefore, elucidating the target engagement of a given 
mAb is a crucial step towards characterizing its therapeutic potential and in determining its 
pharmacological dynamics, which helps define the optimal dosing regimens to achieve maximal 
therapeutic efficacy. Target engagement, or receptor occupancy (RO), is the ratio of occupied 
receptors of interest over total receptors of interest present on the targeted cells. Establishing the 
RO profile of any therapeutic mAb via pre-clinical/clinical studies is critical towards projecting 
the first-in-human dosages, to ensure minimal anticipated biological effect level [183] and 
minimize potential dose-limiting toxicity [184-186]. Antibody RO is often a valuable intermediate 
measurement for establishing dose (or exposure)-response relationships, especially at early 
stages of mAb development when defined biomarkers for a mAb’s pharmacological effects are 
not available [120,186,187]. Although many other factors should be considered when interpreting 
RO, such as receptor epitope properties [188,189], antibody-receptor binding is the first step 
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required to elicit a pharmacological effect, and the binding kinetics of a given mAb to its targets 
within the tumor microenvironment dictates its general therapeutic potential. 
      Tremendous efforts have been expended towards creating a reliable and cost-effective 
method to quantify antibody RO. Flow cytometry (FCM), due to its ease of operation, is 
routinely used to determine RO [120,190], however, FCM is only ideally suited to antibodies that 
have targets present on circulating blood cells. Moreover, the constraints on sampling 
accessibility and high spatial heterogeneity often hinder the use of FCM towards antibodies 
targeting peripheral tissues. Large disparities have been observed between antibody 
concentrations in circulating plasma and in solid tumors [191,192]. Due to the large sizes, high 
binding affinities, and high target specificities [193], the distribution of antibodies in dense 
interstitial matrix is often limited to the perivascular area, resulting in fractional accessibility of 
targets to mAbs. In solid tumors, antibody-target binding kinetics and the resultant RO are 
subject to complex biologic variables, including tumor-blood perfusion, antibody extravasation 
across the tumor vasculature, tumor extracellular matrix densities, and the expression levels and 
accessibility of antigens on tumor cells that are recognized by mAbs. All these factors 
complicate reproducibly quantifying antibody-target binding kinetics and the resultant RO in 
solid tumors.  
       One approach to quantify antibody RO in solid tumors is to perform immunohistochemistry 
staining on tumor biopsies. However, this approach lacks temporal resolution and often fails to 
incorporate dynamic factors present in in vivo situations that could greatly influence mAb-target 
interactions [44]. Another approach to assess antibody RO within solid tumors is to perform 
radiotracer replacement studies, which usually require two steps: first, giving subjects a small 
dose of radiolabeled antibody, and then giving increasing doses of unlabeled antibody. Due to 
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competitive binding, the radioactivity levels in the tumors decrease as doses of unlabeled 
antibody increase, indicating an increased RO, until a plateau is gradually achieved. Determining 
mAb RO using this approach is often complicated by the rapid endocytosis of the radiotracers by 
tumors [194]. The estimation of RO is further biased by the unstable radioactivity in the control 
group, which should have relatively constant radioactivity without competitive replacement by 
unlabeled antibodies [195].  
      Other radiolabeling methods, including positron emission tomography/single-photon 
emission computed tomography (PET/SPECT), are often applied to quantify mAbs 
pharmacokinetics, tissue distribution and tissue-specific RO. These approaches raise safety 
concerns when determining the mAb RO due to elevated radiation accumulation [196]. 
Fluorescence imaging has also been explored for both preclinical and clinical applications 
[50,122,197-200]. However, fluorescent imaging suffers from fluorescence quenching that caused 
by external excitation light, and poor signal:noise ratios due to the high autofluorescence of 
biologic tissues. Aside from these intrinsic disadvantages, most current non-invasive in vivo 
imaging methods have a common drawback to RO quantification, namely, they are unable to 
distinguish signals arising due to specific target engagement versus non-specific background 
signals. At the tissue level, it is difficult to distinguish the signals of bound mAbs from those of 
free mAbs present in blood circulating within tissues. Probes or tracers can exhibit non-specific 
binding and residualization in tumors, which greatly bias RO quantification [195,201,202]. 
Therefore, a non-invasive imaging technology that exclusively enables the visualization of 
antibody-target interactions in vivo is greatly desired. 
In the present study, we developed a bioluminescence resonance energy transfer (BRET) 
based system to non-invasively quantify antibody RO in live animals. BRET detection schemes 
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are based on Förster resonance energy transfer, in which resonance energy is transmitted from a 
luciferase molecule (donor) during substrate catalysis, to a fluorescent molecule (acceptor) which 
then re-emits the light according to its own emission spectra [203]. In BRET-based protein-
protein interaction studies, the donor (luciferases) and acceptor (fluorophores) molecules are 
tagged onto two distinct proteins of interest. Interaction between the proteins of interest, upon 
appropriate stimuli, brings the luciferase and fluorophore into close proximity, enabling the 
luciferase to efficiently transmit energy to the fluorophore resulting in BRET [204-210]. BRET 
efficiency is governed by both the distance and orientation of the donor and acceptor molecules 
relative to each other. Given the stringent requirements of distance separation (~10 nm) between 
donor-acceptor molecules for efficient BRET, it offers a large signal:noise ratio, high sensitivity 
at physiologically relevant temporal resolutions, and therefore has found wide utility in 
ligand/target interaction studies [209,211]. Recently, BRET imaging was applied to visualize a 
propranolol-dye conjugate (acceptor-ligand) binding to a N-terminal NanoLuc-tagged human 
GPCR 𝛽2-adrenoreceptor (donor-receptor) in real time [210], demonstrating the noteworthy 
performance of BRET imaging for monitoring ligand-receptor binding in vivo. In present study, 
we extended the BRET approach to clinically attractive mAb therapies. Cetuximab (CTX), a 
therapeutic mAb currently deployed in many clinical trials for solid tumors, and its cognate 
target receptor, epidermal growth factor receptor (EGFR), were selected as a model system. 
EGFR is one of the most well-studied receptors, mediates key growth factor response pathways 
driving cell survival, proliferation and growth and has been implicated 
(overexpression/mutations) in numerous human malignancies [212-217]. Herein, we present a 
BRET based imaging approach to directly monitor the temporal profiles of antibody-target RO in 
live animals using CTX binding to EGFR. 
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2.3 Materials and Methods 
Design of the NanoLuc-EGFR / DY605-cetuximab BRET imaging system 
The SigNL-EGFR plasmid, containing the NanoLuc luciferase fused to the N-terminus of 
EGFR, was a kind gift from Promega Life Science (Seattle, WA, USA). The plasmid map is shown 
in Figure 6. A hydrophilic fluorescent dye, DY605 (Dyomics GmbH, Jena, Germany), was 
selected as the BRET acceptor because of its outstanding molar absorbance (110,000 M-1cm-1) and 
spectrum (λex/em  = 600/625 nm). DY605 was covalently appended onto the lysine residues of 
cetuximab (Erbitux, Eli Lilly) using N-hydroxysuccinimide (NHS) chemistry to generate the 
DY605-cetuximab (DY605-CTX). Briefly, the pH of the cetuximab solution was adjusted to 
8.0−8.5 by using a solution of 7.5% sodium bicarbonate (Gibco®, Gaithersburg, MD, USA) before 
the DY605 stocking solution (13.3 nmol/µl) was added. The mixture of DY605 and cetuximab 
was blended at room temperature for 1 hr. Lysines are a common site for nonspecific conjugation 
of fluorescent dyes using ester chemistry [51]. There are 44 lysines on cetuximab, about 3/4 of 
which are on the heavy chain [218]. As conjugation between cetuximab and DY605 is nonspecific, 
most of DY605 is expected to be appended on heavy chain of cetuximab. After conjugation, free 
dye was removed using desalting columns from GE Healthcare (Piscataway, NJ, USA). Antibody 
concentrations and dye/antibody ratios (DARs) were measured using Nanodrop 1000 (Wilmington, 
DE, USA) as the equations below. DY650 was appended to IgG (control) using an identical 
protocol.  
Antibody concentration (mg/mL) = 	$%&'($)''	·	+,--./01,2	34/0,-
5.7
         Eq. 1 
The antibody concentration was estimated by assuming 1.4 Aprotein units = 1 mg/mL (for 
IgG). Correction Factor for DY605 = 0.552. 
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DAR = $)''·42018,9:	;,<./=<4-	>.1?@0	(?/;,<)
42018,9:	/,2/.20-401,2	(;?/;D)	·	;,<4-	48E,-842/.	(F(5	/;(5)
          Eq. 2 
Cetuximab molecular weight = 150, 000 g/mol. DY605 molar absorbance = 110,000M-1. For 
the study evaluating the DAR effect on the DY605-CTX pharmacokinetics (PK), cetuximab was 
labeled with DY605 at three DARs (1.6, 5.9, and 13) for comparison. The DARs were tuned by 
changing the loading amount of DY605 when conjugating to cetuximab. 
The schematic of how this BRET system works is illustrated in Figure 7. In the absence of 
DY605-CTX binding, the addition of the NanoLuc (NLuc) substrate (furimazine) results in the 
single emission peak at 460nm of NLuc (donor) is observed (Figure 7A). However, upon DY605-
CTX binding to NLuc-EGFR (bringing NLuc into close proximity with the DY605 fluorophore), 
the addition of furimazine produces two distinct peaks, at 460nm (NLuc) and at 625 (emission 
peak of DY605), the latter arising from the robust BRET observed between NLuc and DY605 
(Figure 7B). Both donor (at 460nm) and acceptor (at 625nm) emission peaks are ~165nm apart 
ensuring robust spectral separation and reliable detection (Figure 8).  
Cell culture, transfection, and clonal Isolation 
The cell model was developed on wild type HEK293 cell line (WT HEK293) due to its 
intrinsically low EGFR expression [219]. HEK293 cell line was obtained from UNC tissue culture 
facility. HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium (Gibco®, 
Gaithersburg, MD, USA) containing 1% penicillin/streptomycin supplemented (Gibco®, 
Gaithersburg, MD, USA) with 10% fetal bovine plasma (EMD Millipore, Burlington, MA, USA). 
Prior to transfection, WT HEK293 cells were seeded in 12-well plates and cultured in complete 
growth medium. The transfection of the SigNL-EGFR plasmid was conducted using 
LipofectamineTM 3000 Transfection Reagent (Invitrogen; Carlsbad, CA, USA) according to the 
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manufacturer’s protocol. Selection of stably transfected HEK293 cells expressing NLuc-EGFR 
was performed with 1000 µg/mL geneticin (Invitrogen; Carlsbad, CA, USA). Single cell colonies 
with the highest expression of reporter protein were selected by measuring the NLuc activity in 
the presence of the NLuc substrate furimazine (Promega, Madison, WI, USA). NLuc activities of 
wildtype versus NLuc-EGFR expressing cells (suspensions) were compared under identical 
conditions  (same cell density and concentrations of the furimazine substrate). Furimazine was 
added to cells according to manufacturer’s protocols (25 µL per well after a 20-fold dilution). The 
NLuc activity was measured using Cytation 3 (Biotek; Winooski, VT, USA) using a 460/40 nm 
bandpass filter set at room temperature. The clone selection scheme was summarized in Figure 6. 
These stably transfected cells exhibiting the highest NLuc luminescence were used in all 
subsequent experiments. 
         NLuc-EGFR expression was also evaluated using anti-EGFR antibody probing (DY605 
labeled cetuximab, DAR = 3.8). NLuc-EGFR HEK293 cells and WT HEK293 cells were 
suspended in Opti-MEM at equal cell densities and incubated with 100 nM of either DY605-CTX 
or DY605-IgG for 1 hr at 4 °C. After the incubation, cells were recovered, spun down, washed 
three times using cold Dulbecco’s phosphate-buffered saline (Gibco®, Gaithersburg, MD, USA) 
and then resuspended in Opti-MEM (Gibco®, Gaithersburg, MD, USA). The cell suspension was 
transferred to black 96-well plates (Corning Inc. Corning, NY, USA), equalized for volume. The 
fluorescence was quantified using Cytation 3 fluorescence monochromator with 16 nm bandwidth 
at λex/em = 580/610 nm with a gain of 100. For both NLuc activity evaluation and EGFR probing, 
at least 5 technical replicates were included in one experimental group. The experiments were 
repeated at least three times. 
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In vitro BRET assay  
CTX-EGFR binding was quantified using BRET measurements. Briefly, NLuc-EGFR 
HEK293 cells were seeded in white 96-well plates 24 hr before the experiments. Complete medium 
in 96-well plates was then replaced by Opti-MEM 1 hr prior to the experiments. A dose titration 
of DY605-CTX or DY605-IgG was performed in the presence/absence of 1 mM unlabeled 
cetuximab. After incubation for 1 hr at room temperature, the NLuc substrate furimazine was 
added to each well following manufacturer’s instructions (25 µL per well after a 20-fold dilution). 
The luminescence was measured at 460 nm and 625 nm by Cytation 3 equipped with 460/40 nm 
bandpass filter and 610 nm longpass filter. The BRET ratio was calculated by dividing the 625 nm 
emission by the 460 nm emission and was corrected using the baseline BRET ratio, as Eq. 3 shows. 
BRET ratio (in vitro) = Acceptor emission (sample)
Donor emission (sample)
 - Acceptor emission (Blank)
Donor emission (Blank)
       Eq.3 
Three technical replicates were included in the in vitro BRET assay. The experiments were 
repeated at least three times. 
Effect of DARs on target binding and pharmacokinetics (PK) of DY605-CTX in mice 
Antibody PK alterations due to fluorophore types or DAR have been reported [51,220,221]. 
While increased DAR elevates the intensity of BRET acceptor emissions, it has been shown to 
accelerate the clearance of dye-antibody conjugates [51]. In the present study, the effect of DARs 
on PK was investigated, prior to the in vivo receptor occupancy (RO) study. We labeled cetuximab 
with DY605 at three different DARs (1.6, 5.9, and 13). The filtered DY605-CTX (DAR= 1.6, 5.9, 
and 13) were diluted in saline to 0.64 mg/mL for the following PK study in mice.  
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      Female nude mice were obtained from the Division of Comparative Medicine at UNC. Each 
mouse was injected with 100 µl of DY605-CTX saline solution via tail vein (3.2 mg/kg, n = 3/DAR 
group). Blood samples were collected in a rotating manner within three subsets per group, and the 
total amount of blood removed from each subgroup was kept consistent throughout the study. 
Blood samples (30 µl) were collected via tail vein at 0, 18, 24, 48, 72, 96, 120, and 168 hr post 
dosing. Plasma fluorescence was measured immediately after sampling and the rest of the sample 
was snap frozen and stored at -80°C. Plasma concentrations of DY605-CTX were measured based 
on fluorescent intensities according calibration curves. All animal studies were conducted in 
compliance with the Institutional Animal Care and Use Committee (IACUC) of UNC. 
Stability of DY605-CTX in mouse plasma 
The conjugate stability was tested as previously described [51,222]. Briefly, DY605-CTX was 
added into mouse plasma at the final concentrations of 1 µg/µl or 0.02 µg/µl. Plasma aliquots were 
stored at –80°C, then thawed and incubated at 37°C for 9 days for DY605-CTX, 5 days for DY605 
-IgG. The mixtures were thawed in reverse order, namely, the one thawed on the 9th day served as 
the first time point (day 1) of DY605-CTX, so that all samples were measured on the same day.   
      After incubation, 2 µl of either the DY605-CTX or the DY605-IgG plasma samples were 
mixed with 200 µl of saline in each well in a 96-well plate. The total fluorescence of incubated 
conjugates was measured by Cytation 3 (Biotek; Winooski, VT, USA) and normalized to the ones 
at day 1. The conjugate-specific fluorescence was determined after SDS-PAGE separation. 
Specifically, the DY605-CTX or the DY605-IgG plasma samples were mixed with LaemmLi 
buffer (Bio-Rad; Hercules, CA, USA) at 0.33 mg/mL and heated at 95℃ for 5 min. The conjugate 
solutions were loaded on 12% polyacrylamide gel (Bio-Rad; Hercules, CA, USA), free dye was 
used as a control. The electrophoresis was performed in Tris/HEPES/SDS running buffer (Bio-
 
 35  
Rad; Hercules, CA, USA) for 45 min at 100 volts. Immediately after electrophoresis, the gels were 
removed and scanned with FluorChem M (Cell Biosciences, Inc., Santa Clara, USA). The 
fluorescent intensities of the DY605-CTX, DY605-IgG, and free dye bands were quantified using 
ImageJ (National Institutes of Health, Bethesda, MD). The ROI signal intensities of the free dye 
were normalized to the signal intensities of antibody-dye conjugates with the same incubation time.  
Assessment of RO in live mice 
A mouse xenograft model of NLuc-EGFR HEK293 was established using female nude mice 
(4 - 6 weeks). To establish tumor models, 5 × 106 NLuc-EGFR HEK293 cells were suspended in 
0.1 mL of PBS/ Matrigel (BD Biosciences; San Jose, CA, USA) (1/1, v/v) and inoculated 
subcutaneously into the inguinal flank of the nude mice. After ~4 weeks, mice with similar tumor 
sizes (> 500 mm3) were selected for the imaging experiments. 
        Tumor growth was measured using calipers every other day. Tumor volumes were calculated 
according to the equation below. 
Tumor size (mm3) = <.2?0@	(;;)·>.190@	(;;)·>.190@(;;)
%
                                              Eq. 4 
       Once the tumor sizes surpassed 500 mm3, the mice were randomly assigned to 4 groups: 
control (DY605-IgG at 1.9 mg/kg) or 3 treatment groups for DY605-CTX at 1.0, 8.5, and 50 mg/kg 
(n = 5/dose). The DY605-CTX (DAR = 4.6) and DY605-IgG (DAR = 5.6) were administered via 
tail vein injection. Animals were anesthetized and fixed to prevent moving during the image 
acquisition. Prior to image acquisition, furimazine (0.25 mg/kg) was injected via tail vein. Images 
were acquired at time 0, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hr after the injection of either 
DY605-CTX or DY605-IgG. The images were acquired around 45 s after substrate administration 
with the same order (620 nm first). The parameters used during the imaging were, 1 min exposure 
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time (luminescent f/stop = 1) with either 620/20 nm or 500/20 nm bandpass filter set. All the in 
vivo images were acquired using an IVIS Kinetic optical imaging system (Caliper Life Sciences, 
Alameda, CA, USA) that was equipped with an electron multiplying charge-coupled device 
camera. 
       Acquired images were processed and quantified using Living image 4.5.2 (Caliper Life 
Sciences, Alameda, CA, USA). For tumor size and receptor density analysis, the whole tumor area 
was gated and the total flux at tumor area was measured. The signal intensity was quantified using 
the total flux and the average radiance, which reflected the total NLuc-EGFR HEK293 amount 
and density, respectively. For RO quantification, up to 6 non-overlapped regions of interest were 
gated at the tumor areas on each image at 620/20 nm and 500/20 nm. To keep consistency, the 
sizes and locations of all ROIs for each tumor were the same at each time point. The total flux of 
all ROIs on corresponding acceptor/donor images were quantified. The average DY605-IgG 
BRET ratio that was measured within the first 48 hrs post administration was used as background, 
which was subtracted from raw BRET ratios in 50 mg/kg, 8.5 mg/ kg, and 1.0 mg/kg DY605-CTX 
group. The BRET ratio of a given ROI was calculated as the equation below. 
BRET ratio (in vivo) = Total flux acceptor (DY605-CTX)
Total flux donor (DY605-CTX)
 –  Total flux acceptor (DY605-IgG)
Total flux donor (DY605-IgG)
               Eq. 5 
       In addition, at each time point, 30 µl blood samples were collected via tail vein for PK 
assessment. After the study, the animals were euthanized.  
       The five highest BRET ratios obtained throughout the in vivo RO assessment (DAR = 4.6; 50, 
8.5, and 1.0 mg/kg dose groups, from 0 to 168 hr post injection) were selected and their average 
defined as RO = 100%. The remaining RO was calculated using the equation below. 
 
 37  
RO% = 100%· BRET ratio (DY605-CTX)
Highest BRET ratio (DY605-CTX)
                   Eq. 6 
Data analysis 
The PK data was analyzed using Phoenix WinNonlin 7.0 (Certara, Princeton, NJ, USA) to 
calculate the PK parameters including maximum concentration (Cmax), area under the curve 
(AUC0-168hr), and clearance (CL). The max values, terminal slopes (λZ), and AUC of receptor 
binding and RO data were also calculated. All experimental findings were statistically evaluated 
using GraphPad Prism version 7.0d (GraphPad Software; La Jolla, CA, USA).  
2.4 Results 
Design of the NanoLuc-EGFR / DY605-cetuximab BRET imaging system 
NanoLuc (NLuc) [128], which has shown significant advantages over other luciferases in 
BRET based studies, such as enhanced maximal light output, improved signal stability, ATP-
independent light generation, and resistance to auto-inhibition among others [210,223,224], was 
fused to the N-terminus of EGFR to generate the NLuc-EGFR fusion protein (Figure 6).A 
fluorescent dye, DY605, was covalently labeled onto CTX to generate the DY605-cetuximab 
conjugate (DY605-CTX). In the absence of DY605-CTX binding, the addition of the NLuc 
substrate (furimazine) results in the single emission peak at 460 nm (NLuc, the BRET donor) 
(Figure 7A). However, upon DY605-CTX binding to NLuc-EGFR (bringing NLuc into close 
proximity with the DY605 fluorophore), the addition of furimazine produces two distinct peaks 
at 460 nm and at 625 nm (emission peak of DY605, the BRET acceptor), the latter arising from 
the robust BRET observed between NLuc and DY605 (Figure 7B). Donor (at 460 nm) and 
acceptor (at 625 nm) emission peaks are ~165 nm apart ensuring robust spectral separation and 
reliable detection. 
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Characterization of the BRET system  
To characterize NLuc-EGFR expression in our HEK293 cells stably expressing NLuc-EGFR, 
we measured both  NLuc and EGFR expression levels using bioluminescence signal intensity 
and anti-EGFR antibody fluorescence, respectively. As expected, the NLuc signal in the NLuc-
EGFR HEK293 cells is several orders of magnitude higher than the background signal in the 
parental wild type (WT) HEK293 cells (Figure 9A). Antibody probing for EGFR revealed a 
robust upregulation (5-fold) of EGFR protein levels in the NLuc-EGFR HEK293 cells compared 
to the parental WT HEK293 cells (Figure 9B).  
      Next, we characterized the DY605-CTX binding affinity to NLuc-EGFR. DY605-IgG was 
used as a negative control and binding specificity of DY605-CTX to NLuc-EGFR was evaluated 
using a competition assay in the presence of a saturating concentration of unlabeled CTX (1 
mM). The saturation binding curves (Figure 9C) suggested a single-site binding of DY605-CTX 
to NLuc-EGFR with an affinity of KD = 0.1 ± 0.01 nM, which is in agreement with previously 
reported KD for CTX-EGFR binding (0.39 nM) [225]. The binding of DY605-CTX to NLuc-
EGFR could be completely blocked by a high concentration of unlabeled CTX, suggesting that 
DY605-CTX retains its site specificity towards EGFR, compared to unmodified CTX. DY605-
IgG exhibited no non-specific binding to NLuc-EGFR. Collectively, the BRET signal observed 
from interaction between DY605-CTX and NLuc-EGFR could be used to quantify its binding 
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Effect of dye per antibody ratio (DAR) on binding affinity and potentially altered 
pharmacokinetics (PK) of DY605-cetuximab in mice 
In order to determine the effect of DAR on CTX’s affinity to NLuc-EGFR, we generated 
DY605 labelled CTX at multiple DARs (1.6, 5.9 and 13). As shown in Figure 10A and Table 1, 
the KD values of DY605-CTX to NLuc-EGFR remain consistent across a wide range of DARs 
(KD = 0.15 ± 0.04, 0.12 ± 0.03, and 0.12 ± 0.03 nM at DAR = 1.6, 5.9, and 13, respectively). As 
expected, a greater maximal BRET signal (Bmax) was observed at higher DAR, Bmax = 4.8 ± 0.3, 
13.4 ± 0.6, and 15.7 ± 0.8 at DAR =1.6, 5.9, and 13, respectively. Compared to DAR =1.6, Bmax 
at DAR = 5.9 increased ~3-fold. However, Bmax only increased ~1.2 folds between DAR = 5.9 
and 13 conditions (Figure 10A and Table 1), indicating that the BRET signals achieved are near 
saturation at the highest DAR tested herein. 
     We also compared the PK of DY605-CTX at different DARs. Nude mice were injected with 
three DY605-CTX DAR variants (DAR = 1.6, 5.9, and 13) at 3.2 mg/kg via tail vein. Blood 
samples were collected at 0, 18, 24, 48, 72, 96, 120, and 168 hrs post dosing. As shown in 
Figure 10B, three DY605-CTX conjugates at the same dose level had significantly different 
systemic clearance. The PK parameters were summarized in Table 1. While the  DY605-CTX 
displaying the highest Bmax was DAR = 13, DY605-CTX with DAR = 13 showed the fastest 
clearance (0.100 ± 0.014 mL/hr), compared to 0.009 ± 0.005 and 0.065 ± 0.39 mL/hr for labeled 
CTX at DAR = 1.6 and = 5.9, respectively, and had concentration below detectable level by 96 
hrs post-dosing. To maintain the BRET imaging efficiency while minimizing any DAR-
associated alteration to antibody PK, we therefore aimed to label CTX at DAR that closed to 5.9 
for subsequent RO assessment.  
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Plasma stability of DY605-CTX  
In order to assess the plasma stability of the DY605-CTX and DY605-IgG conjugate (DAR = 
4.6 and 5.6, respectively), we first confirmed that the residual free dye in the drug samples was 
negligible (Figure 11A, 3.6% for DY605-CTX and 3.3% for DY605-IgG). DY605 conjugated 
IgG and CTX were incubated in mouse plasma at 37°C for 5-9 days, following which their total 
fluorescent intensities were evaluated. Plasma incubation had no significant effect on the 
fluorescent intensities of either DY605-CTX or DY605-IgG conjugates (Figure 11B, p = 0.7), 
suggesting minimal fluorescence quenching. Throughout the incubation, no conjugate 
dissembling was detected in either DY605-CTX or DY605-IgG (Figure 11C). Thus, DY605-
CTX and DY605-IgG conjugates are stable in mouse plasma at body temperature over extended 
periods of time (up to 9 days).  
Development of NLuc-EGFR HEK293 xenograft 
A schematic of the study design and sampling strategy for the in vivo experiments is 
summarized in Figure 12A. Tumor sizes were monitored every other day using calipers. 
Implanted tumors exhibited exponential growth during the observation period (Figure 12B and 
Figure 13), and as expected, the normalized tumor sizes at the end of the in vivo RO study (day 
35) are significantly greater than the ones at the beginning (day 28) (p < 0.0001). During the 
study period, tumor growth was also quantified using bioluminescence at the NLuc emission 
wavelength (collected using a 500/20 nm band pass filter). The caliper-measured tumor sizes and 
the total bioluminescence photon flux at tumor area were normalized to the initial values. The 
increase in total flux was statistically significant during the study (p = 0.01), and the increase in 
NLuc luminescence closely matches the increase in overall tumor size as measured using 
calipers (p = 0.73) (Figure 12C). This close relationship between tumor size (caliper 
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measurements) and relative NLuc luminescence (imaging) is expected, given that the total 
photon flux generated is directly dependent on the number of NLuc-EGFR molecules present in 
the tumor, which is determined by number of tumor cells (tumor size). The receptor density was 
estimated using average radiance, which represents the photon flux per unit area and unit solid 
angle. The receptor densities did not change significantly over the course of this study (Figure 
12D and 12E, p =0.34). 
Measurement of RO in live mice 
      The RO assessment was initiated on day 28 and was continued until day 35, with a duration 
of 168 hours (Figure 12B – 12D). While monitoring DY605-CTX/NLuc-EGFR target 
engagement, we sought to establish the PK profile of DY605-CTX (DAR = 4.6) at multiple 
dosing paradigms: 50 mg/kg, 8.5 mg/kg, and 1.0 mg/kg. The PK curves revealed linear kinetics 
across all dosages tested (Figure 14).  As shown in Table 2, the different doses had similar dose-
normalized Cmax (255 ± 17, 303 ± 32, and 214 ± 22 L-1, for 50 mg/kg, 8.5 mg/kg, and 1.0 mg/kg 
respectively). The antibodies at 50 mg/kg and 1.0 mg/kg groups had similar dose-normalized 
AUC (3025 ± 453 and 3814 ± 513 hr/L, respectively). The antibodies at 8.5 mg/kg and 1.0 
mg/kg groups showed similar clearance (0.19 ± 0.02 and 0.25 ± 0.03 mL/hr, respectively). The 
dose-normalized AUC at 8.5 mg/kg was slightly higher than those of other two groups, but in 
general, the PK of DY605-CTX was linear within dose ranges of 1.0 – 50 mg/kg. 
     Next the RO was quantified by BRET ratios, as described in the Transparent Methods (Eqs. 5 
and 6). As expected, due to intra-tumoral heterogeneity, the BRET signal intensities were not 
homogenous across the entire tumor area (Figure 15A – 15C). In order to prevent RO 
measurement biases arising from tumor intrinsic factors (intra/inter tumoral heterogeneity), we 
quantified the average gated ROI BRET ratios across all animals in any given dosage group, 
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accounting for both intra-tumoral heterogeneity and inter-tumoral variances. The BRET signal of 
the control group (DY605-IgG) was negligible throughout the observation period (Figure 15D 
and 15E). In addition, the linear regression slope of DY605-IgG raw BRET ratios versus time 
data is not significantly different from zero (p = 0.58), suggesting negligible nonspecific 
interactions between IgG and EGFR, further highlighting the robust signal:noise ratio offered by 
our BRET-based imaging approach. Time dependent increase in BRET signal (DY605-
CTX/NLuc-EGFR binding) was observed, suggesting that most of the DY605-CTX was still in 
the vascular space immediately post administration with increasing tumor penetration and target 
engagement over time (Figure 15A – 15C and 15E). Across all doses of DY605-CTX, the 
BRET signal (and thus maximal DY605-CTX target engagement) observed gradually increased 
and peaked ~ 4 hrs post administration (Figure 15A – 15C and 15E). Times of maximal target 
engagement were consistent across all doses tested. The maximum BRET ratios observed for 50, 
8.5, and 1.0 mg/kg doses were 337 ± 123, 194 ± 76, and 77 ± 39 mBRET units, respectively 
(Table 3). 
       BRET signal arising from DY605-CTX and NLuc-EGFR interaction displayed a biphasic 
decay, with a rapid decay phase between 12 – 24 hr followed by a slower decay phase between 
24 – 168 hr, while the NLuc donor emission did not decrease over the course of the study 
(Figure 15A – 15D) Interestingly, the BRET signal of DY605-CTX exhibits a distinct decay 
profile compared to plasma clearance kinetics (Figure 14), indicating the discrete kinetics 
between plasma concentrations and target binding in solid tumors. Similar terminal slopes (𝜆Z) of 
BRET profiles for the different doses were observed, 𝜆Z = 0.011 ± 0.002, 0.013 ± 0.006, and 
0.010 ± 0.011 for 50, 8.5, and 1.0 mg/kg groups respectively. The BRET ratios for 1.0 mg/kg 
dose group decayed to levels comparable to IgG controls at 48 hr post-injection (p = 0.23). We 
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also calculated the AUC of BRET ratios (BRET integral) and found that total AUCBRET does not 
increase in a dose-proportionally manner. A trend of AUCBRET saturation is observed (Table 3). 
      The RO was determined by dividing the BRET ratios at each time point by the average of the 
five highest BRET ratios observed throughout the study (Eq. 6 - see Transparent Methods). All 
five highest BRET ratios were observed in 50 mg/kg dose group, either at 4 hr or 12 hr post 
injection. As shown in Figure 15F, the ROs of three groups showed a trend similar to the BRET 
versus time curve (Figure 15F vs. 15E). The maximum average ROs were 72 ± 26, 41 ± 14, and 
18 ± 6.0% at doses of 50, 8.5, and 1.0 mg/kg, respectively (Table 3), suggesting fractional target 
accessibility. Similar to the AUCBRET, the AUCRO did not increase in a dose-proportional 
manner. The dose-normalized AUCRO were 612 ± 197, 2304 ± 674, and 6417 ± 2600 %·hr/nmol 
for doses of 50, 8.5, and 1.0 mg/kg, respectively. Consistent with target binding versus time 
curves (Figure 15E), the RO curves declined in a biphasic manner even though the plasma 
concentrations declined in a nearly mono-exponential manner between the 12 – 168 hr. A strong 
kinetics discrepancy was suggested between the systemic PK and RO in tumors. 
Dose –exposure – RO relationships 
The relationships between the dose and system exposure and between the system exposure 
and tumor RO were investigated. As shown in Table 2, DY605-CTX exhibited linear PK in the 
studied dose ranges (1.0 – 50 mg/kg), which was consistent with the dose – AUCPK plot, as 
shown in Figure 16A. A nonlinear relationship was observed between the AUCRO and the 
AUCPK (Figure 16B), indicating the discontinuity between systemic exposure and specific RO at 
tumor sites. The point-to-point relationships between the RO and drug plasma concentrations 
were described by hysteresis loops (Figure 16C), suggesting that the tumor ROs were not 
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synchronized with plasma concentrations with a significant delay (several hours) existing 
between peak plasma concentration and maximal tumor RO.  
2.5 Discussion 
Target engagement is a critical factor for the successful development of therapeutic 
antibodies, yet direct evidence of antibody-target interactions can be difficult to reproducibly 
achieve in vivo [226]. Many state-of-the-art tools have been applied to quantify RO. In FCM 
assays, RO is assessed by probing the ligand and/or receptors on circulating cells to provide 
evidence of sufficient target engagement. Despite its high sensitivity when assessing RO on 
circulating cells, FCM is not an ideal approach to assess RO in solid tumors. Solid tumors are 
highly heterogeneous, and the homogenization procedures required for FCM analysis disrupt 
tumor integrity, cause a loss of intra-tumoral spatial resolution, and compromise the overall 
accuracy of RO quantification if applied to solid tumors [227]. Additionally, the current methods 
immunohistochemistry and FCM for antibody target engagement in solid tumors require invasive 
procedures to obtain the necessary tissue biopsies. In this regard non-invasive whole animal 
imaging approaches provide significant advantages in assessing the antibody-target interactions. 
However, commonly used displacement approaches for non-invasive RO assessment, in which 
small doses of radiotracer are replaced by increasing doses of unlabeled antibodies, are often 
complicated by cellular endocytosis and local turnover of the radiotracer. Non-invasive imaging 
approaches based on fluorescence are limited by high autofluorescence and fluorescence 
quenching [227]. One common drawback of these imaging approaches is the lack of a signal 
specificity towards direct target engagement, which means that these imaging approaches cannot 
distinguish the signals of bound antibodies from those of free ones sequestered in the tissue of 
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interest, or those bound non-specifically to non-target cells (endothelial, stromal or other tumor 
associated cell types), resulting in a poor estimation of RO [53,195,201,202].  
In the present study, we developed a BRET system that directly visualizes antibody-target 
interactions in live animals. In this BRET system, the bound DY605-CTX is triggered by 
substrate-dependent activation of NLuc (fused to EGFR), whereby any BRET emission reflects 
direct CTX-EGFR binding (Figure 7). Compared to conventional fluorescent imaging methods, 
the designed BRET method does not need external excitation light; thus, the disadvantages of 
autofluorescence are avoided while a high signal-to-noise ratio is promised. Despite limited 
spectrum overlap between NLuc emission (460 nm) and DY605 excitation (600 nm) (Figure 8), 
the high quantum output of NLuc is sufficient for triggering robust BRET [128,210,223]. The long 
Stokes shift (165 nm) between DY605 emission peak (625 nm) and NLuc emission peak (460 
nm) ensures robust spectral separation and enables the reliable detection of both the NLuc and 
the DY605 emission peaks. Mostly importantly, this BRET based approach can be used to 
provide a direct measurement of antibody-target interaction in live animals. This observed BRET 
signal represents a real-time quantification of antibody-target complex. Thus, since the derived 
RO is interpretable to several key physiologically relevant variables, such as antibody-antigen 
binding, antibody-antigen complex internalization, target turnover, and potential antibody-
mediated trogo- or phago-cytosis, RO measured by this approach could be used to directly 
compare the in vivo target engagement and therapeutic efficacy of different ligands for a given 
receptor [228]. 
As expected, a temporal delay was observed between plasma concentrations of an antibody 
and its RO to the targets in tumors. The binding peaked in three DY605-CTX groups at about the 
same time after dosing (Figure 15A – C, E), which suggested that the delay between systemic 
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exposure and binding in the tumors was likely caused by a slow but linear diffusion process. 
Interestingly, this observation is inconsistent with the previous studies, which indicated dose-
dependent tumor penetration [229,230]. The reason for this inconsistency is unclear, but it might 
be associated with the quantification methods used in the present study, or the relatively uniform 
vascularization in our xenograft models, evidenced by the lack of distribution-void necrotic area. 
High vascularization does not necessarily mean a full RO. As a matter of fact, only about 70 – 
80% of RO was achieved at the highest dose in the present study (Table 3). The fractional target 
binding could be caused by a mechanism called “binding site barrier”[231], which describes that 
the antibody-antigen complexes in the immediate proximity of blood vessels significantly 
decrease the penetration of free antibodies into deeper tumor tissue. 
      Interestingly, the CTX-EGFR binding in the present study exhibited a biphasic decline after 
peaking (12 – 168 hrs), while the PK was largely mono-exponential within the same observation 
period. This is in contrast to the linear decline of pharmacodynamics in Levy’s “direct effect 
model” [232]. The kinetic disassociation between antibody system exposure and target binding at 
tumor sites well supports our notion that plasma kinetics is not reflective to RO for antibodies 
that have targets in peripheral tissues [22,23,86]. In addition, the target engagement level (AUCRO) 
did not increase in a dose-proportional fashion (Figure 16B). Comparing doses at 8.5 mg/kg and 
50 mg/kg, the average AUCRO increased approximately two-fold. This non-dose-proportional 
increase of the AUCRO and the average ROmax may be explained by the fractional target 
accessibility. Although the receptors were highly expressed in our system, as shown in in vitro 
results (Figure 9A and 9B), only a fraction of receptors were “accessible” to the antibodies, 
leading to a fractional RO, which was consistent with a previous study [233], in which a high 
 
 47  
dose of panitumumab was assessed in A431-derived xenografts and only a small fraction of 
EGFR was occupied. 
      Overall, the present study provides a novel paradigm for selectively and directly monitoring 
of antibody target engagement in live animals using a non-invasive approach. The non-invasive 
imaging technique described in this study could be utilized to establish solid tumor dose-RO-
response relationships of mAbs that are critical in evaluating their therapeutic efficacies and 
support further exploration of the factors that affect mAb efficacy and toxicity. 
Although the developed approach demonstrated feasibility in directly assessing RO in live 
animals, the approach has several technical limitations. First, we used the average of the five 
highest BRET signals to define 100% RO. Because of the lack of in vivo calibration curves, all 
derived ROs in the study are relative values rather than absolute quantifications. While a true 
‘100% RO’ measurement cannot be quantified, the BRET based system described herein 
provides a rapid and cost-effective way to evaluate ‘saturating RO’ concentrations/dosing for any 
given drug-target pair in live animals in a temporally trackable format. Second, although the long 
Stokes shift (165 nm) limited the signal leakage from NLuc emission to DY605 emission, the 
background of the in vivo BRET measurement, that is the BRET ratios of DY605-IgG, was not 
zero. The highest signal-to-noise ratio observed in the quantified BRET ratio was approximately 
4.2. This ~ 20% background impaired the sensitivity of the RO assessment. Third, BRET ratios 
were quantified with inherent, protocol constrained biases because of the restrictions on signal 
decay and filter settings. Due to the intrinsic limitations of the imaging system, images at 500 nm 
and 620 nm could not be acquired simultaneously. Because of signal decay, the measurements at 
500 nm were lower than the maximum potential peak value. In addition, the NLuc emission (460 
nm) was collected using a non-optimal 500/20 nm bandpass filter, leading to an underestimation 
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of donor emission signals. Fourth, the complex mixture of tumor and stroma cells in a given 
tumor microenvironment may further influence the BRET signals that can be achieved. Even 
though a non-homogenous cell distribution (as evidenced by a non-homogenous NLuc signal)  in 
HEK293 xenograft (Figure 12E, 15A – C) was observed, it may fail to capture the 
microenvironment present in ‘real’ tumors which may contain  strong stromal and/or immune 
components. Therefore, further evaluations of our approach in representative tumor models are 
warranted. 
While we acknowledge that these results are incremental in nature, our proof-of-concept 
study represents an extended use of BRET based strategies towards mAb-target interactions, 
demonstrating the mAb-dye conjugates retain the mAb pharmacokinetic features and the binding 
specificity and affinity to mAb’s cognate antigens. Those features made BRET based imaging 
methods amenable to determine both spatial and temporal kinetics of mAb-target interactions. 
While the study by Alcobia et al demonstrated that small molecule (ligands) can be labelled and 
utilized for BRET visualization, we demonstrate that this approach can be extended to mAbs, 
further bolstering their initial finding and extending the utility and applicability of BRET-based 
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Figure 6: Overview of NanoLuc-EGFR plasmid and selection scheme for generating the stable NanoLuc- 
EGFR HEK293 cells 
(A) The NanoLuc-EGFR plasmid was a kind gift from Promega. NanoLuc was expressed at the N-terminus of 
EGFR by linking NanoLuc gene to the full-length human EGFR gene by 15GS linker. CMV promoter was designed 
for target gene (NanoLuc-EGFR sequences) and SV40 promoter was for Kan/Neo resistance gene. The size of the 
plasmid was 8429 bp. (B) The NanoLuc-EGFR HEK293 cells selection scheme. Transfection of SigNL-EGFR 
plasmid was conducted using LipofectamineTM 3000 Transfection Reagent according to the manufacturer’s protocol. 
Selection of stably transfected HEK293 cells expressing NanoLuc-EGFR was performed with 1000 µg/mL 
geneticin. Single cell colonies with the highest expression of reporter protein were selected by measuring NanoLuc 
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Figure 7: Schematic of the NanoLuc-EGFR/DY605-cetuximab BRET system. 
NanoLuc (a 19 kDa luciferase), was fused to the N-terminus of the epidermal growth factor receptor (EGFR) 
extracellular domain to generate the BRET donor moiety. A fluorescent dye, DY605, was covalently appended onto 
cetuximab to generate the BRET acceptor moiety. (A) In the absence of DY605-cetuximab binding, only the 
NanoLuc-EGFR fusion donor emission at 460 nm was detected upon addition of the substrate (furimazine), since the 
distance between unbound acceptor and donor moieties is too large to trigger BRET. (B) In the presence DY605-
cetuximab and upon its target engagement with the NanoLuc-EGFR fusion, furimazine administration generates two 
distinct emission peaks, at 460nm (NanoLuc) and at 625nm, the latter arising from DY605-cetuximab as a result of 
the robust BRET between NanoLuc and DY605, now brought into close proximity by the NanoLuc-EGFR:DY605-
cetuximab interaction. Donor (at 460nm) and acceptor (at 625nm) emission peaks are ~165nm apart ensuring robust 
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Figure 9: Generation and characterization of stable NanoLuc-EGFR HEK293 cells. 
(A) Under identical conditions, the BRET donor (NanoLuc) bioluminescent signal of NanoLuc-EGFR HEK293 
stable cells was ~10,000 fold higher compared to wild type HEK293 cells (two tailed, unpaired Students t test, p < 
0.0001). (B) EGFR fusion expression levels were probed using DY605-cetuximab and found to be ~5-fold higher in 
the NanoLuc-EGFR stable cells compared to wild type HEK293 cells (two tailed, unpaired Students t test, p < 
0.0001). For both panel (A) and (B), representative results are shown. Each data point represents one technical 
replicate. Error bars represent ±SD values. At least three independent biologic replicates were performed per 
experiment. (C) BRET activity from the NanoLuc-EGFR/DY605-cetuximab system is concentration-dependent (KD 
= 0.1 ± 0.01 nM, Bmax = 9.9 ± 0.24 mBRET units). No BRET was observed for the DY605-IgG control indicating 
negligible non-specific binding. Moreover, DY605-cetuximab binding to NanoLuc-EGFR is highly specific since no 
BRET signal was detected in the group containing DY605-cetuximab + unlabeled cetuximab (1 mM) due to the 
competition for the same EGFR domain. Each data point represents the mean value of three technical replicates. 
Data are presented as mean ± SD. The experimental results are representative of at least three biologic replicates. 









Figure 10: Evaluating the effects of dye-antibody ratios (DAR) on in vitro binding affinity and in vivo  
pharmacokinetics. 
(A) The binding affinities of DY605-cetuximab to NanoLuc-EGFR at various dye per antibody ratios (DARs) = 1.6, 
5.9, and 13 were similar (0.15 ± 0.04, 0.12 ± 0.03, and 0.12 ± 0.03, respectively), while the maximum BRET signals 
increased (4.8 ± 0.3, 13.4 ± 0.6, and 15.6 ± 0.8, respectively). (B) High DAR is correlated with increased DY605-
cetuximab clearance in vivo. Plasma concentrations were normalized to initial concentrations. Plasma concentrations 
below the detection limits were noted as BDL. For both panel (A) and (B), each data point represents the mean value 
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Figure 11: Stability of DY605-cetuximab and DY605-IgG in mouse plasma  
(A) The residual free dye percent in DY605-cetuximab (3.6%) and DY605-IgG (3.3%) stock solution was 
determined by SDS-PAGE. The fluorescent intensities of the bands were quantified by ImageJ. (B) Total 
fluorescence of DY605-cetuximab and DY605-IgG mixture did not change during the incubation. The total 
fluorescence intensities of incubated conjugates-plasma solutions were normalized to the ones at day 1. The trend of 
total fluorescence was evaluated by testing the null hypothesis that “the slope of linear regression of the dataset was 
significantly non-zero”, which was rejected by a p value of 0.7. (C) No detectable conjugate dissembling was found 
in the DY605-cetuximab or the DY605-IgG throughout incubation. The ROI signal intensities of the free dye were 
normalized to the signal intensities of antibody-dye conjugates with the same incubation time. IgG = human IgG. 
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Figure 12: In vivo characterization of NanoLuc-EGFR tumor growth kinetics 
(A) Schematic overview of the tumor inoculation, drug conjugate administration, IVIS bioluminescent imaging, and 
blood sample collection for animals administered DY605-antibody conjugates. Red arrow: tail vein injections of 
either DY605-cetuximab or DY605-IgG (control); Blue arrows: tail vein injections of the NanoLuc substrate 
(furimazine); Black arrows: imaging acquirements and blood sample collections. (B) Tumor growth curve from the 
day that the tumor was inoculated (day 0) to day 35. The caliper-measured tumor sizes were normalized to the first-
observed tumor volumes and fitted to the exponential growth curve. Normalized tumor volumes at day 28 and day 
35 were compared using a two tailed, unpaired Student’s t tests. ****: p £ 0.0001. (C) Tumor total photon flux at 
500 ± 20 nm (NanoLuc emission) relative to caliper-measured tumor growth were normalized to the initial 
measurements at the first day of in vivo receptor occupancy (RO) study (day 28). The trends of the normalized 
tumor-NanoLuc total photon flux and the normalized tumor volumes, measured by calipers, were compared using a 
null hypothesis, “the slopes of the linear regressions are same for all datasets”.  The null hypothesis was rejected by 
a p value of 0.736. (D) The NanoLuc-EGFR tumor densities were estimated using normalized tumor average 
radiances. The trend of average radiances was evaluated by testing the null hypothesis that “the slope of linear 
regression of the dataset was significantly non-zero”, which was rejected by a p value of 0.34. During the in vivo RO 
detection phase of the study, NanoLuc-EGFR densities did not change significantly. For panels (B) – (D), the RO 
detection phase of this in vivo study is highlighted by the green area (day 28 to day 35, 0 – 168 hr post dosing). All 
the animals (n = 19) were included in the tumor size, tumor area total flux, and average radiance analysis. Each data 
point represents the mean value of the tumor size, tumor area total flux, and average radiance of 19 individuals at the 
same time point. Data are presented as mean ± SD. (E) Representative images of the tumor NanoLuc-EGFR 
densities (radiance intensity) measured throughout the in vivo RO phase of the study.  
  
 




Figure 13: Caliper measurements quantifying tumor growth of NanoLuc-EGFR HEK293 xenografts 
Subcutaneous inoculation was performed on day 0. Palpable tumors were observed by day 8 – 13. The in vivo 
receptor occupancy detection phase was day 28 – 35, as denoted by green shadow. The tumor sizes at the end of in 
vivo RO detection study were significantly greater that the beginning of the study (two tailed, unpaired Students t 
test, p < 0.0001). The tumor growth was fitted to an exponential growth curve (R2 = 0.32). Each data point 
represents the mean tumor size of 2 – 19 subjects. Error bars represent ±SD.  
 




Figure 14. Establishing DY605-cetuximab pharmacokinetics in vivo.  
Profiles of mean (± SD) plasma concentrations versus time after a single tail-vein injection of 1.0 (LD), 8.5 (MD), 
and 50 (HD) mg/kg DY605-cetuximab or 1.9 mg/kg DY605-IgG (control) in tumor-bearing animals. The decay 
phases of DY605-cetuximab and DY605-IgG PK curves exhibited a similar trend. Plasma concentrations of 50 
mg/kg and 8.5 mg/kg groups were below detection limits at the 144 hr, whereas the plasma concentration of the 
1mg/kg group fell below detection limits at the 120 hr. The detection limits are 15, 5, 0.7, 3 nM for HD, MD, LD, 
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Figure 15. DY605-cetuximab/NanoLuc-EGFR receptor occupancy (RO) measurement in vivo.  
(A) BRET images (at 620 nm) of mice that received 50 mg/kg (HD) of DY605-cetuximab. The BRET measurement 
of HD group at 6 hr post administration was absent due to a problem in data collection. (B) BRET images (at 620 
nm) of mice that received 8.5 mg/kg (MD) of DY605-cetuximab. (C) BRET images (at 620 nm) of mice that 
received 1.0 mg/kg (LD) of DY605-cetuximab. (D) BRET images (at 620 nm) of control group mice. The mice in 
control group received 1.9 mg/kg of DY605-IgG. DY605-IgG showed no binding with NLuc-EGFR during the 
study. For panels (A) – (D), the representative NanoLuc images (at 500 nm) of each dose group at day 1 (the first 
day of in vivo RO study) and day 7 (the last day of in vivo RO study) were showed at right. (E) Quantified 
NanoLuc-EGFR/DY605-cetuximab binding for the 1.0 mg/kg (LD), 8.5 mg/kg (MD), and 50 mg/kg (HD) groups 
and 1.9 mg/kg DY605-IgG (control). For HD, MD, and LD groups, the bindings peaked at about 4 - 12 hrs and 
experienced biphasic decay after 12 hrs post injection. No binding was observed for DY605-IgG. (F) Quantified RO 
in live mice. Quantification of DY605-CTX RO revealed a maximum average RO for the HD, MD, and LD groups 
of 72 ± 26, 41 ± 14, and 18 ± 6 %, respectively. For (E) and (F), each data point represents the mean value of at least 
15 unique ROIs  (n= 2-6 per mice). Error bars represent the ±SD. The difference in RO across groups was evaluated 
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Figure 16. Direct assessment of dose-exposure-receptor occupancy (RO) relationships.  
(A) Drug conjugate doses and plasma exposure (AUCPK) exhibited a linear relationship (R2= 0.94). (B) AUCPK and 
the area under the curve of RO (AUCRO) showed a sigmodal relationship, suggesting a discontinuity between system 
exposure and RO in the tumor. For panel (A) and (B), each data point represents the mean of AUCPK or AUCRO values 
(n = 5). Error bars represent ±SD. The linear trends between AUCPK and dose and between AUCRO and AUCPK were 
evaluated by nonlinear regression. (C) Relationships between RO and plasma concentrations. Hysteresis loops were 
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CHAPTER 3 




Antibodies have become an attractive class of therapeutic agents for solid tumors, mainly 
because of their high target selectivity and affinity. The target binding properties of antibodies 
are critical for their efficacy and toxicity. Our lab has developed a bioluminescence resonance 
energy transfer (BRET) imaging approach that directly supports the measurement of the binding 
dynamics between antibodies and their targets in the native tumor environment. In the present 
study, we developed a spatially resolved computational model analyzing the longitudinal BRET 
imaging data of antibody–target binding and exploring the mechanisms of biphasic binding 
dynamics between a model antibody cetuximab and its target, the epidermal growth factor 
receptor (EGFR). The model suggested that cetuximab is bound differently to EGFR in the 
stroma-rich area than in stroma-poor regions, which was confirmed by immunofluorescence 
staining. Compared to the binding in vitro, cetuximab bound to EGFR to a “slower-but-tighter” 
degree in the living tumors. These findings have provided spatially resolved characterizations of 
antibody–target binding in living tumors and have yielded many mechanistic insights into the 
factors that affect antibody interactions with its targets and treatment efficacy.     
                                               
3 This chapter has been adapted from the paper published in the Scientific Reports. The original citation is 
Tang, Y.; Cao, Y. Modeling the dynamics of antibody-target binding in living tumors. Sci Rep 2020, 10, 
16764, doi:10.1038/s41598-020-73711-y. 
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3.2 Introduction 
The therapeutic antibody is an important class of therapeutics for treating solid tumors. More 
than 30 therapeutic antibodies have been approved for treating tumors at various stages [181,234]. 
These broad applications of therapeutic antibodies in solid tumors are largely due to their high 
target binding selectivity and affinity compared with traditional cytotoxic agents. Once bound to 
their targets, therapeutic antibodies eradicate tumor cells mainly by three mechanisms: blocking 
the pathogenic ligand-receptor interactions, triggering cell apoptosis pathways, or activating host 
effector functions [34]. The mechanisms of action are not exclusive but usually differ depending 
on the design of the different classes of antibodies.  
Regardless of the mode of antibody action, antibody-target engagement is the first and most 
critical step for antibody efficacy. The patterns of target binding are often associated with the 
cellular response of the target cells and treatment efficacy. Many studies have revealed that 
tumor cells can receive information by altering the temporal behavior (dynamics) of their 
signaling molecules [235,236]. A classic example of this behavior is the extracellular signal-
regulated kinase pathway for the epidermal growth factor receptor (EGFR). Transient activation 
(or blocking) of EGFR is associated with tumor cell proliferation, whereas sustained activation 
can lead to cell differentiation [237]. In addition, once antibodies have bound to their target cells, 
they can direct effector cells to elicit antibody-dependent cellular cytotoxicity (ADCC). Thus, the 
residence time of the antibody-target complex on tumor cells (determined by the off-rate) 
becomes critical for increasing lipid raft formation and the probability of ADCC [238,239]. Many 
tumor cells can initiate fast endocytosis upon antibody binding, leading to resistance to antibody 
attack [240-242]. Therefore, different target binding patterns can lead to distinct cellular reactions 
and treatment responses.  
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The target binding affinity is often assessed in vitro, using either surface plasmon resonance 
(SPR) or ligand competition assays. In SPR analysis, the antibody binds to target molecules that 
are immobilized on the sensing layer. Binding leads to changes in conformation and the angle of 
reflectivity, from which the association (kon) and dissociation (koff) can be quantified [243]. As in 
other routinely applied technologies that measure binding dynamics, the kon and koff that are 
determined by SPR merely reflect antibody–target interactions at the molecular level. These 
techniques are valuable for antibody screening, but they are not relevant to binding under 
physiological conditions. The target binding properties in living systems remain largely 
uncharacterized. 
Tumor tissues are known to be very heterogeneous, both between and within tumors. In 
addition to complex tumor genotypes, morphological and phenotypic features can differ, even 
within the same tumor. The stromal environment where each tumor cell resides largely shapes its 
phenotypic properties [244]. However, how these stromal components can influence the binding 
dynamics between an antibody and its targets remains largely undefined. Unlike in vitro assay 
systems, where all targets are freely accessible, tumors present many physical barriers that 
influence the diffusion of antibodies, as well as their interactions with the targets [71]. Previous 
studies have shown that antibodies are unable to freely reach their targets or cannot drift away 
after dissociating from the targets in the presence of spatial obstacles [245]. The resulting shifts in 
binding dynamics within living tumors can reduce the cellular response or even lead to treatment 
failure. 
We have developed a bioluminescence resonance energy transfer (BRET) imaging system 
that can directly monitor the antibody–target binding dynamics in living systems[129]. This 
imaging system leverages a high signal-to-noise ratio and stringent energy donor-acceptor 
distance to provide specific measurements of antibody–target binding dynamics in a selective 
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and temporal fashion. It is a minimally invasive system, enabling longitudinal monitoring of in 
vivo antibody–target interactions. We have previously used this approach to demonstrate that 
cetuximab binds to its target, EGFR, in a biphasic and dose-shifted manner. In the present study, 
we have developed spatially resolved computational models for the analysis of the longitudinal 
imaging data of antibody–target binding in living tumors, and we have compared their binding 
dynamics in spatially distinct tumor areas. With these models, we have assessed possible 
mechanisms that could explain the biphasic features of cetuximab–EGFR binding in a xenograft 
tumor. The results of this study have provided many insights into the dynamic features of 
antibody–target binding in living tumors and the stroma factors that potentially influence those 
dynamics.    
3.3 Materials and Methods 
Study Design 
Our lab has developed a BRET approach to support the investigations of antibody–target 
binding dynamics in the native tumor environment. Specifically, a small but bright luciferase, 
NanoLuc, was fused to the extracellular domain of EGFR to serve as the energy donor in the 
BRET pair [129]. An anti-EGFR antibody, cetuximab, was labeled with DY605, a fluorophore 
with an emission wavelength at 625 nm, to serve as the energy acceptor. Prior to the binding 
between DY605-labeled cetuximab (DY605-CTX) and the NanoLuc-fused EGFR (NLuc-
EGFR), the distance of NanoLuc to the DY605 was too large to trigger BRET, and only the 
bioluminescence emission at 460 nm for NanoLuc was observed. However, binding of DY605-
CTX to NLuc-EGFR increased the proximity between NanoLuc and DY605 and allowed the 
transfer of bioluminescence energy to DY605 and the emission of fluorescence signals at 625 nm 
(Figure 17). The binding affinity between DY605-CTX and NanoLuc-EGFR was 0.10 nM, 
which is in agreement with previously reported KD for CTX-EGFR binding (0.20 nM) (Figure 
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17) [246]. The kon of DY605-CTX: NanoLuc-EGFR binding was about 0.20 nM-1min-1 and the 
koff was 0.02 min-1 (Figure 18), which are close to the constants of CTX-EGFR binding 
measured by SPR[247]. The DY605-CTX: NanoLuc-EGFR BRET pair allowed robust and 
reliable quantification of CTX-EGFR interaction. 
The experimental design is shown in Figure 17. In total, 20 nude mice were inoculated with 
NLuc-EGFR-expressing HEK293 cells. To establish tumor models, 5 × 106 NLuc-EGFR 
HEK293 cells were suspended in 0.1 mL of PBS/ Matrigel (1/1, v/v) and inoculated 
subcutaneously into the inguinal flank of the nude mice. The BRET imaging study was 
performed when the tumor sizes had reached 500 mm3. The imaging study was initiated by 
injecting the DY605-labeled cetuximab via the tail vein of the xenograft mice at three doses: 1.0, 
8.5, and 50 mg/kg (n = 5 /dose group), or DY605-labeled human IgG (n = 5).  Blood samples (30 
µL) were collected at the designated times for pharmacokinetics (PK) assessment. The plasma 
concentrations of cetuximab were quantified based on fluorescent intensities. Images at both 460 
nm and 625 nm were acquired using an IVIS Kinetic optical imaging system (Caliper Life 
Sciences, Alameda, CA, USA) upon administration of NanoLuc substrate furimazine (i.v., 0.25 
mg/kg). The fluorescence intensity was determined to quantify the concentrations of the 
antibody–target complex, and the receptor occupancy (RO) was calculated (Figure 19).  
The tumors were collected at the end of the study (at approximately 192 h) and snap-frozen 
in liquid nitrogen.  
Plasma PK model 
The antibody plasma PK was described using a two-compartment model with a linear tissue 
distribution (CLD) and a linear systemic clearance (CLP) (Figure 20). The PK data in three dose 
groups (1.0, 8.5, and 50 mg/kg) were analyzed simultaneously using the PK model, using a naïve 
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pooled-data (NPD) approach. The volume of plasma (Vplasma) was set to 0.001 L for 20 g mice 
[24].  
Modeling antibody-target binding dynamics in tumors 
The dynamics of antibody–target binding in solid tumors were further characterized to obtain 
mechanistic insights by implementing a sequential modeling strategy. Here, the PK model was 
first optimized and then fixed during the second step to explore the antibody–target binding 
dynamics.  
The solid tumors were conceptually dissected into two anatomical compartments: a stroma-
rich and a stroma-poor area, to account for the spatial histological heterogeneity (Figure 20). 
The stromal-rich compartment described the area where tumor cells grew relatively quickly, 
without any spatial restriction by stromal cells. By contrast, the stroma-poor tumor compartment 
represented the area where tumor cells grew in the presence of dense tumor-associated stromal 
cells (e.g., fibroblasts). The relative volume and blood flow in the two tumor areas were 
evaluated as model parameters.  
The extravasation of the antibody from the tumor blood vessels to the interstitial space was 
assumed to be dominated by convection and was described by a vascular reflection coefficient 
(σK) and the convective lymph flow into either the stroma-rich area (Lr) or the stroma-poor area 
(Lp). The value of σK was set at 0.78, a value reported for subcutaneous xenograft models [24]. 
The values of Lp and Lr were functions of the tumor blood flow (TBF) [248], the total tumor 
volume (Vtumor), and the relative fraction between the two tumor areas (ft), as described in the 
following equations: 
L- = ((1 − f0) ∙ V0=;,- ∙ TBF-) ∙ fD 
LU = (f0 ∙ V0=;,- ∙ TBFU) ∙ fD 
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where TBFp and TBFr describe the tumor blood flows in two tumor areas. The value of fL was set 
to 0.2% [249]. The total tumor volumes (Vtumor) were measured using a caliper.  
The spaces for antibody distribution and for antibody–target interaction in both tumor 
compartments were set to a fraction (fav) of the total interstitial space. 
V-_4 = (1 − f0) ∙ V0=;,- ∙ f1EW ∙ f4K 
VU_4 = f0 ∙ V0=;,- ∙ f1EW ∙ f4K  
The available fraction fav was set at 27.5% [24,250]. Notably, the antibody–antigen bindings 
occurred in the same space that was accessible to antibodies (Vr_a and Vp_a). The target (i.e., 
EGFR) was assumed to be synthesized by tumor cells at a zero-order rate constant (ksyn) and to 
be endocytosed at a first-order rate constant (kdeg). The cetuximab-EGFR complex was assumed 
to be internalized by the tumor cells at a first-order rate constant (kint). All parameters regarding 
the target protein (ksyn, kdeg, and kint) were assumed to be conserved inside the tumors. The 
association rate between the antibody and target is denoted as kon and the dissociation rate 
constant is koff.  
We used the developed modeling framework primarily to investigate two competing 
hypotheses: (1) the antibodies bind to the targets differentially across two tumor areas (the 
heterogeneous binding model, HBM) and (2) the antibodies are distributed differentially into two 
tumor areas, but with the same binding profile (the heterogeneous distribution model, HDM). 
The differential equations for both models are provided in Figure 19. We optimized both models 
against the data and evaluated which model made more consistent predictions to the observed 
RO data. The selection of the most suitable model and the parameter estimates were confirmed 
by visual inspection, the measured data vs. individual conditional model prediction plot, the 
individual conditional standardized residual vs. model prediction plot, the individual conditional 
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standardized residual vs. time plot, the CV% of estimated parameters, and the physiological 
plausibility of the estimated parameters.  
Immunofluorescence (IF) staining 
We assessed the spatial distributions of the antibody in tumors by IF staining after the 
imaging study. The tumor samples were preserved and sliced in OCT medium (Fisher scientific, 
Waltham, MA, USA). The sliced tumor tissues were fixed in methanol/acetone (1:1) at 4°C. 
After blocking with phosphate buffered saline (PBS) containing 2% fetal bovine serum (FBS) 
(Millipore Sigma, Burlington, MA, USA;), the tumor slices were stained with anti-EGFR and 
anti-α-SMA antibodies. In brief, the slides were incubated with Alexa Fluor 555-conjugated 
primary rabbit anti-human EGFR antibodies (Thermo, Waltham, MA, USA, 1:1000 diluted in 
PBS) and primary mouse anti-mouse α-SMA antibodies (Thermo, Waltham, MA, USA, 1:1000 
diluted in PBS) at 4°C overnight and then incubated with Alexa Fluor 555-conjugated goat anti-
mouse antibodies (Thermo, Waltham, MA, USA, 1:1000 diluted in PBS) at room temperature for 
1 h. The immunofluorescence images were acquired with a Live Cell Imaging Microscope 
(Nikon, Melville, NY, USA). 
Model simulation 
The developed model was applied to simulate the profiles of antibody–target binding 
dynamics and the resultant RO at different conditions. The concentrations of free antibodies, free 
targets, and antibody–target complexes in both tumor areas were simulated and compared. In 
addition, the SPR-measured binding parameters were applied to replace the optimized 
parameters to allow an examination of differences in antibody–EGFR binding dynamics in the 
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Sensitivity Analysis 
The sensitivity of model to parameters was evaluated by a local sensitivity analysis of the 
final model and parameters. All of the 8 estimated parameters (kdeg, R0, kon, koff_p, koff_r, ft, TBF, 
and kint) were included in the sensitivity analysis. Area under in vivo RO curve (AUCRO) at three 
doses (50 mg/kg, 8.5 mg/kg, and 1.0 mg/kg) was chosen as relevant model output and the 
percentage change in AUCRO was selected as local sensitivity indices. The percentage change in 




	 ∙ 100 
Where 𝐴𝑈𝐶cde represents the AUC obtained with the optimized parameter set and 𝐴𝑈𝐶±f'% 
refers to the AUC obtained following a 50% increase or decrease in a single parameter value.  
Association kinetic assay of the DY605-CTX: NanoLuc-EGFR BRET pair 
HEK293 cells stably expressing NanoLuc-EGFR were seeded 24 hours prior to the 
experimentation at 20,000 cells/well on white 96-well opaque plates and incubated at 37℃/5% 
CO2. NanoLuc substrate furimazine was added 5 mins prior to the experiment. DY605-CTX 
(Dye per antibody ratio [DAR] = 4.6) or DY605-IgG (DAR = 5.6) were added to reach the final 
concentrations at 1, 3, 6, 12, and 25 nM.  The data collection and quantification were described 
in our previous study [129]. The BRET ratios were calculated every 4 mins for up to 25 mins. 
3.4 Results 
Plasma PK and antibody–target binding dynamics in tumors 
In this study, DY605-CTX showed bi-exponential and linear PK profiles [129], as the area 
under the curve (AUC) and the peak plasma concentrations increased proportionally to the doses. 
A temporal shift was observed from the antibody plasma PK to the ROs in the tumors. The tumor 
ROs peaked at approximately 4 h post-dosing, which was consistent across doses, suggesting 
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that the extravasation of DY605-CTX into tumors is a slow and linear process. The increase in 
the tumor ROs was less than dose proportional, indicating a nonlinear process was involved in 
the conversion of free antibodies in the plasma to bound antibodies in tumors. Notably, the target 
EGFR in the tumors was not saturated, even at a supra-therapeutic antibody dose (50 mg/kg), 
suggesting fractional target accessibility. Furthermore, the RO profiles declined in a biphasic 
manner and showed a shallow terminal declining phase, particularly at the two higher doses. 
Interestingly, the transition from the rapid to the slowly declining phases was not consistent 
across doses.  
The antibody–target binding profiles in tumors were well recapitulated by the HBM  
The average plasma concentrations and tumor ROs were used for model competition. As 
shown in Figure 21A, the two-compartment PK model adequately recapitulated the PK profiles 
at all doses. This confirms the linear PK properties of DY605-CTX in xenograft mice within the 
assessed dose range. The estimated PK parameters and CV% are shown in Table 4. The 
estimated systemic clearance and volume of tissue distribution were consistent with those of 
previous reports. 
The tumor RO profiles were well characterized by the HBM at all three doses (Figure 21B 
and 22A). The model suggested different antibody–target binding dynamics across two tumor 
spatial areas. The optimized parameters are shown in Table 5. The association rates (i.e., kon) 
between cetuximab and its target EGFR in both tumor compartments were estimated to be close 
and were therefore considered as a shared parameter in the two tumor compartments. The 
estimate of kon was 0.03 nM-1∙h-1, a value approximately 1% of the rate measured using SPR  
[247], indicating the impact of physical barriers on the association rate in the living tumors 
compared to the in vitro buffer conditions. Interestingly, the complex dissociation rate (i.e., koff_p 
and koff_r) was markedly different between the two tumor areas. The optimized koff_p was 0.61 h-1 
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in the stroma-poor tumor area, which is close to the SPR measured values. However, the 
complex dissociation rate was estimated as much slower (koff_r = 0.0017 h-1) in the stroma-rich 
tumor area [247]. The estimated endocytosis rate (kint in Table 2) revealed the net endocytosis rate 
of EGFR antigen after subtracting the fraction of recycling, which explains the relatively slower 
endocytosis rate estimated in our model compared to literature values [251].  
Notably, HBM elucidated the heterogeneous binding in living tumors in a robust and 
physiologically-relevant manner. The diagnostic plots showed the goodness of fitting of HBM 
(Figure 23A). The final parameters of HBM were physiologically-relative (Table 5). For 
example, TBF was estimated to be 15.4 mL/100mL/min and comparable to reported xenograft 
tumor blood flow (27.5 mL/100mL/min)[248]. HBM was not sensitive to R0, which cannot be 
experimentally measured (Figure 23B). 
Unfortunately, as shown in Figure 22B, the HDM failed to capture the RO profiles across 
the three doses and a clear model misspecification was indicated. Even with a sharp distribution 
gradient across tumor areas, the model could not provide a good prediction of the biphasic 
dynamic feature in the RO profiles. The RO peaks at 50 mg/kg were drastically under-predicted, 
while the RO values at 1.0 mg/kg were over-predicted. The poor performance of HDM indicated 
that heterogeneous antibody distribution could not be the primary mechanism for the biphasic 
declining feature of antibody–target binding in tumors. The parameter estimations of HDM are 
presented in Table 6. 
The different performance between HBM and HDM was also indicated by the Akaike 
information criterion (1505 vs. 1520). We concluded that the biphasic dynamic feature of RO 
was better explained by the different binding profiles than by the different distribution profiles in 
the two tumor compartments. Therefore, we selected the HBM as the model for further 
exploration. 
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Cetuximab persisted longer in the stroma-rich area than in the stroma-poor area 
At the end of the imaging study, we sectioned the tumors and stained the EGFR-positive 
tumor cells, tumor-associated fibroblasts, and cetuximab to evaluate the residual antibodies and 
their spatial distributions. Figure 24 shows representative images of the spatial distribution of 
the antibody (DY605-CTX), tumor-associated fibroblast (GFP Fibroblasts), and EGFR-positive 
tumor cells (TRITC EGFR). Area P represents the tumor area without many stroma cells and 
with evenly distributed tumor cells. Area R represents the stroma-rich area, where tumor cells 
were surrounded by tumor-associated fibroblasts. As shown in Figure 24, by 192 h after 
antibody dosing, some antibodies were still present in the stroma-rich area, while detection of 
antibodies in the stroma-poor area was negligible. No residual antibodies were observed for 
nonspecific IgG, suggesting that the residual antibodies were associated with Fab binding and 
not with non-specific binding (Figure 25A). 
A close inspection of the spatial location indicated that residual antibodies had a very high 
co-localization with tumor cells (Figure 24). We observed that most of the residual antibodies in 
the stroma-rich area were retained on the surfaces of the tumor cells, likely as antibody–target 
complexes. This observation is consistent with our model predictions whereby antibodies would 
dissociate from the target much more slowly in the stroma-rich area. Only a small amount of 
bound antibodies was observed at the edge of Area P, and most antibodies had been degraded in 
the stroma-poor tumor area. In addition, the total EGFR was sparser in Area R than in Area P, 
suggesting a higher EGFR suppression in the stroma-rich tumor area. These findings agreed with 




 75  
Cetuximab bound EGFR at a “slower-but-tighter” degree in living tumors than in the in 
vitro conditions 
We further examined antibody binding dynamics in tumors in comparison to the binding in 
the in vitro condition, which is usually measured using SPR methods. We replaced the target 
binding parameters in the HBM with the SPR-measured values to predict the RO profiles at three 
doses, which were superimposed on the experimental observations. When kon was set to an SPR-
measured value in both tumor compartments, the model over-predicted the RO. Even though the 
biphasic feature on RO curves was predicted, almost no difference was detected in the predicted 
RO profiles across the three doses (Figure 26A). With the SPR-measured koff in both tumor 
compartments, the model under-predicted the RO data (Figure 26B). The biphasic declining 
feature disappeared in this parameter setting. When both target binding parameters were set to 
SPR-derived values, the model also over-predicted ROs (Figure 26C). Collectively, these 
findings confirmed a marked difference in antibody–target binding dynamics between the living 
tumors and the in vitro buffer systems.   
Cetuximab durably suppressed free EGFR but transiently formed antibody–target 
complexes in living tumors 
We simulated free cetuximab, free EGFR, cetuximab-EGFR complexes, and the RO in both 
tumor areas. The free cetuximab was similar in both tumor compartments at all doses (Figure 
27A), consistent with the model assumption. Free EGFR was rapidly suppressed, and the 
suppression lasted for over 150 h, particularly at 50 mg/kg (Figure 27B). At all doses, the free 
EGFR in the stroma-rich areas (as indicated by the dash lines) was suppressed to a higher degree, 
primarily because of a relatively lower fraction of EGFR-positive tumor cells and a tighter 
antibody-EGFR binding in the stromal-rich tumor areas. Those findings indicated that cetuximab 
was predicted to have a stronger suppressive effect on free EGFR in the stroma-rich area. The 
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magnitude and duration of EGFR suppression were both dose dependent, so a higher antibody 
dose gave a larger and longer suppression of the free target (Figure 27B).  
Compared to the durable target suppression, the formation of the antibody–target complex 
was quite transient (Figure 27C). In both tumor compartments, the complex concentrations 
peaked at around 5 h after dosing, but the complex decayed shortly after the peaks and was 
subsequently maintained at relatively low levels for an extended period. A small difference was 
evident in complex concentrations across doses during the terminal phase. Despite the similar 
concentrations in the two tumor areas, the different binding properties of cetuximab meant that it 
showed relatively higher and more durable RO in the stroma-rich than in the stroma-poor areas 
(Figure 27D). The difference between the two tumor areas became smaller as the dose increased.  
3.5 Discussion 
Our understanding of antibody–target interactions, particularly in the native physiological 
context, is still limited, mainly due to the lack of approaches to detect their binding dynamics 
with temporal and spatial resolution or specificity [69]. For example, immunohistochemistry 
(IHC) staining can quantify the spatial distribution, but it often fails to incorporate the dynamic 
factors present in physiological situations [44]. Most in vivo imaging methods often cannot 
distinguish signals arising due to specific target engagement versus nonspecific signals [129]. We 
previously developed a BRET method that enables longitudinal monitoring of the binding 
dynamics between the antibody and its target in living tumors [129]. Using this method, we 
observed biphasic and dose-shifted binding dynamics between cetuximab and its target EGFR. In 
the present study, we developed a spatially resolved computational model to disentangle the 
dynamic binding patterns and evaluate the mechanisms.  
Heterogeneously-distributed tumor stromal cells are likely to cause uneven spatial 
restrictions and mechanical stress in the solid tumors, possibly altering antibody-antigen 
 
 77  
interactions [252]. Our model accounted for this heterogeneity in solid tumors and elucidated the 
antibody binding dynamics. Compared to the in vitro systems, an antibody in a living tumor 
could bind to its target to a “slower-and-tighter” degree. We observed that cetuximab was bound 
differently to its target in the stroma-rich areas than in the stroma-poor regions (Table 5). 
Cetuximab had a much slower apparent dissociation rate in the stroma-rich areas, which was 
confirmed by immunofluorescence staining. This finding agreed with the longitudinal tumor 
staining results reported before, in which the higher bound antibodies in the stroma-rich regions 
were observed [76-78]. For example, using fluorescently and immunohistochemically stained 
tumor cryosections, cetuximab and trastuzumab showed higher target-bindings at the stroma-rich 
area at the 24 hours post-administration [76,77]. The binding features in the stroma-rich tumor 
area were consistent with experimental observations that the stress stroma could restrict the 
diffusion of antibodies in the tumors [79]. This restricted diffusion could reduce both association 
and dissociation rates. Another possible reason for the lower dissociation rate in the stroma-rich 
tumor regions was the intense extracellular matrix, which would prevent the antibody from easily 
drifting away from the binding zone, thereby resulting in a high fraction of rebinding [245]. The 
slow dissociation rate resulted in the accumulation of residual antibodies in the stroma-rich 
tumor areas, even when the systemic antibodies had been largely eliminated.  
We developed two spatially resolved computational models by assuming either 
heterogeneous binding or heterogeneous distribution between the stroma-rich and stroma-poor 
tumor regions (Figure 22). We then used competition studies to test which of the two models 
would consistently predict the observed the dynamic features of cetuximab–EGFR binding. The 
performance was much better for the model with the heterogeneous binding assumption than 
with the heterogeneous distribution, indicating that an uneven distribution of antibodies in two 
tumor areas was not the primary reason for the biphasic declining features in the tumor RO data. 
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One clarification should be made, namely that the inconsistent predictions produced by the HDM 
only suggest that the uneven distributions of antibodies in tumors do not sufficiently explain the 
observed binding dynamic features. Therefore, this precludes making the implication of uniform 
distribution of antibodies in the tumor. Antibody exhibited high perivascular distributions in 
tumors due to its large size and charges. Of note, our analysis was to compare antibody 
distributions between two histologically different tumor areas, rather than to evaluate antibody 
distribution gradients around tumor vessels. 
Another interesting finding is that cetuximab durably suppressed free EGFR but transiently 
formed antibody–target complexes in living tumors (Figure 27). Cetuximab eradicates tumor 
cells partially by downregulating the EGFR expression [253]. ADCC was also observed in 
cetuximab tumor-killing effects, yet the impact of ADCC on cetuximab treatment effects remains 
unclear. We found that the suppression in EGFR is more sustained than cetuximab-EGFR 
formation, suggesting that the cetuximab-induced EGFR downregulation could have a more 
prolonged impact on cetuximab treatment effects compared to ADCC.  Further exploration in the 
antibody-antigen binding dynamics will provide more insights into the antibody mechanism of 
actions. 
One limitation of this study was that the model was developed based on the imaging data in 
xenografts, which may not recapitulate the complexity of clinical tumors. Compared to the 
HEK293 derived xenograft, clinical tumors such as pancreatic adenocarcinoma usually consists 
of high but varied stromal components, limiting antibody accessibility to tumor cells and shifting 
the binding dynamics. Many drug delivery systems have been recently developed to target 
tumor-associated stromal cells to improve target accessibility and binding properties [254-257]. 
Our approach can support in-depth investigations of the stromal effects on antibody-target 
binding dynamics in various types of tumor microenvironments. Furthermore, two distinctive 
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tumor compartments for stroma-rich and stroma-poor areas are subjective. The tumor vascular 
structure was not considered in the model, which may influence the model results concerning the 
varying degrees of vascularization and vessel membrane structures between stroma-rich and 
stroma-poor tumor areas. The binding kinetic parameters and antibodies strongly influenced the 
spatial distribution of antibodies within tumor tissues. Antibodies with relative lower KD values 
showed strong perivascular distribution with tumor tissues, also known as “binding-site barrier” 
effect, which further influence the anti-tumor effects [231,258,259]. To fully account for the spatial 
gradient, the diffusion-reaction equation should be more appropriate, but it had an identifiability 
issue during model optimization. In addition, the binding parameters we estimated from the 
models are all apparent values that account for the influence of the physical and stromal factors 
in the tumor microenvironment. The IF staining images were acquired at the end of the BRET 
imaging study, which was preferably conducted in a longitudinal manner to match our model 
simulation.  
Overall, in the present study, we combined the strengths of BRET imaging and spatially 
resolved computational models to evaluate the dynamics of binding an antibody to its target in 
living tumors. We demonstrated that spatial heterogeneity exists in antibody-binding profiles 
between stroma-rich and stroma-poor tumor regions. These findings improve our understanding 
of the complex antibody targeting process and should aid in designing antibodies that show more 

















Figure 17: The scheme of the experimental design of the Bioluminescence Resonance Energy  
Transfer (BRET) study.  
A small, but bright, luciferase, NanoLuc, was fused to the extracellular domain of EGFR to serve as the energy 
donor in the BRET pair (Nluc-EGFR). The anti-EGFR antibody cetuximab was labeled with DY605 as the energy 
acceptor (DY605-CTX). The binding affinity (KD) between NLuc-EGFR and DY605-CTX was 0.10 nM. Twenty 
nude mice were inoculated with NLuc-EGFR-expressing HEK293 cells; and the BRET imaging study was 
performed after xenograft tumor sizes had reached 500 mm3. DY605-CTX at three doses (1.0, 8.5, and 50 mg/kg) or 
DY605-human IgG was injected via tail vein (n = 5/dose group). Blood samples (30 µL) were collected at 
designated times for pharmacokinetics assessment. The plasma concentrations of DY605-CTX were quantified 
based on fluorescence intensities. Images were acquired using an IVIS Kinetic optical imaging system upon 
administration of the NanoLuc substrate furimazine (i.v., 0.25 mg/kg). The fluorescence intensity was determined to 
quantify the concentrations of the antibody–target complex and to derive the receptor occupancy (RO). The tumors 
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Figure 18: The association kinetics of the DY605-CTX: NanoLuc-EGFR BRET pair.  
BRET ratios were baseline-corrected to the negative controls (DY605-IgG). Data are shown as mean ± SD. Curves 
were fitted to the association kinetic model with multiple radioligand concentrations. Kon = 0.2 nM-1min-1, koff = 0.02 
min-1, and KD = 0.10 nM. 
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Figure 20: The spatially resolved computational model describing the antibody–antigen binding  
kinetics in xenografts.  
The antibody plasma pharmacokinetics were described using a two-compartment model with a linear tissue 
distribution and a linear systemic clearance. The solid tumors were conceptually dissected into two anatomical 
compartments—stroma-rich and stroma-poor areas—to account for the spatial heterogeneity, as seen in the staining 
slide. The stroma-poor compartment described the area where tumor cells grow without any spatial restriction by 
stromal cells, whereas the stroma-rich tumor compartment represented the area where tumor cells grow in the 
presence of dense tumor-associated stromal cells (e.g., fibroblasts). Antibodies were assumed to extravasate from 
tumor blood vessels into the interstitial space and leave the interstitial space via lymphatic vessels. In both tumor 
compartments, the free receptors were synthesized and degraded on the tumor cells. The antibody–receptor 
complexes were cleared by internalization. The free antibodies bound to free receptors at a rate of kon. The antibodies 
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Figure 21: The PK profiles were well captured by a two-compartment model and the profiles of antibody–
target binding in tumors were well recapitulated by the heterogeneous binding model  
(HBM).  
(A) The two-compartment PK model adequately recapitulated the PK profiles at all doses. (B) The tumor receptor 
occupancy (RO) profiles were well characterized by the heterogeneous binding model (HBM) at three doses. Each 
data point represents the mean plasma concentration or mean RO. Error bars represent ±SD. 
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Figure 22: Uneven distributions of antibodies in tumors could not sufficiently explain the  
observed binding dynamic features in comparison to the heterogeneous binding patterns.  
(A) The heterogeneous binding model (HBM) well-captured the antibody–target binding kinetics, whereas (B) The 
heterogeneous distribution model (HDM) failed to capture the receptor occupancy (RO) profiles across three doses, 
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Figure 23: The model diagnostic plots and sensitivity analysis.  
(A) The measured data vs. individual conditional model prediction plots, the individual conditional standardized 
residual vs. model prediction plot, and the individual conditional standardized residual vs. time plot. (B) The local 
sensitivity analysis of the HBM. kdeg: EGFR degradation rate; R0: EGFR initial concentration in tumor stroma-rich 
and stroma-poor space; kon: cetuximab-EGFR association rate; koff_p: cetuximab-EGFR dissociation rate in stroma-
poor regions; koff_r: cetuximab-EGFR dissociation rate in stroma-rich regions; ft: ratio of tumor stroma-poor volume 
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Figure 24: Cetuximab persisted longer in the stroma-rich area than in the stroma-poor area.  
A representative immunofluorescence (IF) image shows the histology of the tumor collected at the end of the 
bioluminescence resonance energy transfer (BRET) imaging study, revealing the spatial distribution of the antibody 
(Cyan DY605-CTX), tumor-associated fibroblast (GFP Fibroblasts), and EGFR-positive tumor cells (TRITC EGFR 
and DAPI). Area P represents the tumor area without many stroma cells and with evenly distributed tumor cells. 
Area R represents the stroma-rich area, where tumor cells were surrounded by tumor-associated fibroblasts. Cyan 
signal denoted the total antibodies, including free DY605-CTX and bound DY605-CTX. As the white arrows 
indicate, residual antibodies are present at the tumor cell surfaces and largely overlap with EGFR staining, 
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Figure 25: Representative immunofluorescence (IF) images showing the histology of the tumor collected 
at the end of the bioluminescence resonance energy transfer (BRET) imaging study.   
(A) The Cyan signals denoted bound DY605-labeled cetuximab rather than non-specific binding. No residual 
antibodies were observed for nonspecific IgG, suggesting that the residual antibodies were associated with Fab 
binding and not with non-specific binding. (B) The spatial distribution of the antibody (Cyan DY605-CTX), tumor-
associated fibroblast (GFP Fibroblasts), and EGFR-positive tumor cells (TRITC EGFR and DAPI). Area P 
represents the tumor area without many stroma cells and with evenly distributed tumor cells. Area R represents the 
stroma-rich area, where tumor cells were surrounded by tumor-associated fibroblasts. Cyan signal denoted the total 
antibodies, including free DY605-CTX and bound DY605-CTX. Scale bar = 100 𝜇𝑚. 
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Figure 26: Cetuximab bound EGFR at a “slower-but-tighter” degree in the living tumors than in  
the in vitro conditions.  
The target binding parameters in the heterogeneous binding model (HBM) were replaced with the SPR-measured 
values to predict the receptor occupancy (RO) profiles at three doses; these are superimposed on the experimental 
observations. (A) When kon was set to a SPR-measured value in both tumor compartments, the model over-predicted 
the RO. No difference was detected in the predicted RO profiles across the three doses. (B) When a SPR-measured 
koff was used in both tumor compartments, the model under-predicted the RO data. (C) SPR-measured kon and koff 
values could not differentiate the RO profiles across the three doses. 
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Figure 27: Cetuximab durably suppressed free EGFR, but the complex was formed transiently in tumors.  
(A) The free cetuximab concentration, (B) free EGFR concentration, (C) cetuximab-EGFR complex concentration, 
and (D) receptor occupancy in the two tumor compartments were simulated based on the heterogeneous binding 
model (HBM). Blue, red, and green lines represent the three cetuximab dose groups: 50, 8.5, and 1.0 mg/kg. Solid 
lines represent the tumor stroma-poor compartment, whereas the dashed lines represent the tumor stroma-rich 
compartment
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CHAPTER 4 
CHARACTERIZING THE DISTRIBUTION AND TARGET SUPPRESSION OF ANTI-
α-SYNUCLEIN ANTIBODIES IN CEREBROSPINAL FLUID4  
 
4.1 Introduction 
Parkinson’s disease attributes to the neurological condition-caused disability worldwide. In 
2016, Parkinson’s disease was diagnosed in approximately 6.1 million individuals, 2.4 times 
higher than in 1996 [260]. Parkinson’s disease is a complex disorder characterized by the death of 
dopaminergic neurons in the substantia nigra, causing motor and nonmotor symptoms [261]. 
Current drug therapies for Parkinson’s disease primarily relieve the motor-related symptoms 
[262]. So far, there are currently no available marketed therapies to halt Parkinson’s disease 
progression. 
Alpha-synuclein (αSyn), a highly flexible pre-synaptic protein, has been irrefutably tied to 
Parkinson’s disease over the past two decades. The traces between αSyn and Parkinson’s disease 
were demonstrated by the genetic link and the identification of αSyn as a component of Lewy 
body, which is the pathologic hallmark of Parkinson’s disease [261,263-265]. Upon pathogenic 
conditions, αSyn proteins aggregate and form toxic oligomers [266-269], which later form a 
critically dense structure and compact to a Lewy body [270]. Mounting evidence indicates that 
oligomeric forms of αSyn are the culprits for neuronal degeneration in PD [271-276].  
                                               
4 This chapter includes a manuscript in preparation: Tang, Y., Rode,F., & Cao, Y. A minimal 
physiologically-based pharmacokinetic model to characterize anti-α-synuclein antibody distribution and 





Aggregated αSyn can act as a seed to induce further αSyn misfolding, following its cell-to-
cell propagation [277]. Increasing numbers of anti-αSyn antibody products have demonstrated 
that suppressing αSyn in the central nervous system (CNS) can benefit PD patients [278-284]. 
However, these antibody products all face one common challenge: the limited antibody 
penetration in the brain. The astrocytes, pericytes, and tight junctions that located between 
adjacent brain capillary endothelial cells create physical barriers for antibodies to enter brain 
parenchyma and cerebrospinal fluid (CSF) from the blood [89]. As a result, antibody 
concentration in the brain are several orders of magnitude lower than the blood [21,89]. Antibody 
concentrations in the CSF are generally 0.1% of the peripheral blood concentrations [110]. 
Although there are some therapeutic strategies developed to increase antibody brain distribution, 
such as bispecific antibodies with optimized binding to the transferrin receptor, those methods 
are still experimental and have not yet gained successful clinical translation [99,104,285].   
With the low brain distribution, antibodies that have high target affinity and exert treatment 
effects at limited concentrations are highly desired. The current anti-αSyn antibody candidates 
majorly exert treatment effects by neutralizing soluble αSyn in the brain [282,286,287]. Upon the 
binding between αSyn and antibodies, the aggregation of αSyn are hindered, shifting the 
pathogenic equilibrium to slow down the formation of toxic αSyn oligomers and the disease 
progression. The suppression of αSyn by cinpanemab (BIIB054), an antibody that targets 
oligomeric/fibrillar forms of αSyn, showed a significant pathology attenuation in animal models 
[286]. For similar antibodies that act through target neutralization, their treatment effects are all 
associated with the magnitude and duration of free target suppression [16]. As such, free target 
proteins in the CSF are routinely used as a biomarker to evaluate antibody treatment effects and 
effective doses [282,283,288,289]. 
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The neutralization and clearance of pathological targets by therapeutic antibodies in the brain 
is a dynamic process affected by multiple factors, including antibody brain penetrations, 
antibody-target binding dynamics, target replenishing rate, and many physiological factors in the 
brain. Optimizing antibody target affinity (KD) and the binding constants have become important 
steps in antibody development [145]. For instance, in the preclinical development of anti-αSyn 
antibody MEDI1341, a semi-mechanistic model was developed to predict the affinity threshold 
for the optimal target suppression in the brain [282]. Antibody concentrations in the CSF are also 
critical for extending effective target suppression in the brain, as shown in both preclinical and 
clinical studies [283]. The brain is a complex and dynamic organ with constant biofluid 
movement and exchange, which may alter antibody distribution and target binding dynamics, 
leading to different target suppression profiles in the brain than in the peripheral blood [65]. 
Understanding antibody penetration and target binding in the brain and CSF therefore become a 
critical aspect for developing therapeutic antibodies for PD.  
Here, we developed a minimal physiologically-based pharmacokinetic (mPBPK) model to 
characterize the brain distribution and target suppressions of two anti-αSyn antibody candidates, 
TNB and JNB, in rats and monkeys. TNB and JNB bind to the monomeric αSyn proteins in the 
brain to prevent αSyn aggregation and the formation of αSyn oligomers. Our model was further 
generalized to capture the distribution and target suppression profiles of three other anti-αSyn 
antibodies (cinpanemab, MEDI1341, and prasinezumab [PRX002]) in the brain. Our modeling 
framework suggested a low sieving coefficient when antibodies penetrate the blood-CSF 
membrane. Importantly, we revealed antibodies showed distinct target suppressive profiles in the 
brain compared to the blood. Our findings have substantial implications for the development of 




4.2 Materials and Methods 
Animal PK studies 
TNB and JNB (Lundbeck, Denmark) are anti-αSyn antibodies. The KD of TNB is 0.1 nM, 
with a dissociation rate (koff) of 2.88 hr-1.  JNB binds to αSyn with a KD value of 37.5 nM and a 
koff of 108 hr-1.  The binding parameters of TNB and JNB were determined using surface 
plasmon resonance (SPR) methods.    
The schematic of PK analysis of TNB and JNB was summarized in Figure 28A. TNB was 
administered to rats at a dose of 100 mg/kg via tail vein injection at day 0 (n = 11). Free αSyn 
concentrations in the plasma and CSF were measured prior to dose injection. Free TNB and 
αSyn concentrations in both plasma and CSF were determined at 4 hr, then at day 1, 2, 3, 4, 7, 
10, 14, 17, 21, and 24 post-injection.  
Antibody JNB was given to monkeys at 1, 3, 10, 30, and 600 mg/kg via tail vein injection. A 
control IgG group was also included. Three monkeys were included in each of 1, 3, 10, and 30 
mg/kg dose groups, and 10 monkeys were included in 600 mg/kg dose group. In the 1, 3, 10, and 
30 mg/kg dose groups, free αSyn concentrations in the plasma were measured prior to antibody 
administration (day 0). JNB and free αSyn concentrations in the plasma and JNB concentrations 
in the CSF were measured at 0.5, 1, 2, 6 hr, and day 1, 2, 3, 4, 7, 8, 14, 21, 28, 35, 42, 43, 49, 50, 
55, and 57 post-administration. In the 600 mg/kg dose group, 10 monkeys were i.v. injected JNB 
on day 0 and day 20, and free αSyn concentrations in the CSF were measured prior to the first 
administration (day 0), prior to the second administration (day 20), and at day 30 after the first 
administration. Free JNB concentrations in the CSF were measured prior to the second 
administration (day 20) and at day 30 after the first administration. Free JNB concentrations in 
the plasma were measured at 0.5, 6 hr, then day 1, 2, 3, 5, and 10 after the administration on day 
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0. After the second administration on day 20, free JNB concentrations in the plasma were 
measured at 0.5 and 6 hr, then at day 21, 22, 25, 30, 40, 50, 60, 70, 80, 90, 100, and 110.  
An mPBPK model to describe TNB and JNB CSF distribution and target suppression 
A two-step model-building strategy was implemented. The plasma PK profiles was first 
optimized using the mPBPK model without the CSF compartment (Figure 29A). Briefly, the 
model consists of a plasma compartment, two types of tissue compartments based on the tissue 
vasculature characteristics (leaky and tight), and a lymph compartment recycling tissue 
antibodies back to the plasma. Several physiological parameters (plasma and tissue interstitial 
volumes [Vp, Vleaky, and Vtight], lymph flows [L] and lymph volumes [Vlymph], and lymphatic 
reflection coefficient [𝜎L]) were fixed to species-specific values [22]. Three parameters were 
estimated when fitting the antibody plasma concentration vs. time data, including the vascular 
reflection coefficient for tight tissues (𝜎Tight), the reflection coefficient for leaky tissues (𝜎Leaky), 
and antibody systemic clearance (CLp) (Table 7). Due to the low antibody concentrations in the 
CSF and low αSyn concentrations in the plasma (Figure 28B and 28C), the antibody 
distribution to the CSF and antibody-target interactions in the plasma did not noticeably affect 
plasma PK, resulting in the linear PK profiles in the plasma (Figure 28C).  
The second step was to characterize antibody distribution and αSyn suppression in both 
plasma and CSF compartment. A CSF compartment was added on the top of the mPBPK model 
describing antibody CSF distribution and target suppression (Figure 30). The antibody-αSyn 
binding dynamics were included in both plasma and CSF compartments. In this step, we fixed 
𝜎Tight,	𝜎Leaky, and CLp optimized in step 1 to optimize antibody brain distribution kinetics and 
binding dynamics in the CSF. Antibody blood-to-CSF transportation was described by two 
parameters: Qbrain and sieving factor. Qbrain represents the convective flow of antibodies in the 
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CSF. Sieving factor was a fraction of Qbrain, reflecting the net effect of factors involved in 
antibody blood-to-CSF penetration. The reflection coefficient (𝜎L) from the CSF into the 
draining lymph was small and thus fixed to 0.2 [22]. 
In the target-binding section in both CSF and plasma, the free αSyn was synthesized at ksyn (a 
secondary parameter) and degraded at kdeg in both plasma and CSF. Different αSyn baselines 
were considered reflecting different ksyn between the plasma and CSF. Antibodies associated and 
dissociated with αSyn at kon and koff. The antibody-αSyn complexes were eliminated at kint. The 
differential equations of the model were included in Figure 31.  
The models with different assumptions competed. First, we evaluated the model 
performances assuming the same or distinct αSyn binding constants in the plasma and the CSF. 
Second, we compared the model performances when assuming antibody convective flow rates in 
the CSF are close to the bulk flows of species-specific CSF, which are 0.132 mL ∙	hr-1 in 300 g 
rats and 2.46 mL ∙	hr-1 in 3.5 kg monkeys [106,290]. 
Model generalization for other anti-αSyn antibodies 
The mPBPK model structures and the major model conclusions on brain distribution and 
target suppression were generalized to other external anti-αSyn antibodies. The external datasets 
include cinpanemab plasma and CSF distribution profiles in rats, monkeys, and humans [110,283], 
MEDI1341 plasma and CSF distribution profiles, as well as αSyn suppression in the rat CSF 
[282], and prasinezumab plasma distribution profiles and its αSyn suppression in the human 
plasma [291]. All external datasets were digitized using WebPlotDigitizer and data sources were 
summarized in Table 8.  
The model structure and major findings in analyzing antibodies TNB and JNB were tested in 
the external datasets. The models were modified from the full model in Figure 30, based on data 
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availability of cinpanemab, MEDI1341, and prasinezumab. The modified models were described 
in Figure 29B – D. Antibody distribution in the CSF compartment was considered in the the 
MEDI1341 and prasinezumab models. Antibody binding dynamics in the CSF were included in 
the MEDI1341 model (Figure 29C). The prasinezumab model described antibody binding 
dynamics in the plasma (Figure 29D). The bindings were assumed to be at quasi-equilibrium in 
the MEDI1341 and prasinezumab models. 
Model fittings and parameter estimations 
Model fittings were performed using the Naïve Pooled method, except for cinpanemab 
monkey and rat data [110], which was fitted using Individual Fitting method in ADAPT 5. When 
fitting TNB and JNB data to the full mPBPK model, koff values were fixed to the SPR 
measurements, while other parameters were estimated. In the cinpanemab model, 𝜎Tight,	𝜎Leaky, 
CLp, sieving factor, and Qbrain were estimated simultaneously. The baseline αSyn concentration in 
the CSF (R0_CSF) in the MEDI1341 model was estimated, while baseline αSyn concentration in 
the plasma (R0_plasma) in the prasinezumab model was fixed to literature values. 
Human prediction 
We simulated the TNB concentration vs. time profiles and target suppression in both plasma 
and CSF in human. In the human simulation, we assumed that 𝜎Tight and	𝜎Leaky for TNB are 
conserved across species [24].    
Human CLp and Qbrain of TNB was scaled from rats with the allometric equation below, 
Yhuman = Yanimal	∙ (klmnopqklpqrops)
b      (Eq.1) 
In the equation above, Y represents the parameters of interest, namely CLp and Qbrain. BW is 
bodyweight and b is the allometric exponent. We used 70 kg and 0.3 kg as human (BWhuman) and 




U<4E;4, and kint were set to their estimated values in rats. We set parameter variabilities as CV% 
in the estimations for all parameters described above. The baseline concentrations of free αSyn in 
the plasma and CSF were set to 1.66 nM and 1.19 ng/mL in humans [291,293].  
We simulated TNB human PK and target suppression profiles in the plasma and CSF using 
RxODE package in R [294]. Briefly, a total of 100 subjects were simulated based on the mPBPK 
model with parameter estimates and variability described above. Predicted percentiles of the 
simulated data (10, 50, and 90th percentiles) were plotted. 
4.3 Results 
TNB and JNB effectively suppressed free αSyn in the plasma and CSF  
As shown in Figure 28A, free TNB and αSyn concentrations in the plasma and CSF were 
measured up to 21 days post-administration in rats. TNB CSF concentrations peaked at 24 – 72 
hr, showing a temporal delay compared to the plasma TNB concentrations (Figure 28B). The 
baselines of αSyn were higher in the CSF compared to	plasma in rats (0.76 vs. 0.11 nM). Free 
αSyn concentrations rapidly decreased in the plasma and CSF after TNB administration. 
Although there was a temporal delay in TNB CSF penetration, the concentrations of αSyn in the 
plasma and CSF both reached nadir around 48-hour. Free αSyn concentrations in the plasma and 
CSF slowly returned to baselines at the end of observation (600 hr) (Figure 28B). 
Free JNB and αSyn concentrations in the plasma and CSF were measured up to 110 days 
post-administration in monkeys (Figure 28). The dose-normalized area-under-curve (AUC) of 
JNB concentration-time profiles in the plasma was similar across the five dose groups, indicating 
a linear PK of JNB within the dose range of 1 – 600 mg/kg in monkeys. JNB CSF concentrations 
peaked at 48 – 360 hr. The baselines of αSyn in the plasma were about 100-fold higher than CSF 
(1.3 nM vs. 0.014 nM, respectively). The concentrations of αSyn in the plasma decreased rapidly 
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within 48 hr. We also observed a dose-proportional target suppression in the plasma within 1 to 
30 mg/kg. Free αSyn concentrations in the plasma decreased from the baseline to 0.84, 0.31, 
0.11, and 0.075 nM, in 1, 3, 10, and 30 dose groups, respectively. The suppression effect 
extended until day 57. In the 600 mg/kg group, free αSyn concentrations in the CSF decreased 
further after the second dose. 
The developed mPBPK model adequately captured TNB and JNB CSF distribution and 
αSyn suppression 
TNB and JNB plasma concentration profiles were well-described by the developed mPBPK 
model (Figure 29A). The systemic clearances of TNB and JNB were estimated to be 0.4195 and 
0.48 mL ∙	hr-1, respectively (Table 7). 
 In the second step, the extended mPBPK model, with the assumption of different binding 
constants between the plasma and CSF, well captured αSyn suppression profiles (Figure 32). Of 
note, both antibodies (TNB and JNB) bound to αSyn to a “faster-and-tighter” degree in the CSF 
than in the plasma (Table 7). TNB bound to αSyn in rat CSF at a rate of 28 nM-1∙hr-1, 
approximately 200 times faster than the rate in rat plasma (0.14 nM-1∙hr-1), yielding a smaller KD 
in the CSF compared to plasma (0.1 vs. 21 nM, Table 7). A similar target binding property was 
also observed for JNB in monkeys. JNB had a 2-time faster binding association rate in the CSF 
than in the plasma (0.22 nM-1∙hr-1 vs. 0.13 nM-1∙hr-1), resulting in a smaller KD in the CSF than 
plasma (483 vs. 860 nM, Table 7). Notably, the binding affinity of TNB to αSyn in the CSF was 
closed to the SPR-measured value (0.1 nM), while JNB KD in the CSF was larger than the SPR 
measurement (483 nM vs. 37.5 nM, respectively). For comparison purpose, when the same 
binding constants were assumed between the plasma and the CSF, the model failed to capture the 
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αSyn suppression profiles in both rats and monkeys (Figure 33). These observations indicated 
that both antibodies had distinct binding dynamics in the CSF from the plasma.  
Interestingly, we found that the convection rates of TNB and JNB (Qbrain) were significantly 
slower than the bulk flow of CSF. The Qbrain of TNB had an estimated value of 0.0017 mL ∙	hr-1, 
which was only 1% of the rat CSF bulk flow (0.132 mL ∙	hr-1) [290]. The Qbrain of JNB was 
estimated to be 0.89 mL ∙	hr-1, which also much smaller than the CSF bulk flow in monkeys 
(2.46 mL ∙	hr-1) [106]. The sieving coefficients were estimated to be 0.00095 and 0.0014 for TNB 
and JNB. When the Qbrain value was fixed to literature-reported CSF bulk flows [106,290], the 
model failed to capture the CSF αSyn data in rats and monkeys (Figure 33).  
Model generalization to other anti-αSyn antibodies 
To further generalize the model findings obtained in TNB and JNB, we analyzed several 
external datasets using the mPBPK models (Figure 29B – D, Table 8). Of note, the models were 
modified based on the data availability. We highlighted the fitting results of anti-αSyn 
cinpanemab, MEDI1341, and prasinezumab (Figure 34). The mPBPK model, without the target 
binding components, recapitulated cinpanemab concentration-time profiles in the plasma and 
CSF in rats, monkeys, and humans (Figure 29B, Figure 34A). Similar to TNB and JNB, the 
estimates of Qbrain for cinpanemab were smaller than the species-specific CSF bulk flows. The 
estimates of Qbrain and the species-specific bulk flow of CSF are 0.0059 vs. 1.32 mL ∙	hr-1 in rats, 
0.58 vs. 2.46 mL ∙	hr-1 in monkeys, and 1.7 vs. 25 mL ∙	hr-1 in human (Table 9). The sieving 
factors of cinpanemab were comparable across species (0.00094, 0.0017, and 0.0014 in rats, 
monkeys, and humans), which were close to the sieving factor estimations of TNB and JNB 
(0.00095 and 0.0014, Table 7).  
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Using the model with the αSyn binding component in the CSF (Figure 29C), we fitted the 
concentration vs. time and target suppression profiles of MEDI1341 (Figure 34B). The mPBPK 
model well-described the plasma and CSF concentration-time profiles of MEDI1341 and αSyn 
suppression profiles in the CSF. Similarly to all analyzed antibodies, we found that the Qbrain of 
MEDI1341 was about 10-fold smaller than rat CSF bulk flow (0.015 vs. 0.132 mL ∙	hr-1, Table 
9). The MEDI1341-αSyn binding affinity in the CSF was estimated to be 8 nM, which was 
higher than the SPR-measured value (0.074 nM, Table 8). The prasinezumab profiles were 
fitting using the model with αSyn binding component in the plasma (Figure 29D and 34C). The 
estimated KD of PRX002 was 150 nM in the plasma, higher than KD measured in vitro (20 nM, 
Table 8).  
Simulation of JNB PK and αSyn suppression in human 
We extrapolated the mPBPK model to human and simulated the human PK and target 
suppression profiles of TNB at 45 mg/kg (Figure 35), which was the dose level selected for 
cinpanemab Phase II trials [283]. Both CLp and Qbrain were allometrically scaled from rats to 
humans and the predicted values were 0.025 L ∙	hr-1 and 0.1 mL ∙	hr-1, respectively (Eq. 1). We 
assumed other model parameters conserved across species, and the estimates in rats were applied 
in human simulation. 
The human simulation suggested that TNB (at 45 mg/kg) has a low but extended exposure in 
the CSF. CSF TNB concentrations remained detectable within 30-day post-administration 
(Figure 35B). TNB almost completely suppressed free αSyn in the plasma (Figure 35C). Free 
αSyn concentrations slowly increased but did not fully return to the baseline by 100 days after 
dosing. Similar to the blood, TNB rapidly neutralized free αSyn in human CSF (Figure 35D). 
Due to the low antibody exposure, the free αSyn in the CSF slowly returned to the baseline and 




Antibodies that neutralize αSyn in the brain have shown promising efficacy in alleviating PD 
pathology in preclinical and clinical studies [282,283,289,291,293]. The treatment efficacy of these 
antibodies is associated with the magnitude and duration of αSyn suppression in the brain, 
determined mainly by antibody brain penetration, antibody-target binding dynamics, target 
replenishing rates, many physiological factors in the brain. Mechanistic models, especially the 
physiologically-based PK models, are powerful tools for elucidating these processes and 
parameters. These models have shown promise for facilitating antibody development, 
establishing the relationships between dose and target suppression, and optimizing antibody 
dosing regimens [22,110,111,151,281,295]. In this study, we developed a mPBPK model to 
investigate antibody distribution kinetics in the CSF and their abilities to neutralize αSyn in the 
CSF. Our model was applied to characterize the profiles of two anti-αSyn antibodies, TNB and 
JNB (Figure 30). The physiological nature of the mPBPK model facilitates species translation 
and model generalization for other antibody candidates targeting αSyn for the treatment of PD.  
One result was that the antibody convection rate in the CSF was much smaller than the CSF 
bulk flow. The estimate of Qbrain for TNB was about 78-fold lower than rat CSF bulk flow 
(0.0017 vs. 0. 132 mL ∙	hr-1) and Qbrain for JNB was about 2.8-fold lower than monkey CSF bulk 
flow (0. 89 vs. 2.46 mL ∙	hr-1). This observation was verified in the external datasets, in line with 
other studies [109,110]. Rubenstein et al. observed that a human antibody, rituximab, after 
intrathecal administration, was cleared from the CSF at a significant slower rate than the bulk 
flow [109]. Iliff et al. have reported a brain-wide glymphatic pathway, in which CSF recirculates 
through the brain parenchyma and exchange with brain ISF before being cleared. The convective 
transport of antibodies is believed to be significantly constrained by the tortuosity of the brain 
interstitial paths, and the movement of antibodies inside the brain parenchyma could be less than 
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1 mm per day [296]. Another possible explanation is the complexity of CSF bulk flow in nature. 
Previous studies suggested heterogenous and non-directional flow CSF flow in CSF sub-
compartments [55,297-299], which may result in a relatively slow apparent convective flow in the 
CSF. Moreover, it has been proved that CSF turnover rates vary under different conditions, such 
as circadian rhythm [300].  
Another finding was that antibodies had lowered apparent affinities in the host system than in 
the in vitro solutions. TNB KD in the plasma was about 200-time higher than the SPR-measured 
values. JNB KD in the plasma was about 20 times higher than the SPR-measured value. We also 
observed similar decreases of affinity in other anti-αSyn antibodies. The KD for PRX002 in the 
plasma was estimated to be 150 nM, 7-time higher than the in vitro value. MEDI1341 KD in the 
CSF was 8 nM, more than 100-time higher than the in vitro value (Table 9). The lowered 
apparent affinities for antibodies bound to their targets in the host system are associated with 
many physiological restrictions. SPR measurements are usually obtained in static solutions, 
which do not reveal the effects of many biophysical and physiological factors such as fluidic 
shear stress and physical hindrance of extracellular matrix [65]. The diffusivity of antibodies and 
their targets are restricted in the host system, influencing antibody-target binding dynamics [142]. 
We observed that the replenishing rates of tissue interstitial fluids significantly shaped antibody’s 
binding dynamics to its target in the host system [65]. In many anatomical body sites, antibody-
target bindings could not achieve equilibrium, explaining the lowered apparent affinities in the 
plasma in our study [65,301]. 
Interestingly, we also found that TNB and JNB had distinct binding profiles in the CSF and 
plasma. TNB has about 200-time higher affinity in the CSF than in the plasma (21 vs. 0.1 nM), 
and JNB has about 2-time higher affinity in the CSF (860 vs. 483 nM). The relative lower 
binding affinities in the plasma are partly associated with the high shear stress and hydraulic 
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pressures in the blood, inhibiting effective antibody-target association and promoting antibody-
antigen complex dissociation [65]. The distinct antibody-antigen binding dynamics between the 
CSF and plasma greatly shaped the target suppression profiles, explaining why relatively low 
antibody exposures in the CSF could still exert effective target suppression. This observation 
justifies the use of antibodies to neutralize pathological targets in the brain despite limited 
penetration into the brain. The slow convective movement of antibodies may not interfere 
antibody-target binding in the CSF as much as in the blood circulation [65,301].  The slow 
convection rates of antibodies in the CSF permit antibodies to sufficiently bind to their targets 
and realize the potential of high affinity, making it feasible to develop antibodies with high target 
affinities for treating CNS disorders. 
Notably, our study had a few limitations. First, we did not distinguish the oligomeric and 
monomeric forms of αSyn in the analysis. Considering the low percentage of oligomers to the 
total αSyn proteins [302], we did not consider the transformation kinetics between the oligomers 
and monomers. Second, the model only estimated kon (not koff) as the data did not support the 
identification of both binding constants. Overall, we developed an mPBPK model with an 
extended CSF compartment to elucidate the distribution kinetics of antibodies in the CSF and 
antibody-target binding dynamics in both plasma and CSF. The model suggested that the 
antibody convention in the CSF was significantly slower than CSF bulk flow. The model also 
demonstrated distinct antibody-antigen binding dynamics between the blood and the CSF. These 







Figure 28: The schematic and results of TNB and JNB PK study.  
(A) The schematic of TNB and JNB PK study. TNB was administered to 11 rats at a dose of 100 mg/kg via tail vein 
injection at day 0. JNB was given to monkeys at 1, 3, 10, 30, and 600 mg/kg via tail vein injection. A control IgG 
was also included. Three monkeys were included in each of 1, 3, 10, and 30 mg/kg dose group, and 10 monkeys 
were included in the 600 mg/kg dose group. (B) TNB and αSyn concentration-time profiles in the plasma and CSF. 
Free TNB and free αSyn concentrations were measured in the plasma and CSF after i.v. administration of TNB at 
100 mg/kg. (C) JNB and αSyn concentration-time profiles in the plasma and CSF. Free JNB and free αSyn 
concentrations were measured in the plasma and CSF after i.v. administration of JNB at 1, 3, 10, 30, and 600 mg/kg. 








Figure 29: Schematic of the mPBPK models.  
(A) plasma PK profiles of TNB and JNB, (B) cinpanemab concentration-time profiles in the plasma and CSF in rats, 
monkeys, and humans, (C) concentration vs. time and target suppression profiles of MEDI1341, and (D) 
















Figure 30: Schematic of the mPBPK model with extended CSF compartment describing antibody 









TABLE 8. Model parameter estimation  
Species Antibody KD Dose Ref 
Rat  
BIIB054* 0.12 nM 10 mg/kg i.v. [110,283] 
MEDI1341 74 pM 3, 10, 30, 100 mg/kg i.v. [282] 
Monkey 
BIIB054* 0.12 nM 20 and 100 mg/kg i.v. [110] 
Cinpanemab 0.12 nM 1, 5, 15, 45, 90, 135 mg/kg i.v. [281] 







Figure 32: The developed mPBPK model adequately captured TNB and JNB CSF distribution and target 
suppression. 
(A) Fitting results of TNB and αSyn concentration-time profiles in the plasma and CSF of rats. (B) Fitting results of 
JNB and αSyn concentration-time profiles in the plasma and CSF of monkeys. Each dot represents an individual 













Figure 33: The results of the model competition.  
The left column represents the developed mPBPK model describing TNB and JNB CSF distribution and target 
suppression. The middle column represents the fitting performances of the model assuming the same or distinct 
αSyn binding constants in the plasma and the CSF. The right column represents the fitting performances of the 







Figure 34: Model generalization for other anti-αSyn antibodies.  
(A) Fitting results of cinpanemab (BII054) concentration-time data in the plasma and CSF of rats, monkeys, and 
humans. (B) Fitting results of MEDI1341 concentrations in the plasma and CSF and αSyn deductions in the CSF in 
rats. (C) Fitting results of prasinezumab (PRX002) plasma concentrations and plasma αSyn deductions in humans.  












Figure 35: The simulation of TNB PK and target suppression profiles in humans.  











VISUALIZING ANTIBODY-INDUCED IMMUNE-TUMOR CELL CLUSTERING 
DYNAMICS USING A PROXIMITY-DEPENDENT BIOSENSOR SYSTEM5 
 
5.1 Overview 
Engaging innate immune cells to eradicate opsonized tumor cells such as antibody-dependent 
cellular cytotoxicity (ADCC) is a crucial mechanism for therapeutic antibodies. ADCC is 
majorly mediated by natural killer (NK) cells and initiated with immune: target cell conjugations. 
Although broadly studied in vitro, in vivo ADCC and its contribution to antibody treatment 
effects are unraveled due to the lack of technologies to continuously and noninvasively assess 
ADCC in physiological context. We developed a proximity-dependent biosensor system to detect 
antibody-induced NK: target cell conjugation and synapse formation, which is the initial step of 
ADCC. In this biosensor system, structural complementary luciferase units were anchored on 
NK and target cell surfaces by flexible spacers with various lengths. The proximity between 
interacting cells enables the luciferase units binding and formation of an full luciferase, which 
emits bright luminescent signals upon stimulus to indicate NK: target cell conjugation. As a 
model system, we used the anti-CD20 antibody rituximab to target CD20-expressing HeLa cells 
in 3D cell cultures. The biosensor system successfully visualized rituximab-induced NK: target 
cell clustering for up to 48 hours with promising robustness. We also demonstrated the biosensor 
system's capability in accommodating synapse sizes to optimize sensitivity and selectivity. This 
                                               
5 This chapter includes a manuscript in preparation: Tang, Y., & Cao, Y. Visualizing antibody-induced 
immune-tumor cell clustering dynamics using a proximity-dependent biosensor system. 
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biosensor system will facilitate monitoring ADCC in physiological context and provide more 
insights into ADCC in vivo. 
5.2 Introduction 
Revolutionizing many diseases’ treatment landscapes [4], therapeutic antibodies elicit 
treatment effects via multiple actions. A critical one is to activate and engage innate immune 
cells. The Fc domains on therapeutic antibodies bind to Fc gamma receptors (FcγRs) expressed 
in a series of immune cells. Upon Fc-FcγR interactions, the activated effector cells, majorly NK 
cells, can form immunological synapses with target cells and release perforin or granzyme B to 
lyse the target cells. This effect is also known as antibody-dependent cellular cytotoxicity 
(ADCC) [16]. ADCC is crucial for many marketed antibodies, especially for anti-tumor 
antibodies such as rituximab [154,303]. The critical role of ADCC in antibody treatment efficacy 
was demonstrated in studies of various antibodies, target antigens, tumor types, and patient 
populations [152,155-158]. For example, Cartron et al. demonstrated that higher ADCC function, 
which was indicated by the increased FcγR affinity to human IgG1, was associated with 
enhanced responses to rituximab in follicular lymphoma patients [157]. 
ADCC effects have been broadly evaluated at in vitro level by various bioanalytical methods 
[167,242,304,305]. The application of those methods is limited at in vitro and ex vivo levels due to 
high variabilities and lack of physiological relevance. For example, 51Cr release assay remains 
the golden standard to measure ADCC by detecting the chemicals released after cell apoptosis, 
which is hard to be applied to measure ADCC in vivo [167]. Moreover, those bioanalytical 
methods cannot support the continuous observation of effector functions in the living system, 
particularly in the evolving and dynamic tumor microenvironments [306]. Longitudinally 
monitoring the ADCC in tumor samples could yield insights into the antibody mechanism of 
action and treatment responses.  
 
 121 
The adherence of immune cells to target cells and the immunological synapses represents the 
first and most critical step of ADCC. Here we constructed a proximity-based biosensor system to 
detect immunological synapses with high signal-to-noise (S/N) ratios. Briefly, two structurally 
complementary luciferase subunits in the NanoBiT® system [307], Large_BiT and Small_BiT, 
were anchored to the surfaces of immune and tumor cells separately by the spacers of various 
lengths (Table 1). Once immunological synapses are formed, the proximity between tumor and 
immune cells allows the binding of Large_BiT and Small_BiT, forming active luciferases that 
emit strong luminescence upon stimulus [307]. Our biosensor system demonstrated high 
selectivity and sensitivity in detecting antibody-induced immune: target cell interactions. Using 
the optimized biosensor pair, we observed the rituximab-induced NK: CD20-positive HeLa cell 
clustering dynamics in 3D cell culture systems continuously up to 48 hours. Our studies 
demonstrated this biosensor system's great potential in monitoring cell-cell interactions in vivo 
and characterizing the cell clustering dynamics. 
5.3 Materials and Methods 
Construction of plasmids 
The pDisplay vector was used as a eukaryotic expression vector. Briefly, the murine Ig k 
chain leader sequence and platelet-derived growth factor receptor transmembrane domain 
(PDGFR-TM) are located at the inserted gene’s N-terminus or C-terminus, which direct and 
anchor the fusion protein to the cell membrane [308]. The HA and myc epitopes on both sides of 
the expressed recombinant proteins allow the detection of fusion peptides (Figure 36).  
The sequences of SmBiT and LgBiT were kindly provided by Promega. Spacers were added 
to the C terminus of LgBiT or SmBiT to yield different distances between split luciferases and 
cell membranes. The LgBiT-(GGGGS)n or SmBiT-(GGGGS)n sequences were inserted into the 
pDisplay plasmid at XmaI and SaLI restriction sites. The CMV-LgBiT-(GGGGS)n-PDGFR-TM 
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gene was cloned into PBMN-I-eGFP to produce recombinant retrovirus. PBMN-I-GFP was a gift 
from Garry Nolan (Addgene plasmid # 1736 ; http://n2t.net/addgene:1736 ; 
RRID:Addgene_1736) 
Cell culture and transductions 
HeLa cells were cultured in complete media: DMEM with 10% (vol/vol) FBS (Invitrogen), 
100U/mL penicillin, and 100 mg/mL streptomycin (all from Gibco). Phoenix-AMPHO cells 
(ATCC® CRL-3212TM) were cultured in RPMI 1640 medium supplemented with 10% (vol/vol) 
FBS (Invitrogen), 100U/mL penicillin, and 100 mg/mL streptomycin (all from Gibco). Human 
Natural Killer cell line (NK-CD16; no GFP, high affinity 176V; SEQID NO:2) (ATCC® PTA-
6967) were cultured in the Alpha-MEM medium based on the recipe from Dr. Garry Nolan Lab. 
Cells were maintained in a humidified incubator at 37 °C. SmBiT or LgBiT fusion genes 
expressed from pDisplayTM were introduced to HeLa cells via  Lipofectamine 3000 (Invitrogen). 
NK-CD16 cells were transduced based on the protocol described elsewhere [309]. Briefly, the 
Phoenix-AMPHO cells were transfected with the engineered vector (PBMN-IRES-EGFP-
SmBiT) via Lipofectamine 3000 to produce recombinant retrovirus. The retroviral supernatant 
was collected from transfected Phoenix-AMPHO cells for NK-CD16 transduction. NK-CD16 
cells with positive SmBiT expression were selected via cell sorting by probing HA tag (anti-HA 
antibody [Invitrogen #26183, 1:500]; Anti-mouse secondary antibody Alexa Fluor 647 
[Invitrogen #A-21235, 1:200]), probing CD16 (anti-CD16 antibody [Abcam #246222, 1:600]; 
Anti-rabbit secondary antibody Cy3 [Abcam #6939, 1:200]), and probing eGFP simultaneously. 
Examination of SmBiT/LgBiT expressions and functions on HeLa cells 
HeLa cells were transfected with pDisplay-LgBiT plasmids (LgBiT-0, 1, 3, and 12 L) via 
Lipofectamine 3000 (Invitrogen). Transfected cells were harvested at 96 hour post-transfection, 
suspended in Opti-MEM, and transferred to a 96-well plate (1×105 cells per well). HiBiT control 
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protein, a 11 amino acid peptide with a higher affinity to LgBiT than SmBiT (0.7 nM vs. 190 
µM), was used to detect LgBiT expression. NanoLuc substrate (furimazine) solution (1:50 
diluted) containing 40 nM HiBiT control protein was added to the 96-well plate (20 µL per well). 
The luminescence was measured at 460 nm by Cytation 3 equipped with 460/40 nm bandpass 
filter.  
The membranous and cytosolic LgBiT and SmBiT proteins were extracted from LgBiT-
positive, SmBiT-positive, and HeLa WT cells using Mem-PER Plus membrane protein 
extraction kit. SmBiT expression was detected by LgBiT proteins. Membranous and cytosolic 
protein solutions were added to 96-well plates after adjusting the protein level. HiBiT-containing 
(40 nM) or LgBiT-containing (1:100 diluted) furimazine solution to detect LgBiT or SmBiT 
proteins. 
To evaluate the binding function of the engineered SmBiT and LgBiT proteins at absence of 
cellular spatial limitations, HeLa cells were co-transfected or separately transfected by pDisplay-
SmBiT and pDisplay-LgBiT genes via Lipofectamine 3000 (Invitrogen). Transfected cells were 
harvested at 96 hour post-transfection, suspended in Opti-MEM, and transferred to a 96-well 
plate (1×105 cells per well). Furimazine solution was added to each well (1:50 diluted, 20 µL per 
well) 5-min before bioluminescence measurement with Cytation 3.  
To test engineered SmBiT-LgBiT protein binding function with the cellular spatial 
limitations, HeLa cells separately expressed pDisplay-SmBiT or pDisplay-LgBiT 1:1 mixed, 
transferred to a 96-well plate, and briefly centrifuged at 200g before adding the furimazine 
solutions. The luminescence was measured at 460 nm by Cytation 3. 
Detection of antibody-induced cell clustering in suspension system 
The ability of the biosensor system to detect antibody-induced cell clustering was validated 
in HeLa-EGFR:cetuximab:NK system. HeLa cells were transfected by pDisplay-LgBiT-12L 
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cells via Lipofectamine 3000 (Invitrogen). NK-CD16-SmBiT-12L cells were mixed with 
pDisplay-LgBiT-12L- HeLa cells at E:T ratios of 10 or 5 (1×105: 1×104 or 5×104: 1×104 cells in 
100 µL medium per well), with or without cetuximab (MedChemExpress) at concentration of 10 
nM. NK-CD16 WT cells were mixed with pDisplay-LgBiT-12L-HeLa cells at the same 
conditions. After 30-min incubation, the luminescence was measured at 460 nm by Cytation 3.  
Examination of SmBiT expression on NK cells  
SmBiT expression on NK-CD16-SmBiT cells was assessed in addition to HA+ sorting. NK-
CD16-SmBiT cells were transferred to a 96-well plate (1×105 cells per well). HeLa transfected 
with pDisplay-SmBiT genes (SmBiT-0L, 1L, 3L, and 12L) via Lipofectamine 3000 (Invitrogen) 
worked as positive controls. HeLa WT and NK-CD16 WT cells were used as negative controls. 
LgBiT-containing (1:100 diluted) furimazine solution was added to SmBiT+ cells to detect 
SmBiT expression levels. The S/N ratios were calculated as below: 








    (Eq. 1) 
	NK+5)	81,E.2E,- and HeLa+5)	81,E.2E,- represents NK and HeLa cells expressing biosensor subunits. 
Examination of LgBiT and CD20 expression on CD20+LgBiT+ HeLa cells  
CD20 gene (Addgene plasmid # 1890, (van den Heuvel, 1993 #14)) and pDisplay-LgBiT 
genes (LgBiT-0L, 1L, 3L, and 12L) were introduced to HeLa cells via Lipofectamine 3000 
(Invitrogen). Transfected cells were harvested at 96 hour post-transfection. To determine CD20 
expressions, transfected and WT Hela cells were washed with PBS, then incubated with FITC 
anti-CD20 antibody solution (BD B556632, 1:300 dilution) for 30min. Each replicate included 
1×105 cells. After washing with PBS, FITC signal was quantified using Cytation 3 fluorescence 
monochromator at λex/em = 485/528 nm with a gain of 100. To determine LgBiT expressions, 
transfected and WT Hela cells were washed with PBS then suspended in Opti-MEM medium 
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(1×105 cells per replicate). NanoLuc substrate (furimazine) solution (1:50 diluted) containing 40 
nM HiBiT control protein was added (20 µL per replicate). S/N ratios of CD20 and LgBiT 
expressions were calculated as Eq. 1. 
Three-dimensional cell culture and imaging 
At the 96th hour post-transfection, CD20+LgBiT+ HeLa cells were harvested suspended in a 
1:1 mixture of Matrigel (BD Bioscience). Matrigel-encapsulated cells were seeded in 24-well 
plates (20 µL in each well) and solidified at 37 °C for 30 min. In the 3D cell culture imaging 
studies, NK-CD16 cells with or without SmBiT expression were added to solidified 3D cell 
cultures with or without rituximab. The images were acquired at 30-min after substrate 
supplement (furimazine, 1:100 dilution) using an IVIS optical imaging system (Caliper Life 
Sciences) with an electron multiplying charge-coupled device camera. Acquired images were 
processed and quantified using Living image 4.5.2 (Caliper Life Sciences).  
To compare the sensitivities in detecting rituximab-induced cell clustering betwen LgBiT-
3L+SmBiT-12L and LgBiT-12L+SmBiT-12L, corrected bioluminescent signals were calculated 
as below: 
Corrected BLI signal = 
(NK+5)u;k1[Ab] − NK+5)u;k1[control]) − (NK+5)l [Ab] − NK+5)l [control])  (Eq. 2) 
The peak corrected signals of each spacer combinations (LgBiT-0L+SmBiT-0L, LgBiT-
1L+SmBiT-1L, LgBiT-3L+SmBiT-3L, LgBiT-0L+SmBiT-12L, LgBiT-1L+SmBiT-12L, 
LgBiT-3L+SmBiT-12L, and LgBiT-12L+SmBiT-12L) were calculated and normalized by the 
peak signals of control groups: 
Normalized signal = +,--./0.9	kD	E1?24<
vwxyz{
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Construction of proximity-based biosensor system by engineering structural 
complementary NanoBiT 
A proximity-based biosensor system was engineered from NanoBiT, a structural 
complementation system composed of a Large BiT (LgBiT, 18 kDa) and a Small BiT (SmBiT, 
11 amino acid peptide) which can meet and form an active NanoLuc to generate bright 
luminescent signals upon stimulus. LgBiT and SmBiT were anchored separately to target cell 
membranes and effector cell membranes to detect cell-cell interactions. When the LgBiT+ target 
cells and SmBiT+ effector cells interact and form immunological synapses, the two 
complementary parts on cell surfaces come together and emit bright luminescent signals with 
negligible interference with cell-clustering kinetics due to their small sizes and low binding 
affinity (190 µM). Spacers with different lengths were fused to NanoBiT to recapitulate the 
distances between the opposing membranes in the immunological synapse (Figure 36 and 
Figure 37A). The biosensor pair with appropriate combined spacer lengths can demonstrate the 
optimal S/N ratios in identifying antibody-specific cell-cell interactions (Figure 37B, upper 
panel). When combined spacer lengths were too short, the sensitivity of detection by the 
biosensor system will decrease (Figure 37B, middle panel). When combined spacer lengths were 
too long, the biosensor system will create high background signal and reduce the selectivity in 
detecting the formation of immunological synapses (Figure 37B, lower panel). The biosensor 
system yield a wide range of combined spacer lengths from 0 – 48 nm (Table 10). Spacer-fused 
SmBiT biosensor components were constructed in both plasmid DNA and viral vector forms.  
Engineered biosensor system detected cell-cell interactions with high sensitivity 
We first characterized the biosensor system expressions and functions on HeLa cell surfaces. 
As Figure 38A shows, the LgBiT expression in HeLa cells was several orders of magnitude 
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higher than the background signals (p < 0.0001, unpaired Student's t-test). The expression of 
SmBiT in HeLa cells indicated by HA probing was significantly higher than baseline (p < 
0.0001, unpaired Student's t-test). We then investigated the cellular location of LgBiT and 
SmBiT. We found that the expressions of LgBiT and SmBiT, membranous and cytosolic, were 
all significantly higher than baseline (Figure 38B). LgBiT and SmBiT were majorly expressed 
on cell membranes. LgBiT had approximately 40-fold higher expression on cell membrane 
compared to in cytosol (p = 0.0006, unpaired Student's t-test). Membranous SmbiT expression 
was more than ten times higher than cytosolic SmBiT (p = 0.02, unpaired Student's t-test). Those 
observations indicated that the biosensor systems were exposed extracellularly with high 
abundance.  
We also characterized the binding abilities of LgBiT and SmBiT in the biosensor system. 
When co-expressed on the cell membrane, bound LgBiT-SmBiT emitted strong luminescent 
signals (Figure 38C). LgBiT- or SmBiT-positive cells alone had negligible background signals. 
These observations suggested that SmBiT: LgBiT interactions can be indicated by 
bioluminescence with high sensitivity in the absence of cellular spatial limitations. We evaluated 
the biosensor system while taking cellular spatial hindrance into account. HeLa cells were 
transfected to express LgBiT and SmBiT separately. When SmBiT+ and LgBiT+ HeLa cells were 
mixed, suspended, and non-specifically contacting with others in the system, the bioluminescent 
signal was minimal (Figure 38D). We increased the cell contact probability by centrifugation. 
Compared to centrifuged LgBiT- or SmBiT-positive cells alone and uncentrifuged LgBiT: 
SmBiT cell mixtures, the bioluminescent signals of centrifugated LgBiT:S mBiT cell mixtures 
increased by 5 – 10 times (Figure 38D). Those results suggested that the biosensor system is 
capable of detecting cell-cell interactions. 
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We used the biosensor system to investigate antibody-specific cell clustering. Hela: NK-
CD16 interaction induced by anti-EGFR antibody cetuximab was evaluated. SmBiT+ NK-CD16 
cells were incubated with LgBiT+ HeLa cells at different E:T ratios (5 and 10, respectively), with 
or without cetuximab (Figure 38E). No significant difference was observed in the 
bioluminescent signals from the effector-target cell mixtures without cetuximab, regardless E:T 
ratios (p = 0.5, unpaired Student's t-test). Cetuximab increased effector-target cell interactions, 
which was indicated by significantly higher bioluminescent signals in cetuximab groups 
compared to the control groups (p = 0.001 and p = 0. 03, unpaired Student's t-test). Notably, the 
bioluminescent signals were significantly higher in the E:T ratio = 10 group compared to the E:T 
ratio = 5 group (p = 0.02, unpaired Student's t-test), indicating that the effector-target cell 
interactions were promoted by increasing the relative amount of effector cells. These findings 
proved that the biosensor system can detect antibody-induced cell-cell interactions.  
Visualizing rituximab-induced effector: target cell clustering in 3D cell cultures 
We constructed the biosensor system in NK-CD16 and CD20+HeLa cells to evaluate 
rituximab-induced effector: target cell clustering. NK-CD16 cells stably expressing SmBiT 
(SmBiT-0L, SmBiT-1L, SmBiT-3L, and SmBiT-12L cells) had comparable CD16 and HA 
expression levels (Figure 39A). We also evaluated the SmBiT expressions in NK-CD16 cells by 
comparing them to the positive controls, the HeLa cells transiently expressing SmBiT (Figure 
39B). All four SmBiT+NK-CD16 cell lines (SmBiT-0L, SmBiT-1L, SmBiT-3L, and SmBiT-
12L) had substantially higher SmBiT expressions compared to the positive controls (Figure 
39B). No significant difference in SmBiT expressions among the four SmBiT+NK-CD16 cell 
lines was observed (p = 0.1, ordinary one-way ANOVA). CD20 expressions were comparable 
between CD20+LgBiT+ HeLa cell lines (LgBiT-0L, LgBiT-1L, LgBiT-3L, and LgBiT-12L cells) 
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(Figure 39C). While LgBiT-0L and LgBiT-1L had relatively lower LgBiT expressions, LgBiT 
levels in LgBiT-3L and LgBiT-12L were similar (Figure 39C). 
We imaged rituximab-induced NK-CD16 and CD20+HeLa interactions using LgBiT-12L: 
SmBiT-12L pair in 3D cell cultures for 48 hours (Figure 40). The biosensor system directly 
visualized cell clustering in both rituximab and control groups. The bioluminescent signals were 
relatively low at the beginning of the imaging study (0.5 hr), then increased and peaked around 
the 2.5 hour, suggesting frequent effector: target cell interactions (Figure 40A). The 
bioluminescent signals decreased from 2.5 to 9 hour. Substantially different bioluminescent 
signals were observed between the rituximab and control groups from 2.5 to 9 hour. The 
difference was the largest at 2.5 hour, where the peak signals of both rituximab and control 
groups were observed. Figure 40B showed the real-time bioluminescent images of NK-CD16 
and CD20+HeLa interactions in 3D cell cultures. 
Optimizing selectivity and sensitivity of the biosensor system in 3D cell cultures  
We then selected the biosensor pair with optimal sensitivity by evaluating the peak 
rituximab-specific signals from LgBiT+NK-CD16: SmBiT+CD20+HeLa cell interactions in 3D 
cell cultures (Figure 41A). Given the various expression levels of LgBiT in CD20+LgBiT+ HeLa 
cells (Figure 39C), rituximab-specific signals were normalized by the peak signals from the 
control group. The biosensor pair with the shortest theoretical combined spacer length (LgBiT-
0L+ SmBiT-0L) had the lowest rituximab-specific signal. The pair with the longest theoretical 
combined spacer length (LgBiT-12L: SmBiT-12L) had the highest rituximab-specific signal. The 
rituximab-specific signals increased as the theoretical combined spacer lengths increased from 0 
to 12 nm (i.e., LgBiT-0L: SmBiT-0L, LgBiT-1L: SmBiT-1L, and LgBiT-3L: SmBiT-3L. Figure 
41A). However, we found that the theoretical combined spacer length was not the sole 
determinant of the biosensor system selectivity. Although having longer theoretical combined 
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spacer length, the LgBiT-0L: SmBiT-12L pair had lower rituximab-specific signals compared to 
the LgBiT-3L: SmBiT-3L pair (p = 0.005, unpaired Student's t-test). The biosensor pairs with 
different theoretical combined spacer lengths, e.g., LgBiT-3L: SmBiT-3L, LgBiT-1L: SmBiT-
12L, and LgBiT-3L: SmBiT-12L, had comparable rituximab-specific signals (p = 0.9, ordinary 
one-way ANOVA).  
The LgBiT-3L: SmBiT-3L and LgBiT-12L: SmBiT-12L biosensor pairs were used as 
examples to demonstrate the impact of biosensor sensitivity on detecting antibody-specific 
signals due to their comparable LgBiT expression levels (Figure 41B, 41C, and 39C). Compared 
to the LgBiT-12L: SmBiT-12L biosensor pair, LgBiT-3L: SmBiT-3L biosensor pair had lower 
rituximab-specific signals (Figure 41B). The relatively lower sensitivity of LgBiT-3L: SmBiT-
3L biosensor pair than LgBiT-12L: SmBiT-12L biosensor pair in detecting rituximab-induced 
cell clustering was also observed in the real-time images (Figure 41C and Figure 42). LgBiT-
12L: SmBiT-12L biosensor pair was selected for the subsequent studies.  
Rituximab-induced effector: target cell clustering was promoted by increased rituximab 
concentration 
We further investigated antibody-induced effector: target cell interaction kinetics at different 
rituximab concentrations (1 and 100 µg/mL) when keeping other factors constant (e.g., E/T 
ratio). As Figure 43 shows, the rituximab-specific signal peaked at 2 hour in both dose groups, 
similar to the previous observations (Figure 40 – 42). Signals of the low dose group (1 µg/mL) 
were peaking at 2 hour and similar to the baseline at other time points. Compared to the low dose 
group, the high dose group (100 µg/mL) had substantially higher signals throughout the imaging 
study. The high dose group's higher signals were also observed in the real-time bioluminescent 
images (Figure 43B). These observations suggested that the magnitudes of antibody-induced 




Activating ADCC by NK cells is thought to be an important mechanism of action for many 
therapeutic antibodies, especially the ones treating cancers. More than 10 FDA-approved 
antibodies have shown ADCC effects, and the trend of antibody engineering focused on the 
improvement of antibody effector function is expected to continue [154,310]. The mechanisms of 
ADCC have been extensively studied in vitro. ADCC is initiated with immune: target cell 
conjugation and formation of immunological synapse [311]. NK cells encounter and recognize the 
target cells opsonized by antibodies, forming a firm adhesion to the target cell and a stable NK-
target cell interface with a ‘cleft,’ into which cytolytic molecules are secreted to eradicate the 
target cells [311]. There is good evidence that ADCC is involved with cancer treatment responses 
in animal models and patients [155,305,312-314]. However, the mechanisms of ADCC in vivo and 
the contribution of ADCC to antibody treatment responses have not been completely understood. 
Most measurements of ADCC consist of bulk assays or discontinuous methods, obscuring the 
spatial and temporal resolutions of ADCC effects and lacking the physiological context. Tools 
that noninvasively assess ADCC in the living system, especially in the tumor microenvironment, 
are highly desired.   
We developed a proximity-based biosensor system to detect the initial NK: target cell 
conjugation in ADCC effects and monitor the cell-clustering dynamics continuously and non-
invasively. We expressed structural complementary luciferase subunits to the opposing NK and 
target cells to indicate cell conjugation via strong and bright bioluminescent signals (Figure 36 
and Figure 37). To optimize the selectivity and sensitivity of the biosensor system, we equipped 
the split luciferases with different lengths of spacer to capture the distances between the 
opposing membranes in NK-target cell synapse, which are believed to be 15 – 40 nm (Figure 36 
and Figure 37, Table 10) [315,316]. The spacer –(GGGGS)n– was selected to construct the 
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biosensor systems for its flexibility, stability, and linearity [317]. The biosensor system detected 
the cell contacts with high sensitivity and successfully captured the elevated signals from NK-
target cell interactions (Figure 38D and 38E). 
We evaluated the NK-target cell conjugation induced by rituximab, an anti-CD20 antibody 
that mainly elicits treatment effects via ADCC, in 3D cell cultures that mimic the physiological 
conditions in solid tumors and minimize the interfere of shear force on cell conjugations  [318-
320]. The temporal change of NK-target interactions was visualized by robust bioluminescent 
signals (Figure 40). We observed dynamic bioluminescent signals from the control group 
(Figure 40), which indicated that NK-CD16 cells interacted with target cells in the absence of 
rituximab. This non-antibody-specific cell conjugation is possibly mediated by other receptors 
such as IL2R [321-325].  
The significantly higher yet simultaneous peak signals from the rituximab group compared to 
the control group indicated that rituximab increased NK: target cell conjugation frequencies 
rather than substantially shifted the cell conjugation dynamics (Figure 40). Similar findings were 
observed in the cell conjugation kinetics at different rituximab concentrations (Figure 43). These 
findings agreed with previous studies [326,327]. Another interesting finding was that the cell 
conjugation peaked at around 2 hours. This peak time may result from the rituximab and NK cell 
distribution kinetics. While rituximab can opsonize the target cells rapidly, NK cell trafficking to 
the 3D culture in a closed system could be relatively slower  [328,329]. Another possible 
explanation is the sequential killing effects of NK cells [330-334]. A single NK cell can 
sequentially attack successive targets. Choi and colleagues described bursting kinetics of NK 
cells by time-lapse single-cell imaging technology, in which a slow initial kill followed by rapid 
subsequent kills was described. The time taken to establish the first cell conjugate was around 80 
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mins for most NK cells [330]. The subsequent killing events were frequent within 1 – 4 hour 
[333]. These observations agreed with our findings (Figure 40 – 42). 
We observed that the biosensor system's selectivity and sensitivity did not solely depend on 
linker length (Figure 41). The biosensor pairs with inflexible split luciferase components (i.e., 
no spacer, LgBiT-0L) had the lowest S/N ratios regardless of the theoretical combined spacer 
lengths (Figure 41), suggesting that certain degrees of flexibility of the biosensor system are 
required to detect cell interactions. Yielding approximately 12, 26, and 30 nm theoretical 
combined spacer lengths (LgBiT-3L: SmBiT-3L, LgBiT-1L: SmBiT-12L, and LgBiT-3L: 
SmBiT-12L, respectively), which are close to the theoretical distances between opposing cell 
membranes in a synapse (15 – 40 nm), the biosensor pairs showed similar rituximab-specific 
bioluminescent signals. The pair with longer theoretical combined spacer lengths did not show 
superior sensitivity (Figure 41A). These observations could be possibly explained by the 
unstable distances between the opposing cell membranes in synapses. Rather than rigid surfaces, 
cell membranes in the synapse are constantly moving and changing along with synapse 
formation progress. The weak binding (190 µM) between the luciferase subunits in the biosensor 
system can be easily interrupted by the membrane movement even though the biosensor pairs' 
theoretical combined spacer lengths were adequate, limiting the detection sensitivity. LgBiT-
12L: SmBiT-12L pair provided the highest sensitivity in detecting cell conjugations, possibly 
due to the adequate flexibility on both sides of the pair. 
In summary, we showed that the proximity-based biosensor system allowed a continuous and 
noninvasive observation of antibody-induced cell clustering dynamics in tumor-like 3D cell 
cultures. The biosensor system robustly detected signals arising from antibody-specific cell 
conjugations at low target cell levels (less than 0.5 million), which was substantially lower than 
the cell numbers in real solid tumors (at least 1,000 million) [335], demonstrating the great 
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potential of applying this biosensor system in detecting cell clustering dynamics in vivo. 
Moreover, we demonstrated that the biosensor system's selectivity and sensitivity could be 
optimized based on synapse sizes. This feature enables detecting synapses induced by other 
treatment modalities, such as T-cell: tumor cell conjugation induced by bispecific T-cell 
engagers. Our studies have several limitations. Firstly, antibody and NK cell distribution kinetics 
in the 3D cell culture was not investigated. The antibody-specific NK: target cell conjugation 
could be restricted at the periphery of 3D culture due to the slow antibody distribution rate in the 
tumor-like matrix. Secondly, the NK: target cell clustering dynamics were measured in a closed 
system, which did not incorporate the complex physiological factors, including antibody 
pharmacokinetics, NK cell distribution kinetics, and the influences of the complex solid tumor 
microenvironment. Thirdly, we did not establish the relationship between cell conjugation with 






Figure 36: Construction of biosensor system plasmids 
(A) LgBiT or SmBiT constructed in pDisplay vector. (B) The CMV-LgBiT-(GGGGS)n-PDGFR-TM gene was 







Figure 37: A proximity-based luminescent biosensor system can be used to detect immune: target cell  
dynamic interactions with high selectivity and sensitivity.  
(A) The schematic of the biosensor system. Briefly, two structurally complementary luciferase subunits in the 
NanoBiT® system, Large_BiT and Small_BiT, were separately anchored to the surfaces of immune cells and tumor 
cells by the spacers with various lengths. Once immunological synapses are formed, the proximity between tumor 
and immune cells allows integration of Large_BiT and Small_BiT, forming active luciferases that emit strong 
luminescence upon stimulus. The spacer–(GGGGS)n– was selected in constructing the biosensor system for its 
flexibility, stability, and linearity. The length of the GGGGS spacer is 1.9 nm per unit. (B) Optimizing the 
sensitivity and selectivity of the biosensor system by adjusting combined spacer lengths. The biosensor system 
subunits have different spacer lengths, facilitating the optimization of the signal-to-noise (S/N) ratios. When 
combined spacer lengths were too short, the sensitivity of detection by the biosensor system will decrease (middle 
panel). When combined spacer lengths were too long, the biosensor system will create high background signal and 










Figure 38: Engineered biosensor system detected cell-cell interactions with high sensitivity. 
(A) LgBiT and SmBiT were successfully expressed in HeLa cells as indicated by HiBiT probing (Left panel, p < 
0.0001, unpaired Student's t-test) or HA tag probing (Right panel, p < 0.0001, unpaired Student's t-test). (B) LgBiT 
and SmBiT were majorly expressed on cell membranes. Left panel: Compared to HeLa WT cells, LgBiT expression 
on membrane and in cytosol were significantly elevated (p = 0.0005 and p = 0.007, unpaired Student's t-test). 
Membranous LgBiT expression was substantially higher than cytosolic expression (p = 0.0070, unpaired Student's t-
test). Right panel: Compared to HeLa WT cells, SmBiT expression on membrane and in cytosol were significantly 
elevated (p = 0.02 and p = 0.01, unpaired Student's t-test). Membranous SmBiT expression was substantially higher 
than cytosolic expression (p = 0.02, unpaired Student's t-test). (C) Co-expressed LgBiT and SmBiT emitted strong 
luminescent signals compared to LgBiT- or SmBiT-positive cells alone (p < 0.0001, unpaired Student's t-test). (D) 
Biosensor system detected cell contacts that elevated by centrifugation. Compared to centrifuged LgBiT- or SmBiT-
positive cells alone and uncentrifuged LgBiT:SmBiT cell mixtures, the bioluminescent signals of centrifugated 
LgBiT:SmBiT cell mixtures increased significantly (p = 0.0003, p < 0.0001, and p < 0.0001, unpaired Student's t-
test). (E) Hela: NK-CD16 interactions were elevated by anti-EGFR antibody cetuximab. The bioluminescent signals 
were measured after 30-min incubation of Hela and NK-CD16, with or without cetuximab. Cetuximab elevated 
bioluminescent signals significantly in both E/T= 10 group and E/T= 5 group (p = 0.001 and p = 0.03, unpaired 
Student's t-test).  Cetuximab-specific signals were higher in E/T= 10 group than E/T= 5 group (p = 0.03, unpaired 
Student's t-test). From (A) to (E), each data point represents one technical replicate. Error bars represent SD values. 
At least three independent biologic replicates were performed per experiment. MEM = membranous; cyto = 






Figure 39: Constructing biosensor system in NK-CD16 and CD20+HeLa cells. 
(A) NK-CD16 cells were genetically engineered to have high SmBiT (SmBiT-0L, SmBiT-1L, SmBiT-3L, and 
SmBiT-12L) expression. SmBiT-positive cells were sorted by HA tag (Dylight 650) and CD16 (Cy3). (B) SmBiT 
expression in SmBiT-0L, SmBiT-1L, SmBiT-3L, and SmBiT-12L were comparable (p = 0.1, ordinary one-way 
ANOVA) and significantly higher than positive controls, i.e., HeLa cells transiently-expressing SmBiT (p = 0.0001, 
p = 0.002, p = 0.002, and p = 0.0005, unpaired Student's t-test). (C) CD20 expressions were comparable between 
CD20+LgBiT+ HeLa cell lines (LgBiT-0L, LgBiT-1L, LgBiT-3L, and LgBiT-12L cells, p = 0.11, ordinary one-way 
ANOVA). (D) LgBiT expression in CD20+LgBiT+ HeLa cell lines. No significant difference was observed in LgBiT 
expression in LgBiT-3L and LgBiT-12L cells. p = 0.11, unpaired Student's t-test). In (B) and (C), each data point 
represents one technical replicate. Error bars represent SD values. At least three independent biologic replicates 






Figure 40: Visualizing NK-CD16 and CD20+HeLa interactions in 3D cell cultures.  
(A) Baseline-corrected bioluminescent signals from NK-CD16 and CD20+HeLa interactions. LgBiT-12L: SmBiT-
12L pair was used. Each data point represents one technical replicate. Error bars represent SD values. At least three 
independent biologic replicates were performed per experiment. (B) Bioluminescent images of NK-CD16 and 










Figure 41: Optimizing selectivity and sensitivity of the biosensor system in 3D cell cultures  
(A) LgBiT-12L: SmBiT-12L pair showed the optimal sensitivity compared to other pairs. LgBiT-3L: SmBiT-3L 
pair showed higher normalized rituximab-specific signals than LgBiT-0L: SmBiT-0L and LgBiT-1L: SmBiT-1L 
pairs (p = 0.002 and p = 0.03, unpaired Student's t-test). LgBiT-12L: SmBiT-12L pair showed higher normalized 
rituximab-specific signals than LgBiT-0L: SmBiT-12L, LgBiT-1L: SmBiT-12L, and LgBiT-3L: SmBiT-12L pairs 
(p = 0.004, p = 0.04, and p = 0.03, unpaired Student's t-test). (B) Corrected bioluminescent signals indicated LgBiT-
12L: SmBiT-12L pair showed higher selectivity than LgBiT-3L: SmBiT-3L pair. In (A) and (B), each data point 
represents one technical replicate. Error bars represent SD values. At least three independent biologic replicates 
were performed per experiment. (C) Bioluminescent images of NK-CD16 and CD20+HeLa interactions at 0.5, 2.5, 







Figure 42: LgBiT-3L: SmBiT-3L pair showed less sensitivity in detecting NK-CD16 and CD20+HeLa  
interactions compared to LgBiT-12L: SmBiT-12L pair. 
(A) Raw data of bioluminescent signals from NK-CD16 and CD20+HeLa interactions. LgBiT-3L: SmBiT-3L pair 
was evaluated. Each data point represents one technical replicate. Error bars represent SD values. At least three 
independent biologic replicates were performed per experiment. (B) Bioluminescent images of NK-CD16 and 






Figure 43: Rituximab-induced effector: target cell clustering was promoted by increased rituximab  
concentration 
(A) Corrected bioluminescent signals from NK-CD16 and CD20+HeLa interactions, which was visualized by 
LgBiT-12L: SmBiT-12L pair. Each data point represents one technical replicate. Error bars represent SD values. At 
least three independent biologic replicates were performed per experiment. (B) Bioluminescent images of NK-CD16 






WHICH FACTORS MATTER THE MOST: REVISITING AND DISSECTING 
ANTIBODY THERAPEUTIC DOSES6 
 
6.1 Overview 
Factors such as antibody clearance and target affinity can influence antibodies’ effective 
doses for specific indications. However, these factors vary considerably across antibody classes, 
precluding direct and quantitative comparisons. Here, we applied a dimensionless metric, the 
therapeutic exposure affinity ratio (TEAR), which normalizes the therapeutic doses by antibody 
bioavailability, systemic clearance, and target binding property to enable direct and quantitative 
comparisons of therapeutic doses. Using TEAR, we revisited and dissected the doses of up to 60 
approved antibodies. We failed to detect the significant influence of target baselines, turnovers, 
or anatomical locations on antibody therapeutic doses, challenging the traditional perceptions. 
We highlighted the importance of antibody modes of action to the therapeutic doses and dose 
selections, and antibodies that work through neutralizing targets show the highest TEARs than 
those working through other mechanisms. Overall, our analysis provided insights into the factors 
that influence antibody doses, and also inferred factors critical for antibody pharmacological 
effects. 
 
                                               
6 This chapter includes a manuscript under review: Tang, Y., Li, X., & Cao, Y. Which Factors Matter the 





Successfully developing a therapeutic monoclonal antibody requires an integration of 
multidisciplinary expertise. Many aspects need to be rigorously evaluated at each development 
stage, including the target biology and pathological relevance, antibody formats and properties, 
optimal doses and exposures, and efficacy/toxicity profiles [336]. Once antibodies enter the 
clinical stages, the focus of development will be establishing the safety and efficacy profiles and 
determining the optimal dose and regimen that will result in the highest efficacy/toxicity ratio 
[337]. There are many factors that may influence the effective doses for an antibody (Figure 44). 
Model-informed drug development (MIDD) approaches have played substantial roles in antibody 
dose selection, optimization, and individualization [338]. The implementation of MIDD 
approaches in dose selection entails thorough consideration of the target attributes (baseline and 
turnovers), antibody pharmacokinetics (PK), target binding properties, modes of action (MoAs), 
and patient characteristics [22,23,143,339-341]. A systematic analysis of these factors by surveying 
the labeled doses of approved antibodies can help us better understand the factors that contribute 
the most to dose selection. 
However, therapeutic doses are mostly determined on a case-by-case basis. The factors that 
affect antibody therapeutic doses vary considerably, complicating direct and quantitative 
comparisons across antibody classes and indications [342-344]. Because of their diverse clinical 
indications and distinctive dose-response relationships, antibodies often have broadly different 
therapeutic doses, even for those with identical targets and similar target binding properties. For 
example, rituximab and obinutuzumab have very different approved doses and dosing regimens 
for treating chronic lymphocytic leukemia despite their close affinities to CD20 [345]. 
Furthermore, the factors considered in the dose-searching process differ between early and late 
clinical trials. First-in-human (FIH) dose decisions often consider the target and target-binding 
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properties to ensure safe animal-to-human translation. In contrast, the confirmation of the 
therapeutic doses at phase II or III trials is usually based on the clinical efficacy/toxicity profiles 
and dose−response relationships [168,226,342,343,346,347]. As such, the factors affecting antibody 
doses cannot be directly examined across antibodies. Many retrospective studies have 
investigated antibody doses and the relevant factors in regulatory perspectives, without 
quantitative assessments of the pertinent factors that define the therapeutic doses and the 
dose−response relationships [342,343]. 
Here, we developed a dimensionless metric, the therapeutic exposure affinity ratio (TEAR), 
to facilitate direct analyses and quantitative comparisons of the factors that influence therapeutic 
doses across antibodies. Using TEAR, we revisited all the influencing factors and then 
performed a quantitative analysis of up to 60 antibodies that have been approved by either the 
U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) from 
1997 to 2019. We quantitatively evaluated the factors associated with the doses and dose 
selection across antibodies, indications, target properties, and development stages.  
6.3 Materials and Methods 
Definition of TEAR 
TEAR = log (Css/KD). In the definition of TEAR, Css is plasma therapeutic concentration at 
the steady-state under the approved maintenance doses and dosing regimens, and KD is target 
affinity, known as the target dissociation constant measured using the surface plasmon resonance 
(SPR) approach.  




         (Eq. 1) 
 
 147 
where F is the bioavailability; Dose and  are the therapeutic maintenance dose and dosing  
interval, respectively; and CL is the systemic clearance. For approved antibodies with nonlinear 
clearance, the CL at the Css is applied.  
Assuming that the KD derived in vitro reveals the antibody−target binding in vivo, Css /KD 
can be used to reflect the receptor occupancy in the peripheral blood (pRO) at the approved 
therapeutic doses, according to the Hill-Langmuir function, as shown in the equations below. 
pRO = [+~~]
[+~~]wy
     (Eq. 2) 
or    pRO = [+~~]
[+~~]wy
 =   [+~~]/wy
[+~~]/wy5
      (Eq. 3) 
As shown in Eq. 3, pRO is a function of Css/KD. When Css/KD = 100, TEAR = 2 and pRO ≈ 
99%.  Notably, pRO cannot be directly interpreted as the RO at the sites of action when the 
targets are in tissues. However, pRO or TEAR can be taken as an indicator of the relative levels 
of approved therapeutic doses for an antibody compared to others. The specifications for these 
parameters are provided in Table 11. 
Notably, we defined the log-transformed Css/KD as TEAR considering that the log-
transformed Css/KD values fall within a normal distribution, enabling robust statistical 
comparison (Figure 45). 
Target Turnover Rates  
We defined the target turnover rate as the total amount of targets produced by the system per 
hour. The target turnover rate is calculated by multiplying the target baseline concentration (nM) 
with the target first-order degradation rate (hr -1), as shown in the equation below. 
Target turnover rate =   (Eq. 4) 
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Specifically, for a soluble target, the plasma baseline was directly adopted, and the 
degradation rate was derived based on the reported plasma half-life. For a membranous target, 
the degradation rate was set to the antibody-complex endocytosis rate, and the target baseline 
was converted into an equivalent plasma concentration. 
Target plasma baseline =                 (Eq. 5) 
RN is the receptor number/cell. CN is the cell number per 1 L blood or 1 g tissue. For 
tumors, 1 g is close to 109 tumor cells [335]. Vp represents the plasma volume (2.6 L) [21]. The 
target turnover rate reflects the total turnover rate of the target in the system, which enables 
direct comparisons across target types and locations. A summary of all the target turnovers is 
provided in Table 12. 
Data Sources  
In total, 60 antibodies and antibody-based biologics that were approved 
by the EMA or FDA between 1995 and 2019 were included in our analyses. 
The excluded antibodies were: (1) those withdrawn or marketing discontinued antibodies or 
fusion proteins (e.g., muromonab-CD3, efalizumab, tositumomab-
I131, daclizumab, catumaxomab, edrecolomab, Nebacumab, and alefacept); (2)  antibody-drug 
conjugates (e.g., brentuximab vedotin, ado-trastuzumab 
emtansine, inotuzumab ozogamicin, gemtuzumab ozogamicin, and polatuzumab vedotin); (3) bi-
specific antibodies (e.g., emicizumab and blinatumomab); (4) antibodies 
with neither bioavailability (F), non-specific clearance (CL), nor in vitro antigen-binding 
dissociation constant (KD) information available (e.g., Ibritumomab tiuxetan, efmoroctocog-
α, eftrenonacog-α, mogamulizumab, and ustekinumab); (5) single-dosed antibodies that cannot 
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support Css calculation, including abciximab, 
alemtuzumab, basiliximmab, bezlotoxumab, idarucizumab, obiloxaximab, and raxibacumab; and 
(6) local dosing and acting antibodies (e.g., aflibercept, ranibizumab, and brolucizumab).   
We obtained the labeled therapeutic doses and dosing regimens from 
the Drugs@FDA website and the literature. The following information was also collected: 
(1) molecular weight, (2) administration route, (3) F, (4) KD, (5) CL, (6) target abundance and 
half-life, (7) the approved indications, and (8) the modes of 
action. More specifications for these parameters were provided in the Data in Brief.  
Categorization of the Target locations and Properties 
Circulation vs. tissue: We categorized antibodies with targets predominantly expressed in 
either the blood or the lymph system or on circulating lymphocytes as the circulation group. For 
example, CD20 is a membrane-associated receptor that is widely expressed on B-lymphocytes. 
We categorized CD20 into the circulation group because of the location of CD20-expressing 
cells. Antibodies with targets expressed in tissues, such as skin and tumors, were included in the 
tissue group. We included antibodies with targets that are present in both the circulation and 
tissues in both groups. Notably, the distribution of targets is considered under pathological 
conditions. 
Soluble vs. membranous targets: We categorized the receptors expressed on the cell 
membrane as membranous targets, such as epidermal growth factor receptors (EGFR). The 
ligands that freely distributed in the blood, the lymphatic system, and interstitial fluids were 
defined as soluble targets, such as viruses and cytokines. If a target has both soluble and 
membranous forms, it was included in both categories. We did not consider shredding of 




Specific anatomical sites:  
Anatomical sites of cancer: The anatomical locations of antibodies’ initially-approved 
cancer indications were surveyed and grouped according to the National Cancer Institute criteria, 
including breast (pertuzumab and trastuzumab), digestive/gastrointestinal (GI) system 
(ramucirumab, panitumumab, and bevacizumab), gynecological system (atezolizumab and 
durvalumab), head and neck (cetuximab), blood and lymph system (elotuzumab, daratumumab, 
obinutuzumab, ofatumumab, and rituximab), musculoskeletal system (olaratumab), neurologic 
system (dinutuximab),  respiratory/thoracic system (necitumumab), and skin (pembrolizumab, 
nivolumab, ipilimumab, cemiplimab, and avelumab). The anatomical location groups including 
three or more than three antibodies were analyzed.  
Anatomical sites of autoimmune diseases: The anatomical locations of antibodies’ initially-
approved indications in autoimmune diseases were surveyed and grouped into the blood and the 
lymph system (emapalumab, omalizumab, belimumab, mepolizumab, reslizumab, rituximab, and 
siltuximab), synovial fluid (abatacept, rituximab, sarilumab, tocilizumab, adalimumab, 
etanercept, and golimumab), bronchoalveolar lavage fluid (mepolizumab, reslizumab, and 
benralizumab), cerebrospinal fluid (natalizumab and ocrelizumab), skin lesions (brodalumab, 
guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, belimumab, and 
dupilumab), and colons (vedolizumab, infliximab, and dupilumab). The anatomical location 
groups including three or more than three antibodies were analyzed. 
Phase II dose selection rationales 
MABEL-based biomarkers for P2D selection included the experimentally-measured or 
model-informed target saturation on the cell surface targets, the saturation of target-mediated 
clearance, and other pharmacological effects that pre-defined as MABEL. Efficacy-based 
 
 151 
biomarkers included pharmacological responses and clinical outcomes that were not pre-defined 
as MABEL. 
When available, the first-in-human dose (FIHD) and the maximum administered dose 
(MAD) tested in the clinical trials of an approved antibody were analyzed. All the tested doses in 
the phase II trials (phase II doses [P2Ds]) recorded by the U.S. Food and Drug Administration 
(FDA) reviews were also included in this study. For single administration in clinical trials,  was 
set to the mean dosing interval (14 days). FIHD, MAD, and P2D were used to derive three 
metrics similar to the therapeutic exposure affinity ratio (TEAR), namely TEARFIHD (log 
[Css,FIHD/KD]),  TEARMAD (log [Css,MAD/KD]), and TEARP2D (log [Css,P2D/KD]), for comparison 
across antibodies. A summary of the FIHD, MAD, and P2Ds is provided in Table 13. 
6.4 Results 
Definition of TEAR  
Many factors are involved in the cascade of antibody pharmacological actions. These factors 
shape the translation from the dose to the efficacy/safety outcome, including the antibody PK, 
biodistribution into the target tissue, target binding affinity, target turnovers, and many 
immunological events following target activation (Figure 44). The variance of therapeutic doses 
is influenced by almost all the factors involved in antibody pharmacological actions (Figure 44). 
These factors vary drastically across antibody classes and indications, precluding direct and 
quantitative comparisons. 
TEAR was developed as a dimensionless metric, and its definition is shown in Materials 
and Methods. TEAR, by normalizing the therapeutic doses through the use of factors with 
relatively high quantitative certainty, such as bioavailability (F), systemic clearance (CL), and 
target binding property (KD), can help us focus on factors that are difficult to quantify or 
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evaluate, such as MoAs and target anatomical locations. The remaining factors that are not 
included in the TEAR equation account for the variance of TEAR (Figure 44). Instead of 
comparing therapeutic doses directly, TEAR allows us to compare the affinity-normalized 
therapeutic concentration and further compare the factors that influence the therapeutic doses. 
For instance, if most of antibody X’s targets are in the extravascular space, its TEAR should be 
relatively higher to compensate for the antibody-limited extravascular distributions [34]. 
Likewise, if antibody Y’s targets are mainly in the blood, its TEAR should be relatively lower 
than that of antibody X. This speculation is valid only when the target location and antibody 
tissue distribution affect the therapeutic dose levels; otherwise, there will be a limited difference 
between the TEARs of X and Y even with different target locations. Similarly, we can use TEAR 
values to quantitatively and systematically evaluate the factors that influence the therapeutic 
doses, including the target attributes (baselines and turnovers), MoAs, disease types, and even 
the development stages. TEARs make it possible to make comparisons across antibodies. 
Moreover, TEARs have a great dynamic range and follow the normal distribution, ensuring 
robustness in statistical analysis (Figure 45).  
Receptor Occupancy (RO) in the Circulation 
Receptor occupancy (RO) is the most common indicator for dose adequacy, which is often 
used to predict antibody efficacy and safety profile [226,346]. The measure of RO in vivo or ex 
vivo reveals an antibody’s key properties for engaging with its target, a critical step before the 
pharmacological actions and therapeutic responses. Once the safety profile is cleared and the risk 
of hyper-inflammation at the early clinical stages is minimized, a nearly saturated RO (close to 
100%) is usually desired for the highest efficacy potential [226,346]. Together with PK analysis, 
RO measurement is often integrated to support the evaluation of the effective doses and dosing 
regimens of antibodies [226,346]. 
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RO is typically measured on circulating targets or blood cells from peripheral blood samples 
using flow cytometry. Many studies have measured the RO in peripheral blood (pRO) to assist 
dose selection at the early clinical stages [190,348-353]. The phase 2 dose of anti-SLAM-7 
elotuzumab was set at 20 mg/kg given the fact that the SLAM-7 RO at this dose was ≥ 95% 
[348]. The anti-CD38 antibody daratumumab had a phase 2 dose of 16 mg/kg because of the 
nearly saturated target at this dose level [349,350]. Anti-PD-1 pembrolizumab’s phase 2 dose was 
determined based on the evidence that the maximum pRO was reached at ≥ 1 mg/kg every three 
weeks [351]. Notably, the targets of these antibodies are primarily in the circulation or the 
lymphoid tissues, which have high antibody permeability. For the antibodies with targets in 
distant tissues where the antibody has limited distribution, pRO will be limited to reflect the 
target engagement at the site of action [120]. Therefore, the target anatomical location is often 
regarded as an important factor influencing antibody therapeutic doses, which will be reviewed 
in the next section.  
Developed based on the Hill-Langmuir function, TEAR can infer the pRO as the plasma 
concentration was considered in Equation (1). Based on Equation (2), TEAR = 0.5 represents 
pRO ≈ 76%, and TEAR = 2 suggests a nearly complete pRO (≈ 99%). TEAR ≥ 2 indicates that 
the labeled therapeutic dose is more than enough to saturate the peripheral circulating targets. 
Likewise, when an antibody has TEAR ≥ 2, other factors beyond the pRO apparently influence 
the selected therapeutic dose. 
Using TEAR, we evaluated the pRO of most approved antibodies (n = 60) at their therapeutic 
doses. As seen in Figure 46, the TEARs of the 60 approved antibodies ranged from 1.1 to 5.9, 
which yielded approximately 92% to 100% pRO. Interestingly, most of the antibodies (55 out of 
60) had TEARs > 2, suggesting that most antibodies at their approved therapeutic doses could 
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almost completely saturate the circulating targets. Moreover, 38 of the 55 antibodies had 
therapeutic doses at least 10 times higher than the doses yielding 99% pRO (TEAR ≥	3), and 15 
antibodies had therapeutic doses over 100-fold higher than the doses yielding 99% pRO (TEAR 
≥	4). The most intriguing observation was that the antibodies whose targets were primarily in the 
peripheral blood had even higher TEARs than the antibodies with distal targets. For example, 
emapalumab, an antibody that neutralizes the circulating IFNγ, had the highest TEAR (5.83). 
Therefore, we speculate that additional factors beyond pRO are involved in determining 
antibodies’ therapeutic doses, even for those whose targets are in the peripheral blood. 
Effect of Target Anatomical Locations on Therapeutic Doses 
Antibodies typically have poor tissue penetration ability due to their large molecular sizes 
(145 kD) and high polarity [34]; thus, antibodies whose targets are outside the vascular space or 
the lymphoid system are expected to have relatively higher therapeutic doses to achieve 
sufficient exposure at their action sites. The gradient of antibody distribution from the blood into 
the tissue interstitial space is sharp, with an interstitial:plasma concentration ratio of around 5–
15%, and the antibody distribution into the brain is even lower, with a ratio of about 0.1–0.5% 
[21]. Compared to normal tissues, the antibody distribution in pathological tissues such as tumors 
could be different due to alterations in the tissue physiological conditions such as vascular 
structure and leakiness. Many studies have suggested that the antibody distribution into solid 
tumors is extremely low, and relatively high doses are required to achieve therapeutic exposure 
when the distribution is limited in the target tissues [71,233,354]. 
To determine the effect of the target anatomical location on antibody therapeutic doses, we 
divided antibodies into two groups: antibodies whose targets are in the circulation (Circulation) 
and antibodies whose targets are in distal tissues (Tissue). The criteria for categorization was 
described in the Materials and Methods. Conceptually, antibodies whose targets are in distal 
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tissues are expected to have higher therapeutic doses and greater TEARs than those with 
circulating targets. We compared the TEARs of the two groups; intriguingly, they were not 
statistically different (p = 0.99, unpaired Student’s t-test, Figure 47A). This observation was 
contrary to the traditional perception of the strong influence of antibody distribution on 
therapeutic dose selection. 
The antibodies were further divided into two groups based on their target cellular locations: 
membranous vs. soluble targets. We found that the TEARs of the antibodies with soluble targets 
were notably higher than TEARs of the antibodies with membranous targets (3.7 vs. 3.0, p = 
0.0022, unpaired Student’s t-test, Figure 47A). This observation suggested that higher 
therapeutic doses are generally required to effectively suppress soluble targets compared to 
membranous targets. The different TEARs associated with certain target cellular locations are 
correlated with another factor: MoAs. This will be analyzed and discussed in the MoA section. 
To further explore the impact of the target location on therapeutic doses, we cross-examined 
the TEARs in four disease-target scenarios: the circulation-soluble, circulation-membranous, 
tissue-soluble, and tissue-membranous scenarios. As shown in Figure 47B, the prevalent 
diseases in each scenario were autoimmune diseases with targets in the circulatory system 
(circulation-soluble), hematologic malignancies (circulation-membranous), autoimmune diseases 
with tissue targets (tissue-soluble), and solid tumors (tissue-membranous). Notably, the TEARs 
were significantly lower for the antibodies in the circulation-membranous group than in the 
circulation-soluble group (p = 0.0065, unpaired Student’s t-test, Figure 47B). The fact that the 
two groups’ TEARs were different may be associated with distinct MoAs. Antibodies with 
targets such as BAFF, IL-1β, IFNγ, IL-5, IgE, IL-6, and IL-6R were included in the circulation-
soluble group. These antibodies elicit treatment effects by neutralizing soluble ligands. Targets 
of the antibodies in the circulation-membranous group were primarily expressed in the 
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circulating cells, such as PD-1, CD38, SLAMF7, and CD20. The MoAs of these antibodies 
mostly relate to immune dysfunction. No significant difference was detected between any other 
two groups. 
We further explored the target anatomical sites by disease type as described in the Materials 
and Methods. We found that the anti-cancer antibodies targeting the blood and lymph system 
have significantly lower TEARs than those targeting the digestive/GI system (p = 0.006, 
unpaired Student’s t-test, Figure 47C) but have no substantial difference compared to the ones 
targeting the skin. One possible explanation for these observations is the similar MoAs between 
the antibodies in the blood/lymph system and the skin groups and the different MoA of the 
antibodies indigestive/GI system group. The antibodies in the blood/lymph system and the skin 
groups elicit treatment effects via the systemic effects by recruiting the immune cells from the 
periphery towards the induction sites. The antibodies in the digestive/GI system group 
(ramucirumab, panitumumab, and bevacizumab) mainly block the pathogenic receptor-ligand 
interactions. A similar analysis of antibodies in the treatment of autoimmune diseases suggested 
that the TEARs were not significantly different across the anatomical sites (p = 0.39, unpaired 
Student’s t-test, Figure 47D). Notably, the analyzed antibodies for autoimmune diseases have 
the same MoA (neutralizing soluble ligands). These observations suggest that compared to the 
disease type and target anatomical location, antibody MoAs may have a more significant role in 
antibody dose selection.  
Therapeutic Doses for Antibodies with Systemic Effects 
For antibodies with systemic effects, the primary target locations can have a reduced 
influence on the therapeutic doses. For example, for the antibodies treating metastatic 
malignancies, the therapeutic effect should go beyond the primary tumor sites and reach the 
metastatic lesions [165,355-357]. Therefore, the antibody distribution into the primary tumor sites 
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may become less important to the overall response and the required doses for therapy. One recent 
trial showed that the patients whose metastases at multiple anatomical sites responded to a 
similar degree to pembrolizumab are likely to have a better survival benefit, even though these 
anatomical sites could have different degrees of antibody distribution [45,165,166]. The 
dose−response relationships for pembrolizumab and several other checkpoint inhibitors are quite 
flat and sometimes obscure partly owing to the heterogeneity in metastatic sites and lesions [358-
360]. One recent study suggested that the relatively flat dose-response curve for pembrolizumab 
in the dose range of 2 to 10 mg/kg were confounded by various factors due to the intricate 
interplay of patient demographic, disease status, antibody exposure, and treatment response [361]. 
Interestingly, the poor responders to checkpoint inhibitors often have distinct degrees of response 
across metastatic lesions. One theory for this is that systemic activation of the immune function 
is required in the responding patients. The systemic immune activation is closely related to 
antibody exposure in the secondary lymphoid tissues, and is less dependent on antibody 
penetration to either the primary tumor sites or the metastases [162-164]. This theory is reiterated 
by the observation that the antitumor immunity newly recruited from the periphery rather than 
the locally reinvigorated immunity had greater contributions to the response to the checkpoint 
blockade [162-164]. Several studies observed high recruitment of peripherally activated immunity 
in the responding lesions [173,362-364]. The “systemic effect” of checkpoint inhibitors is recapped 
by the responding lesions in the brain, which antibodies almost cannot penetrate [21,364]. Thus, 
the therapeutic doses of antibodies with systemic effects will be less dependent on the extent of 
such antibodies’ distribution into the primary target sites, confirming our finding that there is no 
correlation between the target anatomical location and the therapeutic dose (Figure 47C). The 
flat dose−response curves for many immunotherapies suggest the low threshold of dose and 
exposure for a systemic activation of the immune function [190,351,352,365]. 
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Effect of Target Turnovers on Therapeutic Doses 
Previous theoretical studies have broadly evaluated the factors that may influence antibody 
therapeutic doses. These theoretical analyses were primarily based on the target-mediated drug 
disposition (TMDD) modeling framework [132]. Anticipated antibody doses were simulated 
using the TMDD model with sufficient target engagement. A theoretical study suggested that 
target baseline and turnover significantly influence the effective doses of antibodies [186]. Target 
anatomical locations, antibody mechanism of action, and many other pharmacologically relevant 
factors have not been considered in such analyses [147,186]. 
We evaluated the impact of target baseline levels and target turnover on dose selection. We 
calculated the turnovers of the targets for each approved antibody. The calculation of the target 
turnovers is shown in Materials and Methods, which consisted in multiplying the target 
baseline (target plasma or equivalent plasma concentrations) by the degradation rate. The 
turnovers reflect the total target replenishing amount per hour. A total of 56 antibodies and the 
turnovers of their respective targets are summarized (Data in Brief). Unexpectedly, no significant 
correlation was detected between the TEARs and the target turnovers (p = 0.23, Pearson’s 
correlation). We also did not observe a clear correlation between the TEARs and the target 
turnovers in any subgroup: circulation, tissue, membranous, or soluble (Figure 47E). These 
observations were contrary to the theoretical predictions, suggesting that the influence of the 
target turnovers on therapeutic doses is probably not as significant as is generally thought. We 
did not observe a significant correlation between the TEARs and the target baselines neither 
(Figure 48). 
Furthermore, we examined the antibodies with extremely high or low target turnovers. A few 
antibodies with high target turnovers appear to have high TEARs, such as eculizumab. The target 
of eculizumab (i.e., complement component 5 [C5]) has the highest target turnover (15,385 
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nM∙hr-1) among all the analyzed targets. Eculizumab has a TEAR as high as 4.52, which is 
higher than the TEARs of 90% of the analyzed antibodies (Data in Brief), implying that the high 
dose of eculizumab may be related to the high turnover of its target C5. The target of 
risankizumab (interleukin 23 [IL-23]) has a much lower turnover (0.00193 nM∙hr-1, Data in 
Brief) compared to C5, but risankuzumab was labeled with an even higher therapeutic dose, 
resulting in the TEAR of risankuzumab being as high as that of eculizumab (4.55 vs. 4.52, Data 
in Brief). Another striking case is erenumab, an antibody targeting the calcitonin gene-related 
peptide receptor (CGRPR). CGRPR was found to have one of the slowest turnovers (3.9·10-5 
nM∙hr-1), but erenumab has a 3.78 TEAR, higher than those of 70% of the surveyed antibodies. 
Overall, while the target turnovers probably influence the therapeutic doses of some antibodies, 
their general relevancy to therapeutic doses warrants further investigation.  
Therapeutic Doses for Antibodies with Different MoAs  
In general, therapeutic antibodies elicit pharmacological effects via three distinct MoAs 
(Figure 49A): target neutralization (soluble targets), intracellular signaling suppression 
(membranous targets), and immunomodulation (interaction with the immune systems). The 
schematic of these three types of MoAs is shown in Figure 49A. Antibodies can activate the 
immune function via the Fcγ receptors (FcγR) on the effector cells through their Fc domains 
upon antibody−target binding. Antibodies can trigger natural killer cells to secrete various 
proteins for lysing the target cells (antibody-dependent cellular toxicity [ADCC]), or through 
macrophages for inducing phagocytosis (antibody-dependent cellular phagocytosis [ADCP]). 
Antibody Fc domains can also recruit C1q, triggering complement cascade and exerting 
complement-dependent cytotoxicity (CDC) (Figure 49A). 
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We compared the TEARs of antibodies with different MoAs. The antibodies that suppress 
membranous signaling had significantly lower TEARs than the ones that neutralize targets (p = 
0.02, unpaired Student’s t-test, Figure 49B). For antibodies targeting distinct components of the 
same pathway (receptor vs. ligand), antibodies suppressing the transmembrane receptor generally 
have lower TEARs than those neutralizing the ligands. For instance, the anti-IL-5R antibody 
benralizumab had a lower TEAR than both anti-IL-5 antibodies mepolizumab and reslizumab 
(2.8 vs. 4.1 and  3.7). This trend also holds for anti-IL-17/17R antibodies, where brodalumab has 
a much lower TEAR than ixekizumab and secukinumab (2.1 vs. 3.3 and 3.1). The antibodies in 
both the signaling-suppression and target-neutralization groups had significantly higher TEARs 
than the antibodies in the immunomodulatory-function group (p = 0.0001, p = 0.02, unpaired 
Student’s t-test, Figure 49B). The low TEARs of the antibodies working via the effector 
function might suggest that a relatively low target engagement is required for activating the 
immune function [168,190,352]. Among the five antibodies with TEARs < 2, four act via the 
immune function. For instance, the anti-GD2 antibody dinutuximab, which binds to the 
neuroblastoma cell surface GD2 and induces cell lysis via the effector function, had the lowest 
TEAR among the 60 surveyed antibodies (TEAR = 1.09, Data in Brief). 
We also observed TEAR differences between the antibodies targeting the epidermal growth 
factor receptor (EGFR) but through different MoAs. Panitumumab mainly eradicates tumor cells 
by suppressing intracellular signaling while necitumumab and cetuximab elicit tumor-killing 
effects through both the effector function and signaling suppression [366]. Cetuximab and 
necitumumab, two antibodies acting through multiple cellular immune responses, have much 
lower TEARs than panitumumab, an antibody with limited involvement of cellular effector 
functions (3.3 and 3.6 vs. 4.1, respectively; Data in Brief). On the other hand, anti-CD20 
antibodies obinutuzumab, ofatumumab, and rituximab, antibodies all eliciting strong ADCC in 
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treating chronic lymphoid leukemia, had close TEARs (2.8, 2.7, and 2.5, respectively; Data in 
Brief). The significantly different TEARs of the antibodies in the circulation-membranous and 
circulation-soluble groups (Figure 47B) are also related to their distinct MoAs. In the 
circulation-membranous group, most antibodies elicit an effect via signaling suppression and the 
immunomodulatory function whereas the antibodies in the circulation-soluble group primarily 
work by neutralizing soluble targets. 
Interestingly, in the immunomodulatory-function group, the TEARs of antibodies with higher 
target turnovers were smaller (p = 0.03, Pearson’s correlation, Figure 49C). This is probably 
associated with the rate of endocytosis of the antibody−target complex and its persistence time 
on cell surfaces, which are both critical for the effector function [238,239].  
First-in-Human Doses and Dose Escalation 
The doses that are tested during antibody development include first-in-human doses (FIHDs), 
maximum administered doses in FIH trials (MADs), and phase 2 doses (P2Ds). We analyzed 
these dose metrics and evaluated the potential factors involved in the FIH and phase 2 trial dose 
selection. Similarly, to enable comparisons across antibodies, we derived three metrics: 
TEARFIHD, TEARMAD, and TEARP2D (Materials and Methods). Among the 48 antibodies 
analyzed, we found high variabilities in the FIHDs and in the dose escalation ranges in the FIH 
trials. As shown in Data in Brief, the lowest TEARFIHD was 10,000-fold lower than the highest. 
With regard to the dose escalation ranges of the FIH trials, while the MADs were only two times 
higher than the FIHDs for some antibodies, other antibodies had up to 10,000-fold dose 
escalation ranges in their FIH trials. 
We further explored the FIHDs, dose escalations in Phase I, and the selections of P2Ds in the 
antibodies treating cancer and autoimmune diseases. As shown in Figure 50A, 16 of 19 (84%)  
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anti-cancer antibodies had relatively conservative FIHDs (TEARFIHD values < 2), while the 
analyzed antibodies for treating autoimmune diseases had relatively higher TEARFIHD values. 
The substantial difference in FIHDs between the two groups may result from the 
immunomodulatory functions of anti-cancer antibodies. The majority of antibodies in the cancer 
group have effector functions, in contrast to antibodies in the autoimmune disease group. 
Therapeutic antibodies acting through the effector function (i.e., the immunomodulatory-function 
group) had relatively low and conservative FIHDs compared to the ones suppressing the 
signaling or the ones neutralizing soluble targets (1.5 vs. 2.3, p = 0.01; 1.5 vs. 2.7, p < 0.0001; 
unpaired Student’s t-test; Figure 50B). This observation corresponds to a recent FDA report 
showing that more than half of the immunomodulatory antibodies as investigational new drugs 
were far from saturating their targets at the FIHDs [342]. The conservative FIHD selection for the 
immunomodulatory antibodies was driven by the specific FIH dose selection guidance by the 
FDA [66], suggesting MABEL as the approach for selecting the start doses of biologics with 
immune agonistic properties [226,367]. The antibodies with the highest TEARFIHD in the cancer 
groups, olaratumab and ramucirumab, mainly act by blocking the pathogenic receptor: ligand 
interaction rather than by effector functions.  
We also investigated the impact of target properties in FIHD selection. The antibodies with 
soluble targets (the neutralizing group) had much higher TEARFIHD values than the membranous 
target group (p = 0.002, Figure 51A). Other target properties, including the target locations, 
baselines, and degradation rates, were not found to have a significant impact on FIHD selection 
(Figure 51A-C). Notably, for the antibodies with the effector function, the target turnovers did 
not play a significant role in their FIHDs (Figure 51C). The TEARFIHD values were slightly 
lower in the first-in-class antibodies than in the next-in-class antibodies, but the difference was 
not statistically significant (2.1 vs. 2.4, p = 0.33, Figure 51D). 
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The phase II dose selection and the resultant TEARP2D also differed between the two disease 
groups. About half of the analyzed anti-cancer antibodies had one dose tested in the phase II 
trials. All the antibodies in the autoimmune disease group had multiple doses tested and even 
underwent additional rounds of dose escalation in the phase 2 trials (Figure 50A). These 
observations are probably associated with the enrollment barriers for the antibodies for cancer 
treatment [368], in which low and non-effective doses are not ethically acceptable, limiting the 
dose ranges being tested [369]. For antibodies treating autoimmune disease, finding the optimal 
dose-response relationships with the optimal efficacy/safety profiles is critical. 
Although the efficient dose escalation in FIH trial and appropriate phase 2 dose selection is 
associated with success in late-stage clinical trials of antibodies, there is no guidance for 
selecting phase 2 dose from FIH trials. We surveyed the phase 2 dose selection rationales in 49 
surveyed antibodies. While toxicity-guided phase 2 dose selection was not observed (Data in 
Brief), two types of phase 2 dose selection biomarkers were frequently applied to the surveyed 
antibodies: MABEL-based and efficacy-based biomarkers (Materials and Methods). Phase 2 
dose selection rationale was significantly different in anti-cancer antibodies and anti-
autoimmune-disease antibodies (Figure 50A). There were 17/19 (90%) anti-cancer antibodies 
that adopted the MABEL approach for phase 2 dose selection. Conversely, efficacy-related 
biomarkers were frequently used to select phase 2 doses of the antibodies treating autoimmune 
diseases. Another interesting finding was that the therapeutic doses of anti-cancer antibodies 
were close to the maximum administered doses in FIH trials, which may result from the flat 




6.5 Concluding Remarks 
Selecting the appropriate doses for a given indication is critical for developing a therapeutic 
antibody, especially at its first clinical entry and the following efficacy confirmation and 
optimization trials. The decision-making in antibody dose selection is a multifactorial process 
and many factors contribute to the variance of doses. The factors that influence the effective 
doses beyond antibody PK and its target affinity remain ambiguous. Here, we developed a 
dimensionless metric, TEAR, and used it to revisit the factors that could influence the therapeutic 
doses and dose selection. While showing some similarities with the widely-used metric 
Dose/ED50 in analyzing dose-response profiles [370-372], TEAR, by taking out the factors with 
relatively high certainty, such as clearance and bioavailability, supports analysis of other 
potential factors, including target abundance, turnovers, anatomical locations, and mechanism of 
actions (Figure 44). Our analyses provided insights into the factors that impact therapeutic doses 
as well as the factors that are critical for antibody pharmacological actions. Our review 
highlighted the importance of MoAs and challenged the traditional perception of the importance 
of target turnovers and anatomical locations in selecting therapeutic doses, yielding substantial 
implications for the future development of therapeutic antibodies. Our analyses failed to find a 
significant influence of target abundance on antibody doses, challenging our traditional 
perceptions, and we should be cautious in interpreting the theoretical modeling result [186]. 
While the current analyses suggested that a further understanding of the immunomodulatory 
function in the exposure-response relationship could help optimize antibody efficacy, a closer 
examination is warranted in a variety of antibody development cases not included in the current 
study. 
However, our analyses, however, has a few limitations. First, we applied KD values measured  
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under in vitro conditions to derive the TEARs. Even though we considered the average of 
multiple measurements, there was sometimes a gap between the in vitro and in vivo binding 
conditions. Many physiological factors (e.g., tumor stroma) physically shape an antibody’s 
interactions with its targets [142]. Second, the baseline and turnovers for the targets in solid 
tumors were calculated with the assumption that only 109 tumor cells were present [335]. The 
number of tumor cells varies widely across cancer patients at different stages of diagnosis. Third, 
the time-varying antibody PK and anti-drug antibodies were not considered in the analyses. 
Many studies have shown that anti-drug antibody presence, frequently reported in treating 
autoimmune diseases [373], can substantially alter antibody clearance. Dose adjustments are often 
needed in patient populations with high titers of anti-drug antibodies. Furthermore, altered 
catabolic states of patients can change antibody clearance and affect dose-response relationships 
[373,374]. For example, it has been suggested that cancer cachexia in late-stage melanoma and 
non-small cell lung cancer patients was correlated with rapid catabolism and poorer overall 
survival in pembrolizumab treatment [375,376]. Fourth, the novel antibody formats, including 
antibody-drug conjugates, bispecific antibodies, and antibody fragments, were not included in 
the current analysis due to their distinct PK/PD properties, making it challenging to derive, 
compare, or rationalize their TEARs. Lastly, we only analyzed several pharmacologically 
relevant factors. Decisions regarding antibody doses are often made after considering many 
practical and financial factors, such as ethical restrictions, cost-effectiveness, patient compliance, 
and the standard of care. The roles of those factors on antibody dose selection have been 






Figure 44: Schematic of the therapeutic exposure affinity ratio (TEAR).  
Factors such as the pharmacokinetics (PK) in the peripheral blood, antibody distribution, target turnover and 
baseline, antibody affinity, and modes of action (MoAs) are routinely considered in antibody development. TEAR 
takes into account the components with higher quantification certainty, including bioavailability (F), systemic 
clearance (CL), and binding affinity (KD), and serves as a metric reflecting the peripheral receptor occupancy. The 
factors beyond pRO that are not considered in TEAR, such as the target distribution, target properties, and MoAs, 







Figure 45: Distribution frequency of TEARs of the surveyed antibodies.  
The Css/KD values of 60 surveyed antibodies were log-transformed into TEARs to fall within a normal distribution, 







Figure 46: Most approved antibodies have therapeutic doses oversaturating the targets in plasma, as  
shown by the therapeutic exposure affinity ratio (TEAR) metric.  
Up to 60 licensed antibodies were included in the analysis. Most of the surveyed antibodies had TEARs > 2, 
indicating that such antibodies could saturate their targets in the peripheral blood (peripheral receptor occupancy 
[pRO] ≈ 99%) at the therapeutic doses. As shown in the bar chart, two antibodies had TEARs > 5, 15 had TEARs > 
4, 23 had TEARs = 3 and 4, and 17 had TEARs = 2 and 3, indicating that factors other than CL, F, and KD affect 
therapeutic dose selection. Each dot represents the TEAR of an antibody in mean ± standard deviation. The 
antibodies are numbered in alphabetical order and are shown on the x-axis. F: bioavailability; CL: systemic 







Figure 47: Effects of target anatomical locations, forms, and turnovers on therapeutic doses.  
(A) Target anatomical location does not have a significant impact on antibody therapeutic dose while target cellular 
location may be associated with therapeutic dose selection. While there was no significant difference between the 
therapeutic exposure affinity ratios (TEARs) of the circulation and tissue groups (p = 0.99, unpaired Student’s t-
test), the TEARs of the soluble and membranous groups were significantly different (p = 0.0022, unpaired 
Student’s t-test). Each dot represents the mean TEAR of an antibody. The bars represent the median and quartiles. 
(B) The antibody TEARs are different between certain disease-target scenarios. As shown above, the antibodies 
were categorized into four disease-target scenarios. The major diseases in each scenario are autoimmune diseases 
with targets in the circulation (circulation-soluble), hematologic malignancies (circulation-membranous), tissues 
(tissue-soluble), and solid tumors (tissue-membranous). A significant difference was observed only between the 
hematologic-malignancies and tissue-target groups (p = 0.0065, unpaired Student’s t-test). No difference in TEAR 
was observed between the other groups. (C) TEARs are different between tumor anatomical sites. The anti-cancer 
antibodies targeting the blood and lymph system had significantly lower TEARs than those targeting the 
digestive/GI system (p = 0.006, unpaired Student’s t-test) but have no substantial difference from the ones targeting 
skin (p = 0.88, unpaired Student’s t-test). (D) The pathologic locations of autoimmune diseases have no significant 
impact on antibody TEARs. The TEARs were not significantly different between the target anatomical locations in 
autoimmune diseases (p = 0.39, ordinary one-way ANOVA). In (B) – (D), each dot represents the TEAR of an 
antibody. All the data are represented as mean ± SD. (E) Target turnover is not relevant to antibody therapeutic 
dose. Target turnover was found not to be a significant factor affecting the therapeutic doses in the circulation, 
tissue, membranous, and soluble groups (p = 0.22, 0.98, 0.48, and 0.47, respectively; Pearson’s correlation). The 
horizontal bars represent the SD in the target turnover rates, the vertical bars represent the SD in the TEARs, and the 





Figure 48: Target baseline is not relevant to antibody therapeutic dose.  
Target baseline level was found not to be a significant factor affecting the therapeutic doses in the (A) membranous, 
soluble groups, (B) circulation, and tissue groups (p = 0.91, 0.36, 0.19, and 0.61, respectively; Pearson’s 
correlation). The horizontal bars represent the SD in the target abundance. The vertical bars represent the SD in the 






Figure 49: The mechanism of action is a pivotal factor in discerning therapeutic doses.         
(A) Antibodies elicit therapeutic efficacy via three distinct mechanisms: soluble target neutralizing, membranous 
signaling suppression, and immunomodulatory function. (B) The TEARs are significantly different between 
antibodies with varying mechanisms of action. The antibodies in the immunomodulatory-function group had the 
lowest TEARs (mean TEAR = 2.7) whereas the antibodies that act through soluble-target-neutralization appeared to 
have the highest therapeutic doses (mean TEAR = 3.7). The antibodies in the signaling-suppression group had 
significantly lower TEARs compared to the ones in the soluble-target-neutralization group (3.2 vs. 3.7, p = 0.04, 
unpaired Student’s t-test). The TEARs in the signaling-suppression and soluble-target-neutralization groups were 
significantly higher than those in the immunomodulatory-function group (p = 0.02, P = 0.0001, unpaired Student’s t-
test). Each dot represents the TEAR of an antibody. All the data are represented as mean ± SD. (C) The target 
turnover rates were correlated with the TEARs of the antibodies with an immunomodulatory function (p = 0.03, 
respectively; Pearson’s correlation) but not with the TEARs of the antibodies that neutralize soluble targets or 
suppress membrane signaling (p = 0.47 and 0.46, respectively; Pearson’s correlation). The horizontal bars represent 
the SD in the target turnover rates, the vertical bars represent the SD in the TEARs, and the grey shadows represent 








Figure 50: Mechanism of action has an impact on antibodies’ first-in-human dose (FIHD) escalations. 
(A)The dose-escalating ranges in the FIH trials are denoted by grey bars, whose lower and upper edges represent the 
FIHDs and the maximum-administered doses (MADs) in the FIH trials, respectively. The TEARs of the phase 2 
doses (TEARP2D) are given in mean ± SD and are represented by red bars and shadows. The solid black circles 
pertain to the TEARs of the therapeutic doses. The blue and yellow triangle symbols denote the antibodies that used 
MABEL approaches or treatment efficacy as the P2D selection rationale. Forty antibodies were included in the 
analysis and were grouped by their mechanisms of action. The names of the tested antibodies are indicated on the x-
axis. (B) The TEARFIH values were significantly different between antibodies with varying mechanisms of action. 
The TEARFIH values in the signaling-suppression and soluble-target-neutralization groups were significantly higher 
than those in the immunomodulatory-function group (p = 0.01, P < 0.0001, unpaired Student’s t-test). Each dot 







Figure 51: Effects of mechanisms of actions, antibody development, target locations, forms, and turnovers  
on first-in-human doses (FIHDs).  
(A) Target turnover is not relevant to antibody FIHDs in membranous and soluble groups (p = 0.54, p = 0.98, 
respectively; Pearson’s correlation). However, TEARFIH values are significantly different between membranous and 
soluble groups (p = 0.02, unpaired Student’s t-test). (B) Target turnover is not relevant to antibody FIHDs in 
circulation and tissue groups (p = 0.59, p = 0.32, respectively; Pearson’s correlation). TEARFIH values are not 
different between circulation and tissue groups (p = 0.44, unpaired Student’s t-test). (C) Target turnovers are not 
relevant to TEARFIH values in soluble target neutralizing, membranous signaling suppression, or immunomodulatory 
function (p = 0.98, p = 0.69, p = 0.40, Pearson’s correlation). In all TEAR vs. target turnover plots, dots represent 
the mean values, horizontal bars represent SD in the target turnover rates, and vertical bars represent SD in the 
TEARFIH. The shadows represent the 90% prediction intervals. SD = Standard Deviation. (D) The TEARFIH values 
























TABLE 12. Target information of the included therapeutic antibodies. 
Target Plasma baseline Half life Target turnover  Ref 
BAFF 1.5 ng/mL 70 min 27.84 [517,518] 
C5 0.37 uM 1 min 15384600 [519,520] 
CD20 200000 molecules/cell 426 hr 0.15 [521] 
CD4 46,000 molecules/cell 35 min 1270.88 [522-524] 
CD80 0.13, 0.29, 0.28 ng/ml 14000 s 0.73 (0.23) [525,526]  
CD86 1.46, 1.85, 1.71, 1.76 ng/ml 5† hr 3.36 (0.33) [526] 
CGRP ligand 42 pmol/L 7 min 249.48 [527,528] 
CGRP receptor 2796 molecules/cell 0.98 day 0.039 [529,530] 
CTLA-4 1.61, 3.19, 4.05, 3.90 ng/ml 151 min 27.6 (9.16) [526,531] 
EGFR 50000 molecules/cell 8-24 hr 1.03 [532,533] 
FGF23 26.1 pg/ml 20-40 min 1.61 [534,535] 
GD2 10000000 molecules/cell 114, 462 min 1082.11 (926.25) 
[25,536] 
HER2 100000 molecules/cell 8 hr 2.06 [537,538] 
IFNγ 139.6, 179, 151 pg/ml 94 min 1.54 (0.20) [539,540] 
IgE 368; 1123;1682; 2529 ng/ml 2.4 day 90.27 (57.73) 
[541,542] 
IL-17 α 200; 20; 8.29 pg/ml 24-48 hr 0.042 (0.059) [543-545] 
IL-1𝛽 1 ng/ml 1.59 hr 14.17 [546,547] 
IL-23 477; 799 pg/ml 4 hr 1.93 (0.69) [548,549] 
IL-4R α 25.6 (s) pg/ml 80 – 90 min 0.089 [548,550,551] 
IL-5 26; 15 pg/ml 6 hr 0.16 (0.06) [552,553]  
IL-5R α 42.3 (s) pg/ml 3 hr 0.16  
[554,555] 
IL-6 10  pg/ml 
0.75; 
1.7; 6 hr 0.20 (0.17) 
[543,556,557] 
IL-6R 58000 pg/mL 2-3 hr 380.53 [543,558,559] 
PCSK9 89.5 ng/ml 5 min 10337.25 [560,561] 
PD-L1 42.21; 37.81 pg/mL 18 hr 0.039 (0.0030) [562,563] 
PD1 2.9 ng/mL 281.7 hr 0.14 [564,565] 
PDGFRα 9914 molecules/cell 3 min 65.22 [566,567] 
Plasma kallikrein 70-90 ug/ml 5 min 7560000 [568,569] 
RANKL 0.6 pM 468 hr 0.00089 [570,571] 
SLAMF7 0.255 ng/ml 11 day 0.016 [421,572] 
TNF-alpha 3.27; 7.79; 1000; 170 pg/mL 70 min 6.85 (11.05) [573-576] 
VEGF 75; 30 pg/mL 0.7; 34 min 6.39 (5.25) [577-580] 
VEGFR2 12794, 13625 pg/mL 70 min 35.26 (1.57) [581,582] 









SUMMARY AND FUTURE DIRECTIONS 
Therapeutic antibodies have grown steadily into a clinically successful drug class due to 
advantageous therapeutic properties, such as high specificity and long half-life. Target 
engagement, including antibody-antigen interactions and antibody-dependent immune-target cell 
interactions, is an essential component in antibody pharmacokinetics (PK), pharmacodynamics 
(PD), and dose selection. In this dissertation research, we leveraged the novel imaging and 
mechanism-based modeling methods to elucidate the mechanistic factors influencing antibody 
target engagement in physiological contexts and antibody dose selection. 
The research described in Chapter 2 and Chapter 3 investigated the antibody-target binding 
dynamics in vivo. Cetuximab-EGFR interactions in living tumors were monitored continuously 
and non-invasively for up to 7 days (Chapter 2). Notably, Chapter 2 is the first study using 
BRET to detect antibody binding kinetics in vivo. Various imaging settings can be optimized to 
apply BRET in detecting antibody-target interactions in different scenarios. For instance, 
different DARs and fluorophore combinations could be evaluated to optimize the balance 
between the imaging sensitivity and conjugated antibody PK, facilitating BRET technology's 
future application to assess antibody binding kinetics in deeper tissue and metastatic lesions. 
Based on the imaging data, we developed a spatially-resolved mechanistic model to demonstrate 
tumor-associated stromal cells' influences on antibody binding kinetics (Chapter 3). This study 
suggests that the tumor microenvironment's physiological factors can significantly influence 
antibody distribution and binding kinetics. Restricted cetuximab diffusion in solid tumors caused 
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a slower-and-tighter degree of cetuximab-EGFR binding in the living tumor compared to the in 
vitro systems. Compared to the tumor regions that lack stroma cells, cetuximab had a slower 
disassociation rate constant in the stroma-rich areas, confirmed by immunofluorescent staining 
results showing a high fraction of cetuximab sequestrated (bound) in the stroma-rich tumor 
regions. We focused on evaluating the influences of tumor-associated stromal cells on antibody 
binding kinetics. However, many other factors in the TME can affect the antibody binding 
profiles. More comprehensive evaluations of those components and intratumoral spatial 
information should be considered in future studies. 
Chapter 4 evaluated the antibody distribution kinetics and target suppression profiles of two 
anti-αSyn antibody candidates, TNB and JNB, in the CSF and plasma. By modeling the binding 
kinetics in the plasma and the CSF, we found that anti-αSyn antibody candidates' binding 
profiles can be different at different anatomical locations due to pressure and shear stress. This 
study further proved that physiological factors could greatly affect the antibody binding kinetics, 
highlighting a lack of correlation between antibody binding properties in vitro and in vivo. This 
study also suggested that the brain's complex fluid system, such as the glymphatic pathway, can 
affect antibody distribution kinetics. Such influences can be investigated by powerful imaging 
tools such as intravital imaging technology in future studies. 
Chapter 2 – 4 investigated molecular-level antibody-target engagement at the site of action 
and analyzed the influencing factors on antibody-antigen binding dynamics. In Chapter 5, we 
elucidated cellular engagement induced by antibodies. We developed a proximity-based 
bioluminescent biosensor to assess the antibody-dependent immune: target cell clustering 
continuously and noninvasively. The biosensor system detected the cell interactions in the 3D 
cell culture system, which mimics solid tumors' physiological conditions. The biosensor system 
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showed great potential in visualizing antibody-induced cell-cell interactions in vivo. The 
application of the biosensor system described in Chapter 5 in animal models will provide 
valuable insights into antibodies' effector functions in vivo. Notably, both molecular and cellular 
target engagement, which were investigated in Chapter 2, Chapter 3, and Chapter 5, are the 
initial steps of antibody pharmacodynamic effects. The relationships between the target 
engagement and downstream pharmacological effects should be further investigated to provide a 
comprehensive understanding of physiological factors' influences on antibody PK/PD profiles. 
Lastly, we used a model-based metric, TEAR, to investigate the mechanistic factors 
influencing antibody dose selections. TEAR normalized the therapeutic doses through the use of 
factors with relatively high quantitative certainty, such as bioavailability (F), systemic clearance 
(CL), and target binding property (KD), to help us evaluate the factors that are difficult to 
quantify or evaluate, such as MoAs and target anatomical locations. Using TEAR, we revisited 
and dissected the doses of up to 60 FDA-approved antibodies. We failed to detect the significant 
influence of target baselines, turnovers, or anatomical locations on antibody therapeutic doses, 
which challenged the traditional perceptions. We highlighted the importance of antibody MoAs 
to antibody dose selections. This study provided insights into the factors that influence antibody 
doses. However, limitations should be considered when interpreting the findings in these 
analyses. For example, KD values measured under in vitro conditions were used to derive the 
TEARs, even though there is sometimes a gap between binding properties in vitro and in vivo. 
In summary, this doctoral research demonstrated the applications of molecular imaging and 
modeling methods in answering questions arising from antibody PK/PD profiles. We 
demonstrated that mechanistic PK/PD models are valuable to elucidate the complex PK/PD 
relationships and shed light on factors determining intricate dose-response relationships. Our 
 
 182 
research can help increase the efficiency and quality of antibody discovery, preclinical 
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